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“LENTAMENTE MUORE” 
Lentamente muore, 
chi diventa schiavo dell’abitudine, ripetendo ogni giorno gli stessi percorsi, 
chi non cambia la marcia, 
chi non rischia e cambia colore dei vestiti, 
chi non parla a chi non conosce. 
Muore lentamente chi evita una passione, 
chi preferisce il nero su bianco e i puntini sulle “i” piuttosto che un insieme di emozioni,  
proprio quelle che fanno brillare gli occhi, quelle che fanno di uno sbadiglio un sorriso, 
 quelle che fanno battere il cuore davanti all’errore e ai sentimenti. 
Lentamente muore, 
chi non capovolge il tavolo, 
chi e’ infelice sul lavoro, 
chi non rischia la certezza per l’incertezza per inseguire un sogno, 
chi non si permette almeno una volta nella vita di fuggire ai consigli sensati. 
Lentamente muore chi non viaggia, 
chi non legge, 
chi non ascolta musica, 
chi non trova grazia in se stesso. 
Muore lentamente chi distrugge l’amor proprio,  
chi non si lascia aiutare;  
chi passa i giorni a lamentarsi della propria sfortuna o della pioggia incessante. 
Lentamente muore chi abbandona un progetto prima di iniziarlo, 
chi non fa domande sugli argomenti che non conosce,  
chi non risponde quando gli chiedono qualcosa che conosce. 
Evitiamo la morte a piccole dosi,  
ricordando sempre che essere vivo richiede uno sforzo di gran lunga maggiore del  
semplice fatto di respirare. 
Soltanto l’ardente pazienza porterà al raggiungimento di una splendida felicità. 
                                                                                            Pablo Neruda 
 
 
“SLOWLY DYING” 
Slowly dying, 
who becomes a slave of habit 
who repeating every day the same routes, 
who does not change the march, 
who does not speak to those do not Know. 
Dies slowly who avoids a passion, 
Who prefers black and white and dot the “i” rather than a set of emotions, 
 those who make their eyes light up, those who are a yawn of a smile,  
those that make the heart beat before the error and feelings. 
Slowly dying, 
Who does not overturn the table, 
Who unhappy at work, 
Who does not risk certainty for the uncertainty to chase a dream, 
Who would not at least once in life to flee to sensible advice. 
Slowly dying, 
Who do not travel, 
Those who do not read, 
Who does not listen to music, 
Who does not find grace in himself. 
He died slowly, 
Who destroy the self-respect, 
Who will not be helping; 
Who passes the day to complain its bad luck or the incessant rain. 
Slowly dying, who abandons a project before you start, 
Who does questions on the subjects that do not know, 
Those who do not respond when seeking something familiar. 
Let’s death in small doses, 
Remembering always that being alive requires an effort far greater the sample act of breathing. 
Only ardent patience leads to achieve a splendid happiness. 
                                                                                            Pablo Neruda 
 
 
INDEX 
 
RIASSUNTO pag.   1 
SUMMARY      pag.   7 
I. PEPTIDES AS MODULATORS OF PROTEIN-PROTEIN INTERACTIONS pag.   8 
I.1 REFERENCES                                                                                                        pag.   9 
II. PEPTIDES MIMICKING THE IgE HIGH AFFINITY RECEPTOR FcεRI pag. 10 
II.1 INTRODUCTION pag. 10 
II.1.2 The IgE high –affinity receptor: FcεRI pag. 12 
II.1.3 Structural insights into the interaction between IgE and its high 
affinity receptor FcεRI                                                       
pag. 14 
II.2 PROJECT AIMS                                                                                        pag. 19 
II.3 EXPERIMENTAL PROCEDURES                        pag. 20 
II.3.1 Materials  pag. 20 
II.3.2 Methods                                                                                                    pag. 21  
II.3.2.1 Cloning of α-chain human FcεRI pag. 21 
II.3.2.2 Expression screening for the full-length human FcεRI α-chain pag. 22 
II.3.2.3 Purification of full-length His6x-αchain pag. 22  
II.3.2.4 Purification of full-length GST-αchain pag. 23  
II.3.2.5 Purification of full-length MBP-αchain pag. 23  
II.3.2.6 Purification of periplasmatic full-length His6x-αchain and full-           
length Dsb-His6x-αchain  
pag. 23  
II.3.2.7 Expression and purification of His6x-D1-D2 domain as             
inclusion bodies 
pag. 24  
II.3.2.8 Expression and purification of MBP-D2 domain pag. 25  
II.3.2.9 Expression and purification of His6x-D2 domain pag. 25 
II.3.2.10 Western blotting pag. 26 
II.3.2.11 Vinyl pyridine reaction pag. 26  
II.3.2.12 Gel filtration analysis pag. 26  
II.3.2.13 Protein characterization LC-MS pag. 26  
II.3.2.14 Circular Dichroism analysis pag. 27  
II.3.2.15 Peptide synthesis, purification and characterization pag. 27  
II.3.2.16 Immunoglobulins coating on sensor surface  pag. 28  
II.3.2.17 SPR data fitting and analysis pag. 28 
II.3.2.18 ELISA assay pag. 29  
II.4 RESULTS AND DISCUSSION pag. 31 
II.4.1 Molecular design of FcεRI receptor mimicking polypeptides              pag. 31  
II.4.1.2 Synthesis, purification and characterization of polypeptides pag. 33  
II.4.1.3 Equilibrium affinity measurements between IgE-receptor            
mimicking peptides by SPR assay 
pag. 35  
II.4.1.4 Selectivity affinity measurements between IgE–receptor          
mimicking peptides by SPR assay 
pag. 45  
II.4.2 Expression of human FcεRI αchain as recombinant protein             pag. 47 
II.4.2.1 Expression and purification of full length hαFcεRI                     pag. 47  
II.4.2.2 Expression and purification of D1-D2 domain                           pag. 50  
II.4.2.3 Expression and purification of D2 domain                                   pag. 51 
II.4.2.4 Expression, purification and characterization of His6x-D2     
domain                                                                               
pag. 52 
II.4.2.4a Expression and purification of His6x-D2 domain                           pag. 52  
II.4.2.4b Refolding of His6x-D2 domain  pag. 53  
II.4.2.4c Characterization of His6x-D2 domain                                             pag. 54  
II.4.2.5 His6x-D2 domain – Immunoglobulins E binding assay                pag. 55 
II.4.3 ELISA Competition assay with synthetic peptides                             pag. 60 
II.5 CONCLUSIONS AND PERSPECTIVES                                                                 pag. 62 
II.6 REFERENCES pag. 64 
III. IDENTIFICATION OF A BCL-10 INHIBITORY PEPTIDE          pag. 67  
III.1 INTRODUCTION                                                                                                  pag. 67 
III.1.2 The family of CARD containing proteins                                              pag  68 
III.1.3 BCL10: a modular protein                                                                      pag. 69  
III.2 PROJECT AIMS pag. 71 
III.3 EXPERIMENTAL PROCEDURES                        pag. 72 
III.3.1 Materials  pag. 72 
III.3.2 Methods                                                                                                    pag. 72 
III.3.2.1 BCL10-CARD domain cloning, expression and purification pag. 72 
III.3.2.2 Circular Dichroism analysis pag. 73 
III.3.2.3 Biotinylation of the BCL10-CARD domain pag. 73  
III.3.2.4 Protein digestion with trypsin and peptide fractionation pag. 73 
III.3.2.5 BCL10-CARD domain self-association and binding              
competition ELISA assays              
pag. 74 
III.3.2.6 Peptide synthesis, purification and characterization pag. 75 
III.3.2.7 Size Exclusion Chromatography analysis pag. 75 
III.3.2.8 Serum stability pag. 75 
III.3.2.9 Cell culture pag. 76 
III.3.2.10 Immunoblot analysis and co-immunoprecipitation pag. 76 
III.3.2.11 Fluorescence peptide assay                                                    pag. 76 
III.3.2.12 NFкB luciferase reporter gene assay pag. 76 
III.4 RESULTS AND DISCUSSION                                                         pag. 78 
III.4.1 Expression, purification and characterization of BCL10-CARD     
domain                                                                             
pag. 78 
III.4.2 Identification of BCL10-CARD regions involved in self-association                                                                                pag. 79 
III.4.2.1 BCL10–CARD domain self-association assay                             pag. 79 
III.4.2.2 Protein digestion with trypsin and peptide fractionation           pag. 80 
III.4.2.3 Protein fragments characterization and screening                
             competition assay                                                                          
pag. 80 
III.4.3 Molecular design of BCL10 peptides                                                    pag. 81 
III.4.3.1 Synthesis, purification and characterization of BCL10 peptides                        pag. 82
III.4.3.2 Competitive ELISA assay with BCL10-CARD peptides   pag. 83 
III.4.3.3 Characterisation of the oligomeric state of Peptide I and       
Peptide II by SEC analysis                                                             
pag. 83 
III.4.3.4 Ala-scanning assay                                                                         pag. 84 
III.4.4 Cellular assays                                                                                        pag. 85 
III.4.4.1 Synthesis, purification, serum stability and  characterization of 
TAT-conjugated and FITC-TAT-conjugated Peptide VIII       
pag. 85 
III.4.4.2 Immunoblotting and co-precipitation analysis                         pag. 86 
III.4.4.3 Assessment of peptide entry into HEK 293 cells                                                    pag. 87
III.4.4.4 NFкB luciferase reporter gene assay                                      pag. 88  
III.5 CONCLUSIONS AND PERSPECTIVES pag  90 
III.6 REFERENCES pag. 92  
IV. ABBREVETIONS INDEX pag. 95 
V. SCIENTIFIC PRESENTATIONS                   pag. 97 
VI. PUBLICATIONS    pag. 98 
  
  
  
 1 
 
RIASSUNTO 
 
Uno degli aspetti più importanti nella moderna ricerca biotecnologica riguarda lo 
studio a livello molecolare delle interazioni proteina-proteina essenziali per una 
corretta comprensione dei meccanismi fisio-patologici che regolano i processi 
cellulari.  
Tali interazioni possono scatenare eventi quali il reclutamento di specifiche proteine 
segnale, richieste per svolgere una determinata funzione nei compartimenti cellulari, 
oppure l’induzione di stati conformazionali in grado di cambiare l’attività e/o 
modificare l’accessibilità di una proteina ad altri domini di legame, permettendo 
ulteriori interazioni proteina-proteina. Pertanto, la conoscenza dettagliata dei 
meccanismi biomolecolari responsabili di interazioni proteina-proteina, rappresenta il 
primo traguardo per la modulazione dell’attività biologica di proteine target che 
controllano i processi cellulari.  
Attualmente, l’identificazione di molecole capaci di inibire o promuovere interazioni 
proteina-proteina o proteina-ligandi rappresenta lo scopo ultimo nel processo di “drug 
discovery”. Diversamente dal tradizionale approccio, basato sopratutto sul design di 
inibitori modellati su substrati molecolari specifici per siti attivi enzimatici, lo sviluppo 
di inibitori capaci di modulare interazioni proteina-proteina si presenta come un 
processo più complesso in quanto subordinato a numerosi fattori. In primo luogo, 
l’ampia interfaccia di interazione (750–1500 A2) necessaria per lo specifico 
riconoscimento, implica l’uso di molecole più grandi rispetto ai piccoli ligandi usati 
come inibitori enzimatici. Inoltre, la presenza di regioni multiple e non contigue 
responsabili del legame, piuttosto che un unico sito di legame ben definito, e l’ 
adattabilità delle superfici proteiche che sono in grado di riarrangiare la loro struttura 
in seguito ad interazioni, rendono più complicato e articolato il “rational design”. 
Tuttavia, negli ultimi anni sono stati identificati numerosi ligandi di varie dimensioni 
capaci di modulare e/o distruggere un’interazione proteina-proteina che hanno 
portato lo sviluppo e la commercializzazione di potenti inibitori impiegabili in patologie 
come il cancro e HIV. 
L’obiettivo principale dello studio condotto durante questo lavoro di tesi è stato 
proprio l’identificazione di molecole capaci di modulare interazioni proteina-proteina. 
 
E’ noto che numerose patologie sono associate alla trasduzione di segnali 
biochimici dall’esterno della cellula fino ai compartimenti subcellulari in cui 
avvengono reazioni biomolecolari cruciali per la sopravvivenza della cellula stessa. 
La regolazione dei segnali di trasduzione può avvenire a monte (upstream 
regulation), modulando interazioni proteina–recettore di membrana, e/o a valle 
(downstream regulation), modulando interazioni proteina–proteina che portano 
all’attivazione di fattori di trascrizione attraverso complesse cascate di amplificazione 
del segnale.  
 
La prima parte della tesi è stata incentrata sull’identificazione di molecole 
capaci di modulare l’interazione IgE-FcεRI, uno dei principali target molecolari per 
bloccare le reazioni allergiche di ipersensibilità immediata di tipo I.  
La recente determinazione della struttura cristallografica del complesso, formato 
dalla catena α extracellulare del recettore FcεRI e la porzione Fc delle IgE, ha 
consentito di chiarirne sia il meccanismo molecolare che la stechiometria di 
interazione, aprendo così la strada alla progettazione di molecole di tipo peptidico e 
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peptidomimetico che possano modulare tale interazione. Data la crescente incidenza 
(oltre il 20% della popolazione mondiale), di malattie di natura allergica, questo tipo 
di molecole avrebbero un enorme interesse industriale per lo sviluppo di nuove classi 
di farmaci non di tipo sintomatico come gli antistaminici, ma eziologico. Pertanto, 
l’obiettivo è stato quello di selezionare delle nuove molecole di sintesi, mimanti il 
recettore, capaci di legare specificamente le IgE, da usare come punto di partenza 
per lo sviluppo di modulatori potenti e selettivi della reazione allergica.  
Inoltre, lo stesso recettore in forma ricombinante solubile e attiva può trovare 
applicazione come agente terapeutico oltre a rappresentare il presupposto per 
l’allestimento di saggi biochimici di legame con le IgE da impiegare per la selezione 
di molecole di sintesi, disegnate ad hoc o preparate in maniera “random”, che siano 
capaci di interferire con tale interazione.  
Il progetto è stato sviluppato seguendo due differenti approcci: i) progettazione e 
sintesi di recettore-mimetici (“synthetic receptor”) e ii) preparazione per via 
ricombinante della porzione extracellulare del recettore. La validità della prevenzione 
del legame delle IgE al recettore FcεRI come target è clinicamente dimostrata 
dall’efficacia riscontrata con l’anticorpo monoclonale anti-IgE rhu-Mab E25 
(Omalizumab), già in commercio da qualche anno. 
La regione extracellulare della catena α del recettore FcεRI, costituita da due “Ig-like 
domains”, denominati D1 e D2, interagisce con la porzione Fc-IgE attraverso due siti 
di legame. La determinazione della struttura cristallografica del complesso αFcεRI-
Fc-IgE ad alta affinità (KD=10-9-10-10M) ha permesso di identificare in maniera 
dettagliata gli amminoacidi che sono coinvolti nei due siti di interazione. Utilizzando 
questi dati strutturali è stato disegnato un polipeptide, denominato IgE-TRAP (M.W. 
3474 amu), rappresentato schematicamente in Fig.1, in cui sono stati mimati 
entrambi i siti di interazione. 
 
                                                                      
 
 
 
 
 
 
 
 
 
 
 
                           Figura 1: Rappresentazione schematica del polipeptide IgE-TRAP ossidato 
 
Su entrambe le forme del polipeptide IgE-TRAP, ridotta ed ossidata, è stata condotta 
un’analisi strutturale preliminare in soluzione, mediante dicroismo circolare. Questa 
indagine ha evidenziato per il polipeptide ridotto una conformazione secondaria 
prevalentemente di tipo β-sheet. L’affinità dei peptidi per le IgE è stata determinata 
mediante saggi di legame utilizzando la tecnica SPR.  
I dati SPR sono stati accuratamente analizzati assumendo una stechiometria 1:1 e 
utilizzando un modello bifasico. In tal modo, per ogni fase, è stata estrapolata una 
costante di affinità (KD1 e KD2) ed è stata calcolata una costante di affinità globale 
(KD). Pertanto è stato possibile analizzare il contributo dei singoli siti e il loro effetto 
globale nell’interazione. Entrambi i polipeptidi IgE-TRAP hanno mostrato affinità per 
le IgE. In particolare, per il polipeptide ciclico, sono state estrapolate una KD1 = 65 
2 nd MiniLoop
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µM, KD2 = 60 µM e KD globale di 16 µM, mentre per la forma ridotta una KD1 = 19 
µM, una KD2 = 37 µM ed una KD globale di 6.2 µM. Per entrambi la costante di 
affinità globale è risultata essere più bassa delle singole costanti separate, 
confermando in tal modo la presenza di un meccanismo cooperativo dei due siti. 
Sebbene per entrambi la KD risulta nell’ordine micromolare, il polipeptide ridotto 
mostra una affinità globale 2.5 volte più alta rispetto alla forma ossidata. Tale 
aumento è il risultato complessivo di una maggiore flessibilità conformazionale 
dovuta all’assenza del ponte disolfuro che consente al polipeptide ridotto di adattarsi 
più facilmente alla superficie delle immunoglobuline. Questo effetto si riflette 
soprattutto sul sito 1, in cui la KD1 diminuisce da 65 µM (nella forma ossidata) a 19 
µM (nella forma ridotta), e solo parzialmente sul sito 2. Per aumentare l’affinità del 
polipeptide IgE-TRAP, abbiamo esplorato una possibile correlazione struttura-attività 
utilizzando un set di peptidi derivanti dallo stesso, che riproducono i due siti anche 
separatamente. Mediante analisi SPR è stato confermato che il peptide denominato 
1° Loop (Fig.1) riconosce ancora le IgE e sono state estrapolate una KD1 = 65 µM, 
KD2 = 19x10-5M e KD globale di 19 µM, mentre per il peptide denominato 2° Loop 
(Fig.1), nelle varianti forma ossidata e ridotta, non è stato osservato nessun legame. 
Questi dati evidenziano che il 1° Loop è responsabile del legame, media il 
riconoscimento e promuove il successivo legame del 2° Loop. Infatti, il 1° Loop 
mostrando una KD1 = 65 µM (uguale a quella estrapolata per il polipeptide IgE-
TRAP ossidato) conferma che la presenza o l’assenza del 2° Loop influenza lo stato 
conformazionale incidendo soprattutto sul riconoscimento mediato dal sito 1. Inoltre, 
dall’analisi di peptidi riproducenti separatamente i due siti di legame, è stato 
evidenziato che solo il peptide denominato 2° MiniLoop (Fig.1), che riproduce 
essenzialmente il sito 2, è in grado di riconoscere, sebbene con una debole affinità 
(KD = 8.3x10-4 M), le IgE. I dati SPR, in questo caso, sono stati analizzati 
assumendo una stechiometria 1:1 e utilizzando un modello monofasico. Ciò 
conferma che il sito 2 è stato riprodotto con efficienza, e che il 2° MiniLoop 
rappresenta la sequenza amminoacidica responsabile dell’ancoraggio alle IgE, 
contenuta anche nel 1° Loop (Fig.1). La selettività dei peptidi selezionati (IgE-TRAP, 
1° Loop e 2° MiniLoop) di riconoscere esclusivamente le IgE è stata verificata 
mediante saggi di legame con altre immunoglobuline, IgG e IgA, le più abbondanti 
nel siero, utilizzando ancora la tecnica SPR, dimostrando che i peptidi legano 
esclusivamente le immunoglobuline di tipo E.  
Parallelamente è stata messa a punto l’espressione della catena α del recettore 
FcεRI in forma ricombinante da usare sia per allestire saggi di legame con le IgE per 
lo screening di molecole di sintesi e di librerie peptidiche, sia come antagonista 
solubile delle stesse IgE.  
La catena α del recettore hFcεRI è stata espressa in forma ricombinate sia come 
proteina intera (1-257), sia come dominio D1-D2 (1-170) che come singolo dominio 
D2 (84-170) della porzione extracellulare (ECD). Le varie forme ricombinanti della 
proteina intera e del dominio D1-D2 sono risultate inattive a causa delle difficoltà 
incontrate nella rinaturazione della proteina che contiene 4 cisteine. La presenza 
delle cisteine ha portato quasi sempre alla formazione di aggregati covalenti 
insolubili. Invece, la forma ricombinante del dominio D2, recante al N-terminale una 
coda di 6xHis, è stata purificata in condizioni denaturanti e rinaturata con successo. 
La proteina rinaturata presenta una struttura secondaria prevalentemente di tipo β-
sheet, come atteso dalla struttura cristallografica nota, mentre un’analisi dello stato 
oligomerico, mediante cromatografia ad esclusione molecolare, ha evidenziato una 
forte tendenza della proteina a formare oligomeri di natura non covalente. Il dominio 
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His6x-D2 rinaturato, sebbene oligomerico, è risultato attivo, infatti il legame alle IgE è 
stato confermato sia mediante tecnica SPR che ELISA. Da un’analisi preliminare del 
legame del dominio alle IgE, mediante SPR, sono state estrapolate una KD1 = 8.3 
µM, KD2 = 11.1 µM e una KD globale di 1.8 µM. Anche in questo caso, la 
cooperatività dei due siti è stata confermata dalla costante di affinità globale più 
bassa delle singole costanti separate. Tuttavia, il dominio His6x-D2 ricombinante 
mostra una affinità dell’ordine micromolare per le IgE, più bassa rispetto a quella del 
recettore intero nativo (KD=10-9 M), prevedibilmente sia per la mancanza del dominio 
D1 (il quale pur non essendo direttamente coinvolto nell’interazione contribuisce 
strutturalmente al mantenimento dell’alta affinità) sia a causa dello stato oligomerico 
che rende la proteina meno disponibile al riconoscimento. Inoltre, il legame è stato 
confermato, mediante saggio ELISA, ed è stato ottimizzato variando condizioni di pH 
e di concentrazione salina. E’ stato verificato che l’uso di un tampone leggermente 
più acido (Bis-Tris 25 mM pH 6.5, NaCl 150 mM) rende la proteina più disponibile al 
riconoscimento. Mediante saggio ELISA in tali condizioni, sono stati evidenziati i due 
siti di interazione e sono state estrapolate una KD1 = 112 nM per il primo sito, la cui 
saturazione avviene per concentrazioni superiori a 1 µM, e una KD2 = 4.1 µM per il 
secondo sito, la cui saturazione avviene per concentrazioni superiori a 20 µM. La 
messa a punto del saggio biochimico di legame ha consentito di verificare la capacità 
dei polipeptidi IgE-TRAP, 1° Loop e 2° MiniLoop (selezionati come “binders” delle 
IgE) di spiazzare l’interazione His6x-D2 ricombinante - IgE. Saggi ELISA di 
competizione hanno confermato che il polipeptide IgE-TRAP ridotto riesce a 
spiazzare l’interazione con una IC50 = 36 µM; il 1° Loop e il 2° MiniLoop, 
prevedibilmente, competono ma con IC50 = 103 µM e IC50 = 864 µM, rispettivamente, 
in ottimo accordo con le KD determinate per legame diretto.  
Questi dati indicano che le molecole disegnate soddisfano il requisito della selettività 
per le IgE con un’affinità di interazione dell’ordine micromolare. Pertanto, il peptide 1° 
Loop potrebbe rappresentare il punto di partenza per lo sviluppo di nuove molecole 
più affini. La messa a punto del saggio biochimico di legame tra il dominio His6x-D2 
ricombinante e le IgE consente la selezione di competitori mediante lo screening di 
librerie di composti. 
 
La seconda parte del lavoro di tesi è stata incentrata sull’identificazione di un 
peptide capace di inibire il processo di oligomerizzazione della proteina BCL10.  
BCL10 (B-cell lymphoma 10) è un fattore proteico con una struttura bipartita, 
costituita da un dominio CARD N-terminale e da un dominio C-terminale ricco in 
residui di treonina e serina. Sebbene il completo “pathway” di attivazione della 
proteina non è ancora del tutto chiaro, molti studi hanno confermato che BCL10, 
attraverso interazioni omofiliche con altre proteine, mediate dal dominio CARD N-
terminale, promuove l’attivazione del fattore NF-κB. 
BCL10 è un importante modulatore della risposta immunitaria, infatti l’attivazione dei 
recettori TCR (localizzati sulle cellule T e B) induce, mediante interazioni CARD-
CARD, la formazione del complesso CBM (CARMA1-BCL10-MALT1) che, attraverso 
la fosforilazione del complesso IKK, promuove l’attivazione del fattore NF-κB. 
Modificazioni morfologiche o mutazioni a livello del dominio CARD si riflettono nella 
perdita di capacità da parte della proteina di agire correttamente.  
Recenti dati di letteratura dimostrano, infatti, che la sovraespressione di BCL10 è 
correlata allo sviluppo di linfomi di tipo MALT ed è determinata da una traslocazione 
genica t(1;14)(p22;q32) che pone il gene BCL10 sotto il controllo del gene promotore 
delle catene pesanti delle immunoglobuline. La condizione di sovraespressione 
 5 
favorisce un processo di omodimerizzazione tra domini CARD di molecole contigue 
di BCL10 che sono in grado di assemblarsi in filamenti. Tali filamenti portano 
all’inappropriata attivazione del fattore NF-κB. Pertanto, l’identificazione di un 
inibitore del processo di oligomerizzazione può aprire la strada allo sviluppo di 
molecole capaci di modulare l’attivazione del fattore NF-κB. 
I domini CARD sono costituiti da sei α-eliche con un arrangiamento tipico a chiave 
greca ed hanno una lunghezza di circa 110 residui amminoacidici.  
Il pre-requisito fondamentale per lo sviluppo di inibitori basati sull’interfaccia di 
interazione, è l’identificazione delle regioni direttamente coinvolte nel processo di 
oligomerizzazione di BCL10-CARD.  
Per questo studio, un mutante del dominio CARD di BCL10, in cui le due cisteine 
presenti nella sequenza sono state sostituite da serine, è stato ottenuto per via 
ricombinate; un’analisi conformazionale preliminare in soluzione mediante dicroismo 
circolare ha evidenziato una conformazione secondaria di tipo α elicoidale.  
Avvalendoci del sistema di rivelazione biotina-strepavidina, per verificare l’interazione 
CARD-CARD, è stato allestito un saggio tipo ELISA utilizzando la stessa proteina 
biotinilata. E’ stato verificato che il dominio BCL10-CARD riconosce sé stesso con 
una costante di auto-associazione pari a 1.3 µM.  
La messa a punto del saggio di auto-associazione è stato pertanto il punto di 
partenza per identificare le regioni della sequenza di CARD responsabili 
dell’interazione. Mediante un semplice ed efficiente approccio basato sulla proteolisi 
limitata della proteina, abbiamo selezionato “frammenti proteici” capaci di interferire 
nell’auto-associazione. 
Il dominio mutato CARD-BCL10 è stato idrolizzato con tripsina e i frammenti triptici 
prodotti sono stati separati mediante RP-HPLC in frazioni, che sono state analizzate 
mediante LC-MS e usate per allestire saggi ELISA di competizione. La frazione F8 è 
risultata essere la più efficacia nell’inibire l’auto-associazione del 45%. L’analisi LC-
MS ha rivelato che la frazione conteneva essenzialmente il frammento BCL10[91-
98]. L’analisi di un modello teorico predittivo della struttura del dominio CARD di 
BCL10, ha suggerito che il frammento BCL10[91-98] è localizzato in prossimità 
dell’elica 6, pertanto, per investigare l’influenza della regione contigua del frammento 
91-98 interna al dominio CARD, sono stati disegnati due analoghi di sequenza più 
estesa, contenenti anche le eliche 4 e 5 (Tabella I). I tre peptidi, denominati Peptide I 
BCL10[91-98], Peptide II BCL10[78-98] e Peptide III BCL10[68-98] sono stati 
sintetizzati e sottoposti a saggi di tipo ELISA di competizione analogamente a quanto 
fatto per il saggio di screening. Il Peptide I BCL10[91-98], sebbene più corto, è 
risultato l’unico in grado di inibire ancora l’auto-associazione della proteina, esibendo 
una IC50 di circa 70 nM. I peptidi sintetici II e III invece, pur contenendo la sequenza 
91-98, sono risultati del tutto inefficaci. 
Indagini relative allo stato oligomerico dei peptidi sintetici, eseguite mediante SEC, 
hanno evidenziato che in soluzione il Peptide I BCL10[91-98] è stabile nello stato 
monomerico fino a concentrazioni pari a 400 µM, mentre il peptide BCL10[78-98] è in 
forma dimerica già a 5 µM. Sulla base di tali informazioni, abbiamo ipotizzato che il 
Peptide II BCL10[78-98], alle concentrazioni usate, risulta meno efficace perché i 
residui 78-90 favoriscono la formazione di oligomeri rendendo in tal modo i residui 
91-98 non disponibili per il riconoscimento.  
Partendo dal Peptide I BCL10[91-98] abbiamo condotto uno studio mirato 
all’identificazione degli aminoacidi cruciali per l’interazione. Per tale scopo sono stati 
progettati e saggiati dei peptidi mutati denominati Peptide IV, V, VI, VII caratterizzati 
dalla presenza di doppie mutazioni contigue ad alanina (Tabella I). 
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Tabella I 
 
 PEPTIDE SEQUENCE 
I BCL10[91-98] TQNFLIQK 
II BCL10[78-98] GLDTLVESIRREKTQNFLIQK 
III BCL10[68-98] LLDYLQENPKGLDTLVESIRREKTQNFLIQK 
IV BCL10[91-98]T91A,Q92A AANFLIQK 
V BCL10[91-98]N93A,F94A TQAALIQK 
VI BCL10[91-98]L95A,I96A TQNFAAQK 
VII BCL10[91-98]Q97A,K98A TQNFLIAA 
VIII Tat-BCL10[91-98] -*GRKKRRQRRRPPQ-βA-βA-TQNFLIQK 
IX Tat-BCL10[91-98]T91A,Q92A -*GRKKRRQRRRPPQ-βA-βA-AANFLIQK 
 
L’analisi funzionale di questi peptidi ha dimostrato che: 
 
- la sostituzione dei primi due aminoacidi Thr91 e Gln92 con Ala ha reso il 
peptide completamente inattivo 
- la sostituzione della Asn93 e Phe94 con Ala ha fatto diminuire l’efficacia 
mostrando una IC50 di circa 10-6 M. 
- la sostituzione della Leu95 e Ile96 con Ala, invece, ha portato ad una netta 
diminuzione della capacità di competere. 
- la sostituzione degli ultimi due aminoacidi Gln97 e Lys98 è risultata totalmente 
ininfluente.  
 
Questi dati suggeriscono che i residui di BCL10 [91-98] possono avere un ruolo 
rilevante nel processo di auto-associazione e che le catene laterali della Thr91, 
Gln92, Leu95 e Ile96 possono rappresentare i punti di contatto tra proteine 
monomeriche. 
Inoltre, la capacità inibitoria del Peptide I è stata valutata con esperimenti cellulari sia 
come effetto diretto che indiretto. A tal fine, il Peptide I è stato opportunamente 
coniugato con la sequenza basica della TAT (Peptide VIII) e ne è stata valutata la 
stabilità in siero e, mediante esperimenti di immunoprecipitazione, è stato verificato 
che in cellule HEK293, sovraesprimenti l’intera proteina BCL10 (1-127), il Peptide 
VIII inibisce in maniera dose-dipendente l’auto-assocciazione mostrando la massima 
attività a 100 µM. Mediante microscopia a fluorescenza è stata anche valutata la 
capacità di penetrazione della membrana cellulare e la localizzazione cellulare. 
Come effetto a valle, è stata valutata la capacità del Peptide VIII di inibire 
l’attivazione del fattore NF-κB, indotta sia dalla sovraespressione di BCL10 che 
dall’attivazione della PKC. In entrambi i casi, il Peptide VIII inibisce in maniera dose-
dipendente l’attivazione del fattore NF-κB mostrando, alla concentrazione di 50 µM, 
un’inibizione del 50% e del 70%, rispettivamente.  
Pertanto, il Peptide VIII può rappresentare il punto di partenza per lo sviluppo di 
nuove molecole da usare per il trattamento di specifiche condizioni patologiche 
associate con l’attivazione del fattore NF-κB. 
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SUMMARY 
 
One of the major challenges for the comprehension of physiological and pathological 
functions regulating the cellular processes, is the elucidation of molecular 
mechanisms underlining protein–protein interactions. 
Protein–protein interactions indeed play a key role in a variety of biological processes 
and are therefore important targets for the design of novel therapeutics. Unlike the 
design of enzyme inhibitors, the disruption of protein–protein interactions is far more 
challenging, due to large interfacial areas involved in protein recognition and to the 
relatively flat topologies of these surfaces. Nevertheless, in spite of such difficulties, 
there has been considerable progress in the recent years.  
The purpose of this PhD thesis is the identification of small peptides acting as 
modulators of protein–protein interactions playing a crucial role in pathological 
processes, such as allergy and cancer.  
Different strategies have been employed: in one case, starting from a 
crystallographic structure, the rational design of short polypeptides mimicking the 
receptor binding surface has been achieved. In a second case, potent inhibitors of a 
protein have been identified following an approach of screening of peptide pools 
generated from the protein itself. 
 
In the first part of the study, we have dealt with de novo designed inhibitors of 
the IgE-FcεRI interaction, one of the main target for blocking the IgE-mediated 
allergic reactions. We have selected several short peptides interacting with IgE with a 
dissociation constant in the low micromolar range but with a very high selectivity for 
this immunoglobulin subclass. We have evaluated their kinetic and thermodynamic 
properties and assessed the capacity to block the interaction of IgE with a 
recombinant variant of the receptor second domain. Despite the relatively low affinity, 
these peptides have a potential applicability as modulators of the IgE-FcεRI 
interaction and therefore as new molecules to be developed for contrasting allergy. 
 
In a second study, we have studied a homotypic protein-protein interaction 
mediated by specific α-helical domains, known as Capase Recruitment Domains 
(CARD). We have studied the CARD of the protein BCL10, a main regulator of the 
innate immune response that is a component of the CBM (CARMA1-BCL10-MALT1) 
protein complex, by which it promotes the activation of the NF-κB transcription factor.  
In this case, we have studied a very short peptide derived from the protein 
structure, which is able to block the protein self-interaction. The peptide has been 
selected by functionally ranking CARD-CARD antagonists by a binding competition 
assay between differently tagged recombinant domains. The antagonists have been 
prepared by enzymatically digesting the CARD itself and fractionating the resulting 
peptides. Using synthetic peptides, we have been able to identify single residues 
involved in CARD-CARD contacts. The peptide appears to mimic the protein binding 
interface and is a useful and effective inhibitor of the BCL10 activity in cellular 
assays. 
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  CHAPTER I 
  
I.1 PEPTIDES AS MODULATORS OF PROTEIN-PROTEIN 
INTERACTIONS 
 
Protein-protein interactions play a central role in many cellular functions, including 
DNA replication, DNA transcription and translation, signal transduction, and in 
metabolic pathways [1]. 
One of the main challenges in biotechnological research is the use of enzyme active 
sites as templates for the design of antagonists. Developing inhibitors of protein–
protein interactions is a far more complicated process that involves a numerous 
factors. Firstly, the interfacial surface area necessary for specific recognition is 
typically large (approximately 750–1500 Å2), suggesting that large ligands may be 
required to compete effectively with the natural protein partner, as opposed to ‘drug-
like’ small molecules that have been successfully utilized in enzyme inhibition. 
Secondly, interaction surfaces are often shallow and relatively featureless, rather 
than the well-defined binding pockets present in enzyme active sites, making the 
design of selective inhibitors difficult. Thirdly, the binding regions of protein–protein 
interactions are often non-contiguous, so that mimicry of these domains is not 
possible by simple synthetic peptides or peptidomimetics. In addition, the adaptively 
of the protein surfaces involved in protein–protein interactions suggests that there 
may be binding conformations suitable for small molecules that are invisible in a 
single crystal structure, thereby the design of suitable and effective binders can be a 
very difficult task. Finally, unlike enzyme activity that may simply be monitored by 
commercially available assays, novel and efficient screening assays must be 
developed for the interaction between proteins [1-6]. 
The identification of peptides based on the amino acid sequences found at protein-
protein interfaces can be an excellent and straightforward way to obtain new leads 
for antagonist development, indeed a lot of inhibitors based on the design of 
molecular scaffolds, on protein surface mimetics, alpha-helical mimetics, beta-sheet 
or beta-strand mimetics, as well as beta-turn mimetics, have been successfully 
utilized to modulate protein-protein interactions involved in a number of diseases, 
including cancer and HIV [3,4]. 
The topic of the present thesis work is focused on the identification of small peptides 
that modulate protein-protein interactions. 
 
The first part of the study is focused on the design of inhibitors of the IgE-FcεRI 
interaction, one of the main target for blocking the IgE-mediated allergic reactions. 
Indeed, the determination of Fc-IgE–αFcεRI complex crystal structure has elucidated 
their interactions at the atomic level and has provided a detailed description of the 
complex interaction interface and the role of any single amino acid in complex 
formation, thus opening the way to the design of peptides and “peptidomimetics” 
antagonists [7]. Following a de novo design approach, based on the complex crystal 
structure, we have selected several peptides interacting with the IgE with an activity 
in the low micromolar range. We have evaluated their binding activity assessing 
affinity and selectivity and have assessed their potential applicability as modulators of 
the IgE-FcεRI interaction. 
 
 9 
In the second part, we have studied a homotypic protein-protein interaction mediated 
by specific α-helical domains, known as Capase Recruitment Domains (CARD). We 
have studied the CARD of the protein BCL10, a main regulator of the innate immune 
response that is a component of the CBM (CARMA1-BCL10-MALT1) protein 
complex by which it promotes the activation of the NF-κB transcription factor [8].  
In this case, we have selected a peptide mimetic of the protein self-interaction 
interface by enzymatically producing CARD fragments which have been functionally 
ranked as CARD-CARD antagonists by a binding competition assay between 
differently tagged recombinant domains. By this method, coupled with the use of 
synthetic peptides, we have been able to identify single residues involved in CARD-
CARD contacts and we have proved the concept that the peptides mimicking the 
interface are useful and effective inhibitors of the protein-protein self-interaction. 
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                                                                                                        CHAPTER II 
 
II. PEPTIDES MIMICKING THE HIGH-AFFINITY IgE 
RECEPTOR FcεRI 
  
II.1 INTRODUCTION 
  
The human immune system has been designed to protect the integrity of the host by 
maintaining homeostasis. When this homeostatic mechanism is disturbed through 
challenge from foreign invaders or altered self tissue, the immune system is activated 
to protect the host. 
A large spectrum of pathologies listed as allergic or atopic diseases are associated 
with the inappropriate activation of the immune system by environmental factors and 
affect nearly 20% of the world population [1]. 
In the past two decades an increase in cases has been observed predominantly in 
young people and linked to the Western lifestyle [2]. 
The reason why many patients are affected from particular hypersensitivities remains 
an open debate, but it is generally accepted that genetic and environmental factors 
synergistically influence patients’ susceptibility.  
The immune response involves the coordination of cellular and molecular defence 
mechanisms. The stimulation of the antiboby response leads to the production of 
antibody isotypes that are responsible in stimulating a variety of cellular responses 
from the activation of inflammatory pathways to the targeted killing of infected or 
cancerous cells. Fc receptors, expressed on all hemapoietic cells, play a crucial role 
in immune defense by providing a link between antibody-antigen complexes and 
cellular effector machinery [3]. The diversification in immune responses depends on 
the type of Fc receptor, their cellular localization and their affinities for various 
classes of antibodies. Several Fc receptors are belonging to the Immunoglobulins 
superfamily (Ig-like domain) and include FcεRI, specific for IgE antibodies. FcεRI has 
the highest affinity of all Fc Ig-like receptors with a binding constant in the 10-9 to 10-
10
 range for its ligand.  
Immunoglobulins E play a central role in allergic inflammatory processes such as 
anaphylaxis, allergic rhinitis, asthma and atopic dermatitis, but they are also 
associated with other different immune responses.  
Activation of eosinophils by FcεRI provides defence mechanisms against parasitic 
infection, whereas FcεRI on antigen-presenting cells can deliver IgE-bound antigen 
into MHC class II antigen-presentation pathways. 
Instead the binding of IgE to its high affinity receptor FcεRI, on mast cells and 
basophils, is a key step for allergic reactions.  
In the first phase of an allergic reaction, called sensitization phase, the contact with 
allergens leads to the abnormal production of allergen-specific IgE molecules by B 
cells and this depends partially on genetic predisposition. In normal people the serum 
concentration of IgE, 50–300 µg/mL, is the lowest of all antibodies. 
The produced allergen-specific IgE circulate in the body in a free form able to bind 
cell surface receptors. In a further step, the clustering of multivalent antigens leads to 
the crosslinking of the receptor–bound IgE that induces (its activation) the immediate 
phosphorylation of ITAM motifs in its β and γ chains. In fact, cellular activation is 
brought about by the rapid release of chemical mediators, such as histamine and the 
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biosynthesis of leukotrienes and prostaglandins acting later in the inflammatory 
cascade [4]. 
FcεRI plays an important role in both phases of the allergic reaction. The presence of 
FcεRI-bound IgE may affect mast cell physiology, even in the absence of antigen. 
Recently, it has been observed that monomeric IgE can stimulate mast cell survival 
through signalling pathways that are distinct from those activated by receptor cross-
linking [5,6]. The mechanisms adopted by monomeric IgE to bind to FcεRI stimulating 
mast cell survival is still far from being fully clarified. 
Current pharmacological therapy suggests the use of corticosteroids to control 
inflammation, antihistamines and sympathomimetics to treat other symptoms. They 
are not always effective in allergic diseases and have some side effects [6].  
Allergen immunotherapy (desensitisation) is effective for some allergic disorders too, 
such as pollenosis and insect allergy, but not for others, such as eczema, food allergy 
and asthma. However the use of the immunotherapy is recently decreasing.  
The broad spectrum of different allergy reactions and the side effects caused by 
many symptomatic anti-allergic drugs have increased the interest in the development 
of new alternative therapeutic strategies. 
A challenging strategy consists in the identification of molecules able to prevent IgE-
FcεRI binding and, consequently, activation of the FcεRI receptor. The proof-of-
concept that an anti-IgE therapy has a strong efficacy for the treatment of allergic 
asthma has been demonstrated by the commercialization of the humanized 
recombinant monoclonal anti-IgE antibody, rhu Mab 25 (generic name, Omalizumab; 
trade name, Xolair). Omalizumab is a monoclonal antibody identified using 
conventional somatic cell hybridization techniques. Through this process, 
researchers have identified a murine monoclonal anti-human IgE antibody, MAE11, 
directed specifically toward the IgE-Cε3 domain which is involved in receptor 
engagement. MAE11 was then humanized in a process involving transplantation of 
the complementarity-determining regions (CDRs) onto a human IgG1 antibody 
framework. Additional MAE11 amino acid sequences were also incorporated into the 
humanized antibody to maintain the correct CDR conformational arrangement. This 
process resulted in a humanized monoclonal antihuman IgE antibody, rhuMAb-E25, 
containing approximately 5% non-human amino-acid residues [7-9]. This 
biotechnological drug has been approved for the treatment of moderate and severe 
forms of IgE-mediated allergic asthma and represents a new class of mast cells-
stabilizing drugs that inhibit IgE function by blocking or reducing their binding to 
cellular receptors.  
Considerable interest is currently focused on the study of FcεRI as regards the 
antigen-independent FcεRI-mediated biological responses (upstream regulation) and 
the distinct signalling of FcεRI-activated pathways and its tight control through 
inhibitory mechanisms (downstream regulation) [10]. 
Most of our knowledge is provided by structural biology. The crystal structures of the 
high affinity IgE receptor, the Fc-IgE and the complex of these two proteins have 
clarified their interactions at the atomic level [11] and the mechanisms adopted by 
this family of antibody receptors to achieve specificity and affinity has been 
elucidated unveiling an individual residue involved in the interaction. All of this 
information allows a targeted manipulation of the Fc specificity and affinity for 
receptors and, most importantly, the engineering of new antagonistic molecules of 
potential therapeutic interest. 
The main goal in this field would thereby be the design of inhibitors of the IgE-FcεRI 
interaction that block the IgE-mediated allergic reactions and the identification of 
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small peptides reproducing the binding interface and interacting with either the Fc-
IgE or the receptor could be a valuable starting point for further development in 
combination with medicinal chemistry strategies [12,13]. Attempts of using the 
soluble extracellular domain (ECD) of the FcεRI receptor have also been reported 
and the data indicate that it is a promising candidate for this application [14-19]. 
 
II.1.2 The high–affinity IgE receptor: FcεRI  
 
FcεRI is a multimeric cell-surface receptor that binds the Fc fragment of IgE with high 
affinity (KD=10-9-10-10). It plays a central role as the initial “docking station”, providing 
the starting signal for the allergic signal transduction cascade.  
Two isoforms have been described for FcεRI, a tetrameric and a trimeric complex, 
with different cellular distribution and biological function (Fig.1).  
The αβγ2 isoform is constitutively expressed on mast cells and basophils and activate 
the immediate-type hypersensitivities associated with the allergic responses. 
The αγ2 isoform, expressed on monocytes, eosinophils, Langherans cells in the 
pancreas and on the surface of dentritc cells, is responsible of for antigen 
presentation (anti-parasitic immunity).  
Although rodent FcεRI has obligatory αβγ2 tetrameric structure, both tetrameric and 
trimeric structures are expressed for the human variant [10,20,21]. 
FcεRI is specific for the ε isotype immunoglobulin, but it is not completely species 
specific. Murine IgE indeed bind to both murine and human FcεRI, whereas human 
IgE bind only to human FcεRI [10,22].  
The FcεRI tetrameric receptor complex consists of one alpha (αFcεRI), one beta 
(βFcεRI), and a homodimer of disulphide linked γ-chains (γFcεRI). 
A combination of hydrophobic and electrostatic non covalent interactions builds up 
the complex in the plasma membrane by keeping α, β, and dimeric γ together and 
involves lipids binding. 
The α-chain belongs to the immunoglobulin super-family and comprises two 
extracellular immunoglobulin-related domains binding a single IgE molecule, a 
transmembrane domain containing a conserved aspartic acid residue and a short 
cytoplasmatic tail. The human α-chain contains seven potential N-glycosylated sites. 
These sites are not intrinsically necessary for proper folding of the α-chain but are 
required in the endoplasmic reticulum to mediate the proper interaction between the 
α-chain and the ER folding machinery [23]. The intracellular tail of the α-chain has no 
apparent signalling function.  
The FcεRI β and γ-chains possess an immunoreceptor tyrosine-based activation 
motif (ITAM). The tyrosine residues, contained in this motif, are phosphorylated when 
antigen crosslinking of receptor-bound IgE molecules occurs. ITAM motifs activate 
down-stream signal propagation by recruiting and activating the Src kinase family 
[10]. 
Despite numerous studies on the structure and function of the FcεRI its physiological 
relevance is still an open question.  
Tetrameric FcεRI (αβγ2), expressed in mast cells and basophils, is well known as a 
key regulator of IgE-mediated immediate-type allergic reactions and late-phase 
allergic reactions (Fig.1). Upon crosslinking of FcεRI by IgE and antigen, a signalling 
cascade leads within minutes, through degranulation, to the release of preformed 
mediators, such as histamine, and lipid-mediator synthesis. These events produce an 
immediate-type allergic reaction characterized by vasodilatation, increased vascular 
permeability, up-regulation of vascular adhesion molecules and bronchoconstriction. 
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Upon prolonged stimulation, a late-phase allergic reaction is induced, leading in 
addition to cytokine and chemokine production and inducing the recruitment of 
inflammatory cells and T-cell activation [24,25].  
On the other hand, the antigen-independent effects, mediated by IgE binding to 
tetrameric FcεRI, may result in increased survival of the cell [26,27]. 
Trimeric FcεRI (αγ2), expressed by professional APCs (as Langerhans cells), 
monocytes and macrophages, has a role in the process of allergen presentation and 
a pro-inflammatory function in allergic patients (Fig.1). Crosslinking of trimeric FcεRI 
by IgE and antigen leads to the endocytosis of FcεRI and IgE-bound antigen, 
followed by their uptake in MHC-class-II-rich compartments. In this case the antigen 
processing and loading of antigenic peptides onto MHC class II molecules occurs, 
and ultimately, the presentation of the antigenic-peptide–MHC-class-II complexes to 
T cells.                
     
 
 
On the mast-cells and basophils the antigen crosslinking of FcεRI-bound IgE, initiates 
a complex intracellular signalling cascade, which ultimately leads to effector functions 
[28,29]. 
Recent works have been focused on the separation of proximal FcεRI signalling into 
a primary pathway and a complementary pathway that mainly regulates FcεRI-
induced degranulation (Fig.2). In the basic proximal FcεRI signalling events the β- 
and γ-chains of FcεRI, after tyrosine phosphorylation of ITAMs motifs, bind the SH2 
domains of protein tyrosine kinases (PTKs), mainly those of the SRC kinase family 
as LYN, FYN and SYK. 
 
 
 
Figure 1: Composition of the tetrameric and trimeric FcεRI complex and biological functions: A) 
The tetrameric form consists of one IgE-binding α-chain with two immunoglobulin-like domains in 
the extracellular part, one β-chain and two γ-chains with intracellular immunoreceptor tyrosine-
based activation motifs (ITAMs) for signal transduction. Tetrameric FcεRI is expressed by mast 
cells and basophils. B) The trimeric form lacks the β-chain and is expressed by APCs and 
eosinophils [10]. 
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II.1.3 Structural insights into the interactions between human IgE 
and its tetrameric high affinity receptor FcεRI 
 
Structural studies to elucidate the regions of FcεRI critical for the interaction with IgE 
molecules have been reported by Jardetzky et al. [11] 
The crystal structure of Fc-IgE-αFcεRI shows that the N-terminal region of the αFcεRI 
chain is made up of two “Ig-like domains” called D1 and D2 (Fig.3). These domains 
form a very pronounced acute angle like an inverse V, and the convex surface, 
comprising the D2 domain, constitutes the binding interface with the IgE [11].  
D1 and D2 domains are oriented in a nearly anti-parallel arrangement, with the N- 
and C-terminal part on the same side of the receptor structure. This arrangement 
reveals an unusual grouping of four surface-exposed tryptophans at the top of the 
D1–D2 interface (“tryptophan ridge”) involved in antibody-binding interactions. An 
extensive packing interface forms part of the core fold of the overall structure and 
contributing to its stability. 
Although the D1 domain is not directly involved in the binding with the IgE, it 
structurally contributes to the high affinity maintenance [30]. 
The structural analysis of the Fc-IgE-αFcεRI shows the two Cε3 domains of the Fc-
IgE interact with two different surfaces of αFcεRI (referred to as binding site 1 and 2). 
Each IgE heavy chain contains four constant domains (Cε1–Cε4) but only Cε3 
domain and the linker Cε2–Cε3 domains are directly involved in the interaction with 
αFcεRI. The Cε4 domains of the Fc-IgE provide a structural dimerization scaffold that 
allows two Cε3 domains to form the bivalent interaction with αFcεRI. The Cε2–Cε3 
IgE linker residues adopt an asymmetric, arch-like structure over the top of the 
Figure 2: FcεRI signalling: A) In the primary pathway LYN activation leads to SYK association with 
γ-chains and subsequent SYK activation. Activated SYK allows classical PKC activation and Ca2+ 
mobilization which, ultimately leads to degranulation; B) In the complementary pathway, FYN and 
SYK activation induce a signalling complex which activates PKCδ, ultimately leading to 
degranulation [10]. 
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receptor, while the lower domains Cε4 point away from the interaction site and 
possibly away from the membrane surface [11].  
There are N-linked oligosaccharides in both the Fc-IgE and αFcεRI, but they do not 
contribute significantly to interactions between the two molecules [31,32]. 
Carbohydrate attached to the conserved site (N394 in IgE), lies along the inner face 
of the Cε3 domains (strands A, B and E) similar to that observed in structures of Fc-
IgG. Carbohydrates attached to residue N42 in αFcεRI extends upwards to the top of 
the D1–D2 interface approaching one of the Fc-IgE chains.  
Carbohydrate residues are attached to N21 and N166 of αFcεRI, projecting from the 
receptor surface away from the IgE-binding interface. 
 
                
 
The two distinct binding sites use overlapping but non-identical sets of Fc-IgE 
residues (Fig.4).  
 
Site 1 refers to the interaction of one Cε3 domain with the C–C' region of the receptor 
D2 domain, centered around receptor residue Y131. Twelve amino acids from the 
Fc-IgE and eight amino acids from the αFcεRI form site 1, burying a total of about 
860 Å 2 of surface area. The IgE residues are from four distinct regions of the IgE-Fc 
sequence, including the Cε2–Cε3 linker (residues 334–336), the B-C loop (362–365), 
the D-E loop (393–396) and the F-G loop (residue 424) of Cε3 domain. The receptor 
residues derive from two regions of the D2 domain, involving the C strand (residues 
K117, I119 and Y121) and the C'–E loop (residues A126, Y129, W130, Y131 and 
E132). Two potential salt bridges (αK117–Cε3D362 and αE132– Cε3R334) and four 
potential hydrogen bonds (αK117–Cε3G335, αY129-Cε3D362, αY131–Cε3D364 and 
αY131–Cε3H424) are formed across the site 1 interface. Y131 from the receptor 
Figure 3: Side view of the crystal structure of the Fc-IgE-αFcεRI complex: the two Fc chains are in 
yellow and red, the αFcεRI chain is in blue. Carbohydrate residues are shown as sticks in the same 
colour as the protein chain. Binding sites 1 and 2 are indicated. The cell membrane would lie below 
the receptor [11]. 
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projects into a pocket on the Fc-IgE formed by the B-C, D-E and F-G loops of Cε3 
and the Cε2–Cε3 linker [11]. 
 
Site 2 refers to the interaction of the second Cε3 domain with the D1–D2 interface, 
and involves the cluster of four surface-exposed tryptophans (W87, W110, W113 and 
W156). Interactions at site 2 bury about 970Å2, including ten amino acids from IgE 
and eight from αFcεRI. The IgE residues are localized to two distinct segments of 
Cε3: the Cε2–Cε3 linker region (residues 332–337) and the F-G loop (424–427). The 
αFcεRI contributes residues from three regions: the D1–D2 linker region (85–87); B-
C loop (residues 110 and 113) and F-G loop (156–158) of D2 domain. Residues from 
the D1 domain of the receptor do not form direct interactions with the Fc-IgE. Site 2 
primarily contains hydrophobic amino acids with three potential hydrogen bonds 
across the interface (αW156– Cε3G335, αQ157– Cε3N332 and αQ157– Cε3R334) 
[11]. P426 from the Fc-IgE intercalates between receptor residues W87 and W110, 
forming a hydrophobic proline sandwich. Interactions with αFcεRI cause the Cε2–Cε3 
linker regions to point up and away from the complex interface. The Cε4 domains are 
not directly involved in binding to αFcεRI but act as a scaffold, allowing the Cε3 
domains to assume an appropriate orientation for αFcεRI binding [11]. 
 
 
 
Residues forming the Fc-IgE-αFcεRI interface in site 1 are generally poorly 
conserved (Fig.5A). Three residues are completely conserved (G335, D362 and 
N394 of IgE) in the Fc-IgE sequences, but there is poor conservation in the receptor 
sequences, except for the partial conservation of K117 and the relatively conserved 
Y129. 
Figure 4: Structural basis for the 1:1 binding of Fc-IgE to αFcεRI. The Fc-IgE-αFcεRI complex has 
been taken apart to display the interaction sites. Fc-IgE domain strands and αFcεRI strands in D1 
and D2 are labelled. The Fc-IgE binding residues are shown as sticks in yellow (site 1) and red (site 
2); the D1-D2 linker and D2 binding residues are in blue [13]. 
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The conservation of K117 in three of the four FcγRs receptors matches the complete 
conservation of D362 and G335 in the Fc-IgE sequences, potentially preserving one 
of the two salt bridges and one of the hydrogen bonds of site 1. 
The conservation of Y129 (αFcεRI) as tyrosine or phenylalanine in Fc-IgG, suggests 
that this interaction may be conserved in Fc-IgG complexes with the FcγRs.  
However, Y131 of αFcεRI, which forms a large number of atomic contacts across the 
interface and is buried in a shallow surface pocket on the Fc-IgE, is not conserved in 
the FcγRs (changing to either histidine or arginine). Given the central location of 
Y131 in the site 1 interface, this residue may generally be important in 
immunoglobulin specificity. Four of the five residues that contact Y131 in IgE change 
in the Fc-IgG sequences.  
In the site 2, G335, P426 and L425 in the antibody sequence are absolutely 
conserved (Fig. 5B). In particular P426 interacts with two absolutely conserved 
tryptophans in αFcεRI (W87 and W110), which form a hydrophobic pocket. These 
residues in the Fc-IgE (residues 332–334) interact with the F-G loop of αFcεRI. For 
site 2, the conservation of five residues and the additional functional data suggest a 
conserved binding mode across these members of the FcR family [11]. 
 
 
 
Figure 5: Conservation of amino-acid residues and contacts at the Fc-IgE-αFcεRI interfaces in IgG 
receptors and antibodies. Contacting residues are defined as inter-atomic distances less than 4 Å. a) 
Residues that interact in site 1, and their conservation in related human receptors and antibodies. 
Absolutely conserved residues are highlighted in bold, and partially conserved residues are lightly 
highlighted (yellow for IgE, blue for αFcεRI). Dark lines are drawn for residues making the largest 
number of contacts across the interface, lighter lines for intermediate numbers of contacts, and 
dashed lines for the fewest contacts [11]. b) Residues that interact in site 2, and their conservation in 
related human Fc receptors and antibodies. Receptor residues are highlighted in blue, antibody 
residues in red. Three residues in IgG2 (P, V, A) that affect binding to FcγRs are boxed in black [11]. 
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The crystallographic structure of Fc-IgE-αFcεRI complex reveals a 1:1 stoichiometry, 
in contrast with models proposing a 1:2 stoichiometry for the homologous Fc-IgG 
receptors FcγRIIa and FcγRIIb [11,33-37]. 
The formation of complexes with 1:1 stoichiometry is supported by two structural 
keys: the induction of structural asymmetry in the Cε2–Cε3 linker of Fc-IgE and the 
steric hindrance blocking the binding of a second receptor.  
The Cε2–Cε3 linker regions (residues 328–336) are constrained to an asymmetric 
arrangement by interactions with αFcεRI. The amino acids of the Cε2–Cε3 linker form 
the top of an arch that conforms to the convex surface of αFcεRI, creating an 
asymmetric binding site for a single receptor. 
In addition, four IgE residues (R334, G335, V336 and H424) are common to both 
sites 1 and 2, preventing the simultaneous binding of two receptors to one Fc-IgE. 
Superposition of a second receptor onto the 1:1 complex shows significant steric 
overlap between receptors and the amino acids of the Cε2–Cε3 linker. 
Thus, the binding of one receptor effectively prevents the binding of a second, owing 
to both the induced asymmetry of the Cε2–Cε3 linker of the Fc-IgE and the steric 
inhibition across the Fc dyad axis.  
 
Furthermore the structure of free Fc-IgE shows that the IgE receptor-binding domains 
can undergo a large conformational rearrangement. The Fc domain conformational 
flexibility allows IgE to adopt an “open form” in Fc-IgE-αFcεRI complex and a “closed 
form” when it is free. In the free Fc-IgE crystal structure, the Cε2–Cε3 inter-domain 
angle is more acute than that observed in Fc-IgE-αFcεRI [38,39]. 
Analysis of the αFcεRI structure, in several crystal forms, shows little conformational 
change in the angle between D1 and D2 in the absence of the Fc-IgE and on 
complex formation with the Fc-IgE [38]. The C' strand in the D2 domain (residues 
127–133) shows an unusual conformational adaptability perhaps due to exposed 
aromatic residues (Y129, W130, Y131). The B-C loop in D1 also adopts different 
conformations in different crystal forms, but this region is distal to the Fc-IgE binding 
site [38]. 
 
Multiple binding and dissociation steps for the interaction of the Fc-IgE with αFcεRI 
have been observed using surface plasmon resonance methods. Two association 
and dissociation steps (a fast on/off and a slow on/off) have been detected and 
investigated with substantial experimental controls, leading to the conclusion that the 
binding of the Fc-IgE to the αFcεRI is better represented using a biphasic model 
[19,32,40,41].  
The mechanism underlying the biphasic kinetics remains to be clarified. The 
interaction of each Cε3 domain with distinct surfaces of the αFcεRI structure 
suggests a kinetic scheme in which transient release of one of the Cε3 domains may 
occur within the complex. This could lead to two distinct pathways for the association 
and dissociation of the complex, consistent with the experimental observation of two 
distinct kinetic off-rates. Transient opening of the complex may allow inhibitors to 
enhance the dissociation of receptor-bound IgE by preventing the rebinding of an 
exposed Cε3 domain within the complex. These kinetics may reflect the observations 
that Fc-IgE may adopt both binding (open) and non-binding (closed) conformational 
states in solution [42,43]. For example, in solution the FcεRI-binding loop residues 
would be inaccessible in the closed Fc-IgE conformation, which could interfere with 
receptor binding. Initial interactions might be primarily through the flexible Cε2–Cε3 
linker residues in this IgE conformation. In the open IgE conformation, the receptor 
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binding loops could engage the receptor directly, followed by adaptation of the linker 
region to the receptor, leading to a distinct kinetic rate.  
Alternatively, the binding of IgE sequentially to binding site 1 and then to binding site 
2 may have distinct kinetic rate as compared to sequential binding to binding site 2 
and then to binding site 1. The two dissociation rates of the Fc-IgE may also result 
from distinct disassembly pathways in which bound Cε3 domains are released 
sequentially, with individual microscopic rate constants. The observed flexibility of the 
Fc-IgE structure and the interaction sites on the receptor for each Fc chain are 
consistent with dynamic models for the local dissociation of each antibody chain in 
the complex. If the two Cε3 domains bind independently, with transient exposure of 
each site in the complex, inhibitors for either site 1 or site 2 could potentially 
accelerate the dissociation of receptor-bound IgE. 
 
 
II.2 PROJECT AIMS 
 
The demonstrated efficacy of the drug Omalizumab against allergic asthma is 
pushing research towards the identification of new molecules that can similarly 
regulate IgE-receptor signalling. Smaller molecules, with less antigenic properties 
and without the economical drawbacks typical of large molecules such as antibodies, 
are being studied and developed by combinatorial [12] as well as rational drug design 
approaches [13]. 
The atomic description of the receptor-immunoglobulin interaction interface has 
provided insights on the structural relevance of amino acids directly responsible of 
such interactions, opening the way to peptidic and peptidomimetic design [11]. 
The first part of this thesis is devoted to the selection of new molecules that 
specifically bind IgE and that displace its binding with the high affinity receptor. These 
molecules can indeed be used as efficient tools for the development of more potent 
and selective new chemical entities (NCE) for the modulation of allergic responses. 
Two parallel strategies have been employed. 
The first was based on a de-novo design of IgE-binding polypeptides using the 
receptor structure as template. Several polypeptides have been designed, chemically 
prepared and tested as binders of the immunoglobulins, assessing affinity and 
selectivity. Furthermore, following an approach of progressive size reduction, the 
sites that underlie the recognition between IgE and the polypeptide will also be 
determined.  
In a second approach, the extracellular domain of the hαFcεRI, was expressed 
as a soluble and active recombinant protein and evaluated as IgE binder and 
receptor antagonist. The soluble receptor or functional domains, produced as 
recombinant products in a stable form, could be employed as a high affinity 
biotechnological drug with antagonistic activity for the membrane-bound receptor. 
Binding assays between the soluble receptor and IgE can also be used as tools for 
the selection of new molecules by screening repertoires of synthetic molecules. 
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II.3 EXPERIMENTAL PROCEDURES 
 
II.3.1 Materials  
 
Human αFcεRI cDNA was kindly provided by Prof. J.P. Kinet from the Harvard 
Institutes of Medicine (Boston, Massachusetts, USA). 
pETM vectors for the expression of recombinant proteins are from EMBL 
(Heidelberg, Germany) and pGEX vector are from GE Healthcare (Uppsala, 
Sweden). Oligonucleotides were synthesized by Sigma-Genosys (Sigma-Aldrich, 
Milano, Italy). Pfu DNA polymerase is from Stratagene (Milano, Italy). Restriction 
enzymes are from New England Biolabs (Milano, Italy). All molecular biology kits are 
from Qiagen (Milano, Italy). Escherichia coli bacterial strains are from Novagen 
(Milano, Italy), except for TOP10F’ that are from Invitrogen (Milano, Italy). Isopropyl-
beta-D-thiogalactopyranoside (IPTG) is from Inalco (Milano, Italy). Reagents for 
bacterial medium are from Becton-Dickenson (Milano, Italy). Perfect Protein Marker 
is from Novagen and See Blue Pre-stained Marker is from Invitrogen. PreScission 
protease, SDS-PAGE reagents, chromatography columns and AKTA FPLC are from 
GE HealthCare (Milano, Italy). 4-Vynyl pyridine (4-VP), mouse monoclonal anti-
dinitrophenol immunoglobulins E (IgE), 2,4-dinitrophenol-conjugated human serum 
albumin (DNP-HSA) and o-phenyldiamine (OPD) table sets, reduced and oxidized 
glutathione, are from Sigma-Aldrich (Milano, Italy). Anti-poly-Histidine (His-probe)-
HRP conjugated is from Santa Cruz Biotechnology (California, USA). Trans Blot SD 
semi-dry, blotting grade blocker Non-Fat Dry Milk (NFDM) and Opti-4CN goat anti-
mouse (GAM) detection Kit are from Biorad.  
BIAcore system and reagents are from Pharmacia Biosensor AB (Uppsala, 
Swedens). 
For peptide synthesis, protected Nα-Fmoc-amino acid derivatives, succinic anhydride, 
ethylenediamine, coupling reagents and Rink amide MBHA resin have been 
purchased from Calbiochem-Novabiochem (Laufelfingen, Switzerland). DIEA is 
provided from Applied Biosystem (Foster City, CA). All other reagents and chemicals 
are commercially available from Sigma-Aldrich.  
Analytical characterization of synthetic peptides and recombinant proteins have been 
performed on an LC-MS system comprising an LCQ DECA XP ion trap mass 
spectrometer (ThermoElectron, Milan, Italy) equipped with an OPTON ESI source 
(operating at a needle voltage of 4.2 kV and 320°C temperature) and a complete 
Surveyor HPLC system (including MS pump, autosampler and photo diode array 
[PDA]). Preparative purification of synthetic peptides has been carried out on a 
Shimadzu LC-8A, equipped with a SPD-M10 AV detector.  
CD spectra were recorded using a Jasco J-810 spectropolarimeter (JASCO Corp) 
equipped with a Peltier-type temperature control system.  
UV-VIS spectra were performed by using a UV-VIS Jasco (Easton, MD) model 440 
spectrophotometer with a path length of 1 cm.  
Other reagents and chemical suppliers are indicated in the section of methods. 
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II.3.2 Methods 
 
II.3.2.1 Cloning of hFcεRI α-chain 
 
hFcεRI was amplified as full-length [101-897nt], D1-D2 domains [176-685nt] and D2 
domain [425-685nt] by PCR from the cDNA of hαFcεRI (sequence code NM_002001 
from PubMed) using Pfu polymerase with the oligonucleotides reported in the Table 
XIV. The amplified DNA was hydrolyzed in the presence of BsmBI and XhoI enzymes 
for pET vectors and BamHI and XhoI for the pGEX vector [44]. The digested 
fragments were extracted from 1.2% agarose gel using QIAquick Gel Extraction Kit 
and cloned into the corresponding vectors reported in table I, previously digested and 
dephosphorylated. Ligation products were electroporated into TOP10F’ and 
recombinant colonies were selected by PCR. Each expression vector from positive 
clones was isolated using QIAprepSpin Miniprep kit. All plasmids and expression 
vectors were generated by standard procedures and confirmed by sequencing. 
 
            
    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hFcεRI full-length 
oligonucleotides sequence 
 
vector 
 
Tm 
 
5’-CGCGCGCGTCTCCCATGGCTCCTGCCATGGAATCCCCT-3’ 
          BsmBI 
 
5’-CGCGCGCTCGAGTTACTAGTTGTTTTTGGGGTTTGGCTTAGGA-3’ 
           XhoI    *      * 
 
pETM11 
pETM40 
pETM52 
 
 
54°C 
 
5’-CGCGCGCGATCCCCATGGCTCCTGCCATGGAATCCCCT-3’ 
          BamHI 
 
5’-CGCGCGCTCGAGTTACTAGTTGTTTTTGGGGTTTGGCTTAGGA-3’ 
                         XhoI      *      * 
 
 
 
pGEX 
 
 
 
56°C 
 
5’-CGCGCGCGTCTCCCATGGCTCCTGCCATGGAATCCCCT-3’ 
          BsmBI 
 
5’-CGCGCGCTCGAGGTTGTTTTTGGGGTTTGGCTTAGGA-3’ 
          XhoI   
 
 
pET22 
 
 
54°C 
D1-D2 domain 
oligonucleotides sequence 
 
vector 
 
Tm 
 
5’-CGCGCGCTCGAGTTACTATATTACAGTAATGTTGAGGGG-3’  
                        Xho I       *      * 
 
5’-CGCGCCCGTCTCCCATGGTGTTAGCAGTCCCTCAG-3’ 
                          BsmBI 
 
 
pETM11 
 
 
54°C 
D2 domain 
oligonucleotides sequence 
 
vector 
 
Tm 
 
5’-CGCGCGCTCGAGTTACTATATTACAGTAATGTTGAGGGG-3’    
                       Xho I        *      * 
 
5’-CGCGCGCGTCTCCCATGTTCAGTGACTGGCTGCT-3’ 
                           BsmBI 
 
 
pETMA11 
pETM40 
 
 
56°C 
Table I: PCR primers used for the construction of expression of the: A) hFcεRI α chain full-length; 
B) D1-D2 domain of hαFcεRI C) D2 domain of hαFcεRI. The site of enzyme restriction is 
underline and the stop codons are asterisked.      
A 
C 
B 
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II.3.2.2 Expression screening for full-length hFcεRI α-chain  
 
Optimal expression conditions were selected for each recombinant protein, by 
performing a complete screening in several E.coli strains, using different induction 
time, different temperatures and inducing agent concentration. 100 ng of expression 
vector were chemically transformed into E. coli competent cells from the following E. 
coli strains: Bl21 (DE3), Bl21 (DE3)pLysS, Bl21star (DE3), Bl21star (DE3)pLysS and 
Origami (DE3). Recombinant colonies were grown in 1.5 mL LB medium up to 0.6 
OD/mL at 37°C and when expression was induced with different IPTG concentrations 
(0.1 mM, 0.2 mM, 0.5 mM and 1 mM) for different times and temperature (22°C and 
37°C). Bacterial cultures were harvested, lysed and purified in batch using 
appropriate affinity resin. QIAgen Ni-NTA Magnetic Agarose Beads for His6x-tag, 
Amylose resin (Biolabs, New England) for MBP-tag and Glutathione Sepharose 4B 
resin (GE Healthcare) for GST-tag following the standard instructions of producers. 
15 µL total and soluble fractions from the lysates were re-suspended in 5 µL SDS-
Loading buffer (Tris-HCl 50 mM, SDS 1%, blue bromophenol 0.1%, glycerol 10%, pH 
6.8) and analyzed on SDS-PAGE. For each recombinant protein the optimal 
expression conditions were selected. 
 
II.3.2.3 Purification of full-length His6x-αchain  
 
Full-length hFcεRI α-chain was expressed with an N-terminal His6x-tag using the 
vector pETM11 and the recombinant protein expression was optimised in Bl21star 
(DE3) inducing with 0.2 mM IPTG for 16 h at 22°C. The pellet obtained from 100 mL 
of bacterial culture was re-suspended in 5 mL cold lysis buffer (30 mM Tris–HCl, 150 
mM NaCl, 6 M UREA, pH 8.0) supplemented with protease inhibitor mixture (1 mM 
PMSF, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin and 1 mg/mL 
lysozyme) and incubated at R.T for 30 min. Cells were disrupted by sonication in ice 
using 10” on / 10” off cycles for 10 min. in total. The lysate was then centrifuged for 
30 min. at 4°C at 15 krpm. The supernatant was loaded on a 1 mL His-Trap HP 
column, previously equilibrated with buffer 1 (30 mM Tris-HCl, 500 mM NaCl, 10 mM 
imidazole, 6 M urea, pH 8.0 buffer), using an AKTA FPLC chromatography system. 
The column was washed with buffer 1 and the bound protein was eluted using a 
linear gradient of imidazole from 10 mM to 500 mM in buffer 2 (30 mM Tris-HCl, 500 
mM NaCl, 500 mM imidazole, 6M urea, pH 8) in 30 min. Protein elution was 
monitored by measuring the absorbance at 280 nm. His6x-αchain full-length was 
eluted at 21% buffer 2 (350 mM imidazole). The total cell protein fraction, the soluble 
fraction (supernatant of cell lysate) and the purified fraction were analyzed by 10% 
SDS-PAGE. The full-length His6x-αchain was recovered in 30 mM Tris-HCl, 500 mM 
NaCl, 1 mM DTT and 6 M urea pH 8.0 and dialyzed, slowly decreasing urea 
concentration, up to 30 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 2 M urea, pH 8.0 
buffer. In order to increase the purity of full-length His6x-αchain, a further step of 
anionic exchange chromatography was performed on a Mono Q HR 5/5 column, 
integrated in an AKTA system, using a linear gradient from 10 mM to 500 mM NaCl 
in 30 min. The buffers are reported in table II:  
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Table II 
 
Full-length His6x-αchain eluted at 350 mM NaCl and showed a 60% purity grade. 
Fractions were analyzed by 10% SDS-PAGE.  
 
II.3.2.4 Purification of full-length GST-αchain  
 
Full-length hFcεRI αchain was expressed fused at its N-terminus with the GST-tag 
using the pGEX6P vector and the recombinant protein expression was optimised in 
Bl21 (DE3)trxB induced with 0.1 mM IPTG for 16 h at 22°C. 100 mL bacterial culture 
was pelleted and re-suspended in 5 mL cold lysis buffer (30 mM Tris–HCl, 150 mM 
NaCl pH 8.0) supplemented with the protease inhibitor mixture (1 mM PMSF, 1 
µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin and 1 mg/mL lysozyme) and 
incubated at room temperature for 30 min. Cells were disrupted by sonication in ice 
with 10” on / 10” off cycles for a total of 10 minutes. The lysate was then centrifuged 
for 30 min. at 4°C at 15 krpm and the supernatant loaded on a 1 mL Glutathione 
Sepharose 4B resin (GE Healthcare) in batch, previously equilibrated with buffer 1 
(30 mM Tris-HCl, 500 mM NaCl) [45]. The resin was extensively washed with buffer 1 
and the protein was eluted with 10 mM reduced Glutathione dissolved in 50 mM Tris-
HCl pH 8.0. The total cell protein fraction, the soluble cytoplasmic fraction 
(supernatant of cell lysate), and the purified fraction were analyzed by 12% SDS-
PAGE. 
 
II.3.2.5 Purification of full-length MBP-αchain  
 
Full-length hFcεRI αchain was expressed with an N-terminal MBP-tag using the 
vector pETM40 and the recombinant protein expression was optimised in Bl21 (DE3)  
inducing with 0.1mM IPTG for 16 h at 22°C. 100 mL bacterial culture was pelleted 
and re-suspended in 5 mL cold lysis buffer (30 mM Tris–HCl, 15 mM NaCl, pH 8.0) 
supplemented with protease inhibitor mixture (as described before) and incubated at 
room temperature for 30 min. Cells were disrupted by sonication in ice with 10’’ on / 
10’’ off cycles for a total of 10 min. The lysate was then centrifuged for 30 min. at 4°C 
at 15 krpm and the supernatant loaded on 1 mL of amylose resin (Biolabs, New 
England), previously equilibrated with buffer 1 (30 mM Tris HCl, 500 mM NaCl) [46]. 
The resin was washed extensively with buffer 1 and the protein was eluted with 10 
mM maltose dissolved in 30 mM Tris-HCl, 500 mM NaCl pH 8.0 buffer. The total cell 
protein fraction, the soluble fraction (supernatant of cell lysate) and purified fraction 
were analyzed by 10% SDS-PAGE.  
 
II.3.2.6 Purification of the periplasmatic full-length His6x-αchain and 
full-length Dsb-His6x-αchain.  
 
Full-length hFcεRI αchain was expressed within the periplasmatic space with N-
terminal His6x-tag and Dsb-His6x-tag using the pET22 and pETM50 vectors, 
Buffer A Buffer B 
30 mM Tris-HCl pH 8 
10 mM NaCl 
2 M UREA 
1 mM DTT 
30 mM Tris-HCl pH 8 
500 mM NaCl 
2 M UREA 
1 mM DTT 
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respectively [47]. Full-length His6x-αchain expression was optimised in Origami 
(DE3) inducing with 0.2 mM IPTG for 16 h at 22°C. A pellet from 500 mL bacterial 
culture was re-suspended in 10 mL cold lysis buffer (30 mM Tris–HCl, 20% sucrose, 
1 mM EDTA pH 8.0), supplemented with protease inhibitor mixture (1 mM PMSF, 1 
µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin) and incubated at R.T. for 20 
min. After centrifugation at 8 krpm for 10 min. at 4°C, the resulting pellet was re-
suspended in 5 mL of 30 mM Tris–HCl, 5 mM MgSO4, 10 mM DTT and 4 M urea, pH 
8.0 buffer. The supernatant was loaded on a 1 mL His-Trap HP column, previously 
equilibrated with buffer 1 (30 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole, 1 mM 
DTT, 4M urea pH 8.0), using an AKTA FPLC chromatography system. The column 
was washed with buffer 1 and the bound protein was eluted using a linear gradient 
from 10 mM to 500 mM imidazole in buffer 2 (30 mM Tris HCl, 500 mM NaCl, 500 
mM imidazole, 1 mM DTT, 4 M urea pH 8.0) in 30 min. Protein elution was monitored 
by measuring the absorbance at 280 nm and the full-length His6x-αchain was eluted 
at 16% buffer 2 (80 mM imidazole). The purified fractions were analyzed by 15% 
SDS-PAGE. The periplasmatic full-length His6x-αchain recovered in 30 mM Tris-HCl, 
500 mM NaCl, 1 mM DTT and 4 M urea pH 8.0 buffer was dialyzed, slowly 
decreasing urea concentration, up to 30 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 1 M 
urea pH 8.0 buffer. In order to increase the purity of the full-length His6x-αchain, a 
further step of anionic exchange chromatography was performed on a Mono Q HR 
5/5 column, integrated in an AKTA system, using a linear gradient from 10 mM to 500 
mM NaCl in 30 min. The buffers are reported in table IIII:  
                          
 
 
 
 
 
Table III 
Full-length periplasmatic His6xαchain was eluted at 250 mM NaCl with 90% purity 
grade and fractions were analyzed by 15% SDS-PAGE.  
The full length Dsb-His6x-αchain expression was optimised in Bl21(DE3) bacterial 
strain induced with 0.2 mM IPTG for 16 h at 22°C. The purification was carried out 
using the protocol already described. The full-length periplasmatic Dsb-His6x-αchain 
recovered, in 30 mM Tris-HCl, 500 mM NaCl, 1 mM DTT and 4 M urea pH 8.0 buffer, 
was then dialyzed against 30 mM Tris-HCl, 150 mM NaCl, 1 mM DTT pH 8.0 
maintaining its solubility in buffer with 1 M urea.  
 
II.3.2.7 Expression and purification of His6x-D1-D2 domain as 
inclusion bodies 
 
100 ng of the expression vector D1-D2 domain/pETM11 was chemically transformed 
in Bl21 (DE3), E.coli competent cells. The clone D1-D2/pETM11 was streaked onto 
LB agar plate containing kanamycin (50 µg/mL) and incubated at 37°C for 16 h. A 
single colony was used to inoculate 10 mL of LB medium containing kanamycin (50 
µg/mL) followed by incubation at 37°C in a shaking incubator. Ten millilitres overnight 
culture was then used to inoculate a further 1 L of LB-kanamycin and the culture 
growth continued in a 37°C shaker for approximately 3 h. When the optical density 
(OD), measured at 600 nm, reached the value 0.8, 1 mM IPTG was added (1 mL 
‘uninduced’ culture was taken for SDS-PAGE analysis). After 4 h induction at 37°C (1 
Buffer A Buffer B 
30 mM Tris-HCl pH 8 
10 mM NaCl 
2 M UREA 
1 mM DTT 
30 mM Tris-HCl pH 8 
500 mM NaCl 
2 M UREA 
1 mM DTT 
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mL ‘induced’ culture was taken for SDS-PAGE analysis), cells were harvested by 
centrifugation. The pellet obtained from 250 mL bacterial culture was re-suspended 
in 20 mL of lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 10 mM EDTA, 0.5 mM 
PMSF, 2 mM DTT, 10% glycerol, and 1 mg/mL lysozyme pH 8.0). The cellular lysate, 
incubated at R.T. for 30 min., was sonicated in ice for 10 min. (10’’ on / 10’’ off) and 
centrifuged for 20 min. at 10 Krpm. The supernatant was decanted and the inclusion 
bodies pellet was resuspended in 20 mL of washing buffer 1 (150 mM Tris–HCl, 150 
mM NaCl, Triton 1%, 5 mM DTT pH 8.0) and centrifuged 10 min. at 10 Krpm. This 
step was repeated by resuspending the inclusion bodies pellet in 20 mL washing 
buffer 2 (50 mM Tris–HCl, 150 mM NaCl, 10 mM EDTA, 2 M UREA, Triton 1%, 5 mM 
DTT, pH 8.0) and, for three times, in washing buffer 3 (50 mM Tris–HCl, 15 mM 
NaCl, 10 mM EDTA, 5 mM DTT). The final pellet was dissolved in 6 M guanidine 
chloride, 50 mM Tris-HCl, 100 mM NaCl, 10 mM EDTA and 2 mM DTT, pH 8.0 buffer 
and stirred at 4°C for 12 h till complete solubilization. The residual insoluble part was 
removed by centrifugation at 12 Krpm for 30 min. at 4°C and the soluble protein 
fraction was analyzed by 15% SDS-PAGE.  
 
II.3.2.8 Expression and Purification of MBP-D2 domain 
 
100 ng expression vector D2-pETM40 were chemically transformed into Bl21 (DE3), 
E.coli competent cells. Recombinant colonies were grown in 2 mL LB medium up to 
0.6 OD/mL at 37°C and then expression was induced with 0.1 mM IPTG for 16 h at 
22°C. 100 mL of bacterial culture were resuspended in 5 mL of lysis buffer (30 mM 
Tris–HCl, 150 mM NaCl, 1 mM PMSF, and 1 mg/mL lysozyme pH 8.0), left for 30 
min. at RT and then sonicated 10’’ on / 10’’ off for 5 min. The lysate was then 
centrifuged for 30 min. at 4°C at 15 krpm and the soluble fraction was loaded on 1 
mL amylose resin (Biolabs, New England), previously equilibrated with buffer 1 (30 
mM Tris-HCl, 500 mM NaCl pH 8.0). The resin was washed extensively with buffer 1 
and the protein was eluted with 10 mM maltose dissolved in 30 mM Tris-HCl, 500 
mM NaCl pH 8.0 buffer. The total cell protein fraction, the soluble cytoplasmic 
fraction (supernatant of cell lysate), and the purified fraction were analyzed by 15% 
SDS-PAGE.  
 
II.3.2.9 Expression and Purification of His6x-D2 domain 
 
100 ng expression vector D2-pETMA11 were chemically transformed into Bl21 
(DE3)trxB, E. coli competent cells. Recombinant colonies were grown in 2 mL of LB 
medium up to 0.6 OD/mL at 37°C and expression was induced with 0.2 mM IPTG for 
16 h at 22°C. 100 mL bacterial culture was re-suspended in 5 mL of 30 mM Tris–HCl, 
150 mM NaCl, 4M UREA, 5 mM DTT, 1 mg/mL lysozyme pH 8.0 buffer 
supplemented with protease inhibitor mixture (1 mM PMSF, 1 µg/mL aprotinin, 1 
µg/mL leupeptin, 1 µg/mL pepstatin (lysis buffer), kept for 30 min. at R.T. and then 
sonicated for 10 min. (10’’ on, 10’’ off). After 20’ centrifugation at 4°C and 15 Krpm, 
500 mM NaCl and 10 mM imidazole were added to the soluble fraction. Thus the 
recovered fraction was loaded on a His-trap column (1 mL). The column was washed 
with buffer 1 (30 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole, 1 mM DTT, 4M urea 
pH 8.0) and the bound protein was eluted using a linear gradient from 10 mM to 500 
mM imidazole in buffer 2 (30 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, 1 mM 
DTT, 4M urea pH 8.0). Protein elution was monitored by measuring the absorbance 
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at 280 nm. Under these conditions, His6x-D2 domain was eluted in 30 mM Tris-HCl, 
500 mM NaCl, 290 mM imidazole, 1 mM DTT, 4 M urea pH 8.0 buffer. 
The purified protein dissolved in 30 mM Tris-HCl, 500 mM NaCl, 1 mM DTT, 290 mM 
imidazole and 4M urea pH 8.0 buffer was dialyzed against 30 mM Tris-HCl, 1 mM 
DTT, 500 mM NaCl, 2M urea pH 8.0 buffer over night at 4°C. The recombinant 
protein was refolded decreasing the urea concentration by rapid dilution in 30 mM 
Tris-HCl, 150 mM NaCl, 1mM DTT, pH 8.0. The last step of dialysis was carried out 
in 30 mM Tris-HCl, 150 mM NaCl, 5 mM reduced glutathione, 0.5 mM oxidized 
glutathione pH 8.0 buffer over night at 4°C. The precipitate formed during the 
refolding procedure was removed by centrifugation at 12 Krpm for 30’ at 4°C. The 
recovered His6x-D2 domain was analyzed by 15% SDS-PAGE under reducing and 
non-reducing conditions. 
 
II.3.2.10 Western blotting 
 
The protein was loaded on a 15% SDS-PAGE under reducing conditions and then 
transferred onto a PVDF membrane using Trans Blot SD semi-dry (Bio-Rad), 
according to the manufacturer’s recommendations. After protein transfer, the 
membrane was blocked with 5% NFDM in TTBS (20 mM Tris-HCl, 0.9% NaCl, 0.05 
% Tween 20, pH 7.5 buffer) for 1 h at R.T. After three washes with TTBS, the filter 
was incubated with the His-probe-HRP conjugated diluted 1:1000 in TTBS/0.5% BSA 
for 1 h at R.T. Detection was carried out using an Opti-4CN goat anti-mouse 
detection Kit according to the manufacturer’s protocol. 
 
II.3.2.11 Vinyl pyridine reaction  
 
To assess the presence of disulfide bridges, 50 µg of purified refolded His6x-D2 
domain (at 1 mg/mL) was denatured in 50 µL solution containing 250 mM Tris-HCl, 1 
mM EDTA, and 6 M guanidine chloride pH 8.5 buffer, for 30 min. at 45°C without 
reducing agents. The protein was then alkylated by incubating the sample mix in the 
presence of 0.12 M 4-vinyl-pyridine at 25°C for 60 min. The reaction was stopped by 
cooling the sample at 4°C.  
 
II.3.2.12 Gel Filtration analysis 
 
The oligomeric state of His6x-D2 domain was investigated by gel filtration 
chromatography. To this purpose, 100 µg of His6x-D2 domain and 200 µg of the 
same protein opportunely reduced with DTT, were loaded on a Superdex 75 10/300 
GL column equilibrated with 30 mM Tris-HCl, 500 mM NaCl, pH 8.0 buffer at 0.4 
mL/min. The eluate was monitored at 280 nm. 
 
II.3.13 Protein characterization by LC-MS 
 
LC-MS analyses were performed to estimate the protein purity and assess the 
molecular weight. For this analysis, 0.5 µg of His6x-D2 domain were loaded on a 300 
Å narrow bore 250x2mm C4 Jupiter column (Phenomenex, Torrance, CA) coupled to 
the LC-MS system previously described. A gradient of solvent B (0.05% TFA in 
CH3CN) from solvent A (0.08% TFA in H2O) of 30% to 70% was applied over 40 min. 
Mass spectra were recorded continuously in the mass interval 400-2000 amu, in 
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positive mode (LC-MS, condition 1). Multicharge spectra were then deconvoluted 
using the BioMass program implemented in the Bioworks 3.1 package provided by 
the manufacturer’s instruction. Mass calibration was performed automatically by 
means of selected multiple charged ions, in the presence of a calibrant agent 
(UltraMark; ThermoElectron, Milan). All mass values are reported as average. 
 
II.3.2.14 Circular Dichroism analyses 
 
CD spectra of His6x-D2 domain were acquired in 20 mM phosphate buffer pH 8.0 
solutions with C = 8 x 10-6, as determined by Bradford measurements [48], at room 
temperature. CD spectra of IgE-TRAP polypeptides were acquired in aqueous 
solutions with Cpep = 3.85 x 10-5, calculated by UV measurements using a molar 
extinction coefficient at 280 nm of 31345 M-1cm-1 for IgE-TRAP ox and 31220 M-1cm-1 
for IgE-TRAP red, at room temperature. Spectra were recorded using a 0.1-mm path 
length quartz cuvette. Data were collected at 0.2-nm intervals with a 20 nm min-1 
scan speed, a 2 nm bandwidth, and a 16 s response, within the spectral range of 260 
to 190 nm. The recorded spectra were then signal-averaged over at least three 
scans, and the baseline was corrected by subtracting the spectrum of the buffer. 
Spectra were then transformed in molar ellipticity/mean residue [θ], expressed in 
deg·cm2·dmol-1 and calculated using the following equation: 
 
 
where [θ] obs is the ellipticity measured in millidegrees, mrw is the average MW of 
protein residues, C is the protein concentration in g·L-1, and l is the optical path length 
of the cell used, expressed in cm. 
 
II.3.2.15 Polypetides synthesis, purification and characterization 
 
All peptides were synthesized in batch by solid phase peptide synthesis as C-
terminally amidated and N-terminally acetylated derivatives following standard Fmoc 
chemistry protocol [49]. A Rink-amide MBHA resin (substitution 0.53 or 1.12 mmol/g) 
and aminoacid derivatives with standard protections were used in all syntheses. A 4-
fold excess of amino acids, preactivated with PyBOP/DIEA (1:2), was used 
throughout the synthesis. Coupling and deprotection times were kept at 25 min. and 
15 min., respectively. Standard side-chain protection groups for Fmoc chemistry 
were used for all residues except  lysine (Lys133), introduced as 4 methyl-trityl (Mtt) 
derivative; succinic anhydride and Ethylenediamine were not preactivated. The 
selective deprotection of Lys(Mtt)-containing peptidyl resins were performed by 
treatment with a dicloromethane (DCM)/trifluoroacetic acid (TFA)/tri-isopropylsilane 
(TIS) (94:1:5, v/v/v) mixture for 2 min. at R.T. several times. Succinic acid was 
introduced by resin treatment with a 10-fold excess of succinic anhydride mixed with 
DIPEA (1:2) and the reaction was kept at room temperature for 20 minutes. A 2-fold 
excess of ethylenediamine was instead introduced using ethylenediamine/DIPEA 
(1:1) after on resin pre-activation with conventional reagents and the reaction was left 
at room temperature for 20 minutes. Total cleavage from the solid support was 
performed by treatment with a trifluoroacetic acid (TFA)/tri-isopropylsilane (TIS)/water 
(90:5:5, v/v/v) mixture for 90 minutes at R.T. Crude peptides were precipitated in cold 
diethyl-ether, dissolved in a water/acetonitrile (1:1, v/v) mixture and lyophilized. IgE-
TRAP and 2nd Loop cysteine oxidation were performed in 100 mM carbonate buffer 
pH 8.0 for 16 h at R.T. 
[θ]= [θ] obs mrw/10·l·C  
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Peptide purification was carried out by RP-HPLC using a C18 Jupiter 250x22mm ID 
column (15 µm, 300 Å) applying a linear gradient of acetonitrile in 0.1% TFA from 
10% to 70% in 50 min. at 20 mL/min. Detection was achieved at 210 nm. Peptide 
purity and integrity were confirmed by LC-MS as previously described. 
 
II.3.2.16 Immunoglobulin coating on sensor surface 
 
Binding assays were performed using the SPR technique at 25°C on a BIACORE 
3000 instrument (Pharmacia Biosensor). A specific binding surface was prepared by 
coupling the immunoglobulins to a CM5 sensor chip using the amine coupling kit 
according to the manufacturer’s instructions. The sensor chip was activated using a 
1:1 volume mixture of an NHS solution (50 mM N-hydroxysuccinimide in water) and 
an EDC solution (200 mM N-ethyl-N′-(dimethylaminopropyl) carbodiimide in water), to 
give a reactive N-hydroxy-succinimide ester. The immobilization was efficiently 
performed in 10 mM NaAc pH 5.5 buffer at a flow rate of 30 µL/min. Any residue 
unreacted surface groups was inactivated by injecting a solution of ethanolamine 1M, 
pH 8.0.  
All three types of immunoglobulins IgE, IgG and IgA (Sigma-Aldrich) were efficiently 
immobilized. 
 
II.3.2.17 SPR data fitting and analysis 
 
Data were analyzed using the BIAevaluation analysis package (version 4.1, 
Pharmacia Biosensor). Non specific binding was subtracted from the specific binding 
prior to analysis. A binding data fitting was carried out using a monophasic or 
biphasic model and evaluating the goodness of fitting by analysis of residual [19,32]. 
For the monophasic model the dissociation rate constant (kd) was obtained by fitting 
the dissociation phase data to the following equation: 
 
R=R0*exp(-kd*(t-t0))  
 
where R0 is the response at the start of the dissociation, t-t0 is the time function for 
the dissociation phase.  
The association rate constant (ka) was obtained by fitting the association phase data 
to the following equation: 
 
R=ka*Conc*Rmax/(ka*Conc+kd)*(1-exp(-(ka*Conc+kd)*(t-t0)))+RI 
 
where Rmax is the maximum analyte binding capacity (RU), ka is the association 
rate constant, C is the molar concentration of the ligand, kd is the dissociation rate 
constant, and t-t0 is the time function for the association phase. 
For the biphasic model the dissociation rate constants were obtained by fitting the 
dissociation phase data to the following equation: 
 
R=R1*exp(-kd1*(t-t0))+(R0-R1)*exp(-kd2*(t-t0))+Offset 
 
where R0 is the total response at the start of dissociation, R1 is the contribution to R0 
from component 1 and R0-R1 is the contribution to R0 from component 2, t-t0 is the 
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time function for the dissociation phase, and kd1 and kd2 are the dissociation rate 
constants for the two components.  
The association rate constants were obtained by fitting the association phase data to 
the following equation: 
 
R=ka1*Conc*Rmax/(ka1*Conc+kd1)*(1-exp(-(ka1*Conc*n1+kd1)*(t-
t0)))+ka2*Conc*Rmax/(ka2*Conc+kd2)*(1-exp(-(ka2*Conc*n2+kd2)*(t-
t0))) 
 
where Rmax is the maximum analyte binding capacity, ka1 and ka2 are the 
association rate constants for components 1 and 2, C is the molar concentration of 
the ligand, t-t0 is the time function for the association phase, and n1 and n2 are the 
steric interference factors for the two components, which are set at 1 when the 
binding of one component does not inhibit the binding at another ligand site. Biphasic 
dissociation may be occur for the complex with a stoichiometry 1:1 when re-
association of the release ligand takes place. 
The ability of the models to describe the experimental data was determined by 
examination of the residual plots, which were calculated by subtracting the 
experimental data points from the fitted curve. The residuals should be small and 
randomly distributed around zero for a good fit. 
The affinity constant can either be measured directly by equilibrium binding analysis 
or calculated. The affinity constant KA (or association constant) is simply the ratio of 
the kinetic constants for the interaction :  
 
 
 
Data fitting and Scatchard analysis were carried out by non-linear regression and 
programs implemented within the GraphPad Prism, vers. 4.0 software. 
 
II.3.2.18 ELISA assay 
 
An ELISA assay was set up to check the binding between IgE and His6x-D2 domain 
[50]. IgE at fixed concentrations in PBS buffer (10 mM Na2HPO4, 2 mM KH2PO4, 137 
mM NaCl, 2.7 mM KCl pH 7.4 buffer) was dispensed into 96-well microtiter plates 
(Nunc, Milan, Italy). Some wells were filled with buffer alone and were used as blank. 
After 16h incubation at 4°C, plates were washed three times with PBS-T buffer (PBS 
containing 0.04% Tween-20). The wells were filled to the top with 250 µL BSA 1% in 
PBS buffer and plates were incubated for 2 h at 37°C. After washing, increasing 
concentrations of His6x-D2 domain in the appropriate buffer were added and the 
plate was incubated for 1 h at 37° C. After washing, wells were filled with 100 µL anti-
His6x-probe conjugated with HRP, diluted 1:1000 in PBS, and incubated for 1 h at 
37°C. After washing, 100 µL of chromogenic substrate o-phenyldiamine 0.4 mg/mL in 
50 mM sodium-phosphate-citrate buffer pH 5.0, containing 0.4 mg/mL hydrogen 
peroxide, were added to each well. The reaction was stopped by adding 50 µL of 2.5 
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M H2SO4 in each well. The absorbance was measured at 490 nm using a Synergy 4 
multi-wavelength reader (BIOTEK Instruments, Inc. Highland Park, VT, USA).  
For the competition experiment, IgE at 2 µg/mL in coating and His6x-D2 domain at 5 
µM was chosen as the pre-saturation condition based on previous experiments. In 
dose-dependent competition assays, increasing concentrations of peptide 
competitors (IgE-TRAP red, 1st Loop and 2nd MiniLoop), ranging from 0 to 500 µM 
were pre-incubated with His6x-D2 domain solution at 5 µM for 30 min. at R.T. before 
addition to each well. The subsequent steps were carried out as previously 
described. Data fitting and analysis were carried out by non-linear regression using 
the GraphPad Prism software, vers. 4.0. 
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II.4 RESULTS AND DISCUSSION 
 
II.4.1 Molecular design of FcεRI receptor mimicking polypeptides 
 
In a first attempt at obtaining peptides binding IgE, we designed a set of peptides 
from the known crystal structure of the Fc-IgE–αFcεRI complex.  
The crystal structure of the Fc-IgE–αFcεRI complex, deposited in the Protein Data 
Bank (1F6A), has been used to design a polypeptide mimicking the receptor binding 
sites. As extensively described in the introduction, the residue Y131, located in the 
C’–E region of the receptor D2 domain in binding site 1, resides in a shallow pocket 
formed by residues from one IgE chain (R334, V336, D362, A364, and H424). 
Binding Site 2 is dominated by interactions occurring between surface-exposed 
tryptophans (W87, W110, W113, W156) from the D1–D2 linker region (W87) and 
from the D2 domain (W110, W113, W156) of αFcεRI. In particular, the two conserved 
tryptophan residues (W87 and W110) form a pocket for the IgE residue P426, giving 
rise to a “proline sandwich” and the two non-conserved tryptophans (W113, W156), 
in binding Site 2, form a platform interacting with the IgE-Cε2–Cε3 linker. The 
antibody binding specificity is due to the non-conserved residues. In the following Fig. 
6, the patch of tryptophans (yellow) and the region around the Tyr131 (green) are 
evidenced as “surface”. Also the two distinct D1 and D2 domains are clearly visible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four regions belonging to the αFcεRI were selected as potential recognition surfaces 
for the construction of the IgE-binding peptide and these being from site 1 and site 2. 
It must be underlined here that only residues from the D2 domain are essentially 
needed to bind to the immunoglobulin. The polypeptide structure, named IgE-TRAP 
is reported in Fig.7. It can be seen that it recapitulates both sites which are shared by 
two distinct loop regions, named 1st Loop and 2nd Loop. Site 1, which is entirely within 
the 1st Loop (boxed), contains residues from the C'-E loop of the receptor (129-134, 
YWYEKH). The Asn133 is mutated to Lys in order to exploit its side chain as a linker 
D1 D2
Figure 6: 3D representation of αFcεRI receptor. D1 and D2 domains are 
ringed in red; the binding pocket residues for site 1 and site 2 are highlighted 
in yellow and in green, respectively. The model was built using the programs 
Insight II and WebLab Pro. 
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to join the residues WRNW (from 110 to 113), connecting the NH2є of the Lys side 
chain and the N-terminus of Trp113 (distance about 10.7 Å). On the N-terminus of 
the Trp110, a new Trp, putatively mimicking the Trp87, was joined using a βAla as a 
linker (about 5Å). To join residues corresponding to the region Cys151-Ser162, a 
linker composed of a succinic acid and an ethylendiammine was designed 
(accounting for about 10 Å). This last portion of the molecule was designed as a 
cyclic peptide in order to mimic the turn around the central Trp156-Gln157 peptide 
diade and to reduce the conformational flexibility. For this purpose, a cysteine 
replaced the isosteric residue Ser162.  
In summary, the molecule contained three recognition elements from site 1 
and site 2, ideally encased within two loops, 1st Loop and 2nd Loop (Fig.8). The two 
elements forming the 1st Loop where named 1st miniLoop [residues 129-134] and 2nd 
miniLoop [residues 87, βAla, 110-113]. The aim of this design was to try to preserve 
these regions stabilizing the overall structure with the introduction of mutations and 
suitable linkers to ensure the appropriate distance between the two sites. To increase 
the polypeptide stability, both N-terminal and C-terminal ends were acetylated and 
amidated respectively. 
 
              
Figure 7: Schematic representation of IgE-TRAP polypeptide in the oxidized form. 
 
           
 
 
 
 
 
Figure 8: 3D representation of receptor regions utilized to 
design the IgE-TRAP (in blue). The same structure is reported 
within the complex with the Fc-IgE. The model was built using 
programs Insight II and WebLab Pro. 
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In order to improve the affinity of the designed polypeptide and to understand a 
possible correlation between structure and activity, a set of peptides corresponding to 
the IgE-TRAP polypeptide subregions, reported in the following table IV, were tested. 
 
 
       129  130   131  132  133    134        85            110   111   112   113 
Ac-Tyr-Trp-Tyr-Glu-Lys(HisAc)-Trp-βAla-Trp-Arg-Asn-Trp-Ac      
                                                         
                                         1st Loop [129-134, 85, βAla, 110-113]        M.W.1909.12 
  
      129   130  131  132  133  134 
Ac-Tyr-Trp-Tyr-Glu-Lys-His-NH2                         
  
                                                                   
1st
 
miniLoop [129-134]                             M .W. 1009.12  
                                   
                 85           110   111   112   113    
Ac-Gly-Trp-βAla-Trp-Arg-Asn-Trp-NH2       
                                                                  
                                                                   
2st
 
miniLoop
 
 [85, βAla, 110-113]             M.W.1016.14 
                  
                110  111  112   113        
Ac-Gly-Trp-Arg-Asn-Trp-NH2                        
 
                                                                    
Peptide S
   
[110-113] 
                                               
M.W. 758.84  
 
         
        151   152  153  154  155  156  157   158   159    160  161  162   
Ac-Cys-Thr-Gly-Lys-Val-Trp-Gln-Leu-Asp-Tyr-Glu-Cys-NH2      
 
 
                                             2nd Loop [151-162]                                   MW.1484.70 
 
 
 
II.4.1.2 Synthesis, purification and characterization of polypeptides 
 
All peptides were synthesized and purified by RP-HPLC as described in the section 
II.3.2.15 of methods. The polypeptides IgE-TRAP and 2nd Loop were cyclized by 
spontaneous oxidation in 100 mM carbonate buffer, pH 8.0. To obtain the same 
product in the reduced form, 100 mM DTT was added before purification. All final 
products were characterized by LC-MS. Deconvoluted mass spectra of active 
peptides are reported in Fig.9. 
 
 
 
 
 
 
Table IV: Peptides corresponding to the IgE-TRAP subregions: 1st Loop [residues 129-134, 85, 
βAla, 110-113]; 1st miniLoop [residues 129-134]; 2nd miniLoop [residues 85, βAla, 110-113], Peptide 
S [residues 110-113] and 2 nd Loop [residues 151-162]. 
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A                                                                  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C                                                                       D 
 
 
The polypeptides IgE-TRAP, in their oxidized and reduced form, were characterized 
in solution by far-UV circular dichroism (190-260 nm) to investigate their 
conformational behaviour. The far UV-CD spectra were acquired in aqueous solution 
and at room temperature, using a concentration of 3.85 x 10-5 M for both 
polypeptides. The CD spectra showed no canonical spectral features (Fig.10). The 
spectrum obtained for the polypeptide IgE-TRAP ox shows a random coil 
conformation, with a negative band at 200 nm and no positive band in the 
wavelength region between 190 nm and 200 nm. On the other hand, the positive 
signal at 190 nm and the negative band between 200 nm and 210 nm, observed in 
the IgE-TRAP red spectrum, is more indicative of a β-sheet structure. In both spectra 
the positive signal at 230 nm may reflect contributions from the high density of 
surface exposed aromatic residues [51]. However, an analysis of CD spectra 
indicates that the IgE-TRAP red possesses a higher contribution from the structured 
form (positive band at 195 nm) respected to IgE-TRAP ox.           
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Figure 9: Mass spectra of: A) IgE-TRAP before (MWexp/MWtheor.:3476.8/3476.1amu,) and B) 
after oxidation (MWexp/MWtheor.:3474.2/3474.0 amu); C) 1st Loop 
(MWexp/MWtheor.:1907.9/1909.12amu); D) 2nd miniLoop, (MW exp /MWtheor. :1015.9/1016.14 amu). 
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II.4.1.3 Equilibrium affinity measurements between 
Immunoglobulins E and the receptor mimicking polypeptides by 
SPR assay. 
 
The interaction between the designed polypeptides and IgE was assessed by SPR 
using a BIACORE 3000 system. Immunoglubilins E were efficiently immobilized on a 
CM5 sensor chip, obtaining a signal of about 54700 RU.  
The IgE-TRAP polypeptides (IgE-TRAP red and IgE-TRAP ox, reduced and 
oxidized variant, respectively) were dissolved in a water:acetonitrile buffer (90:10) 
and injected at 20 µL/min flow rate, after proper dilution in HBS (100 mM Hepes, 
150mM NaCl, 5mM EDTA) buffer pH 7.4. Dose-dependent binding curves were 
observed with increasing concentrations between 2.5 µM and 40 µM of the oxidized 
and reduced forms, reaching binding saturation at 30 µM, as shown in Fig.11 and 14. 
The saturating condition at 40 µM is not shown. The association and dissociation 
phases of the response curves were fitted to a biphasic model assuming a 1:1 
(Langmuir) binding. The ability of the model to describe the experimental data was 
evaluated by examination of the residual plots, which were calculated by subtracting 
the experimental data points from the fitted curve. The residual values are 
considerably small thus suggesting an acceptable fitting with the biphasic model. The 
analysis of SPR data for IgE-TRAP ox and red are reported in Fig.12 and Fig.15, 
respectively. 
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Figure 10: Far-UV CD spectrum of the IgE-TRAP ox and red 
polypeptides. CD spectra are reported in molar ellipticity [θ]. 
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The biphasic fit is characterized by two association rates and two dissociation rates 
and these value yield an affinity constant for each phase of the interaction. A 
summary of association and dissociation rate constants obtained by data fitting, as 
well as the calculated affinity constants, are reported in table V. 
The rate constants kd1 (1.06 + 0.15 x 10-2 s-1), kd2 (3.69 + 0.62 x 10-1 s-1), ka1 (1.63+ 
0.19 x 102 M-1
 
s-1) and ka2 (6.14 + 0.70 x 103 M-1 s-1) were extrapolated and averaged 
Figure 11: Overlapping sensorgrams for the interaction of IgE with 
IgE-TRAP ox. The interactions were monitored at seven IgE-TRAP 
ox concentrations (2.5 µM, 5 µM, 7.5 µM ,10 µM, 20 µM, 30 µM and 
40 µM). 
Figure 12: Analysis of SPR data for the binding of IgE-TRAP ox at 2.5 µM to immobilized IgE. The 
fitted lines (black) are overlaid with the experimental curves (fuchsia) for the association phase (A) 
and the dissociation phase (B). The corresponding residual plots are shown (C and D, 
respectively). Curves from all other experiments were similarly fitted. 
IgE-TRAP ox 2.5µM IgE-TRAP ox 5µM IgE-TRAP ox 7.5µM
IgE-TRAP ox 10µM IgE-TRAP ox 20µM IgE-TRAP ox 30µM
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over all experiments, and used to calculate the two equilibrium constants KD1
 
= 65 + 
0.8 µM  and KD2
 
= 60 + 0.9 µM. 
 
 
 
 
Binding constants were further analyzed by plotting the RUmax value against the 
polypeptide concentrations and calculated by data fitting using both a non-linear 
regression and a Scatchard analysis (Fig.13). Data were consistent with KD of 16 ± 4 
µM, which is a measure of a macroscopic apparent association constant resulting 
from the two distinct association-dissociation events. 
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Analyte 
Concentration 
IgE-TRAP ox 
 
Association rate 
(M-1
 
s-1) 
Ka1 
 
Dissociation rate 
(s-1) 
Kd1 
 
Association rate 
(M-1
 
s-1) 
Ka2 
 
Dissociation rate 
(s-1) 
Kd2 
 
 
2.5 µM 
 
3.09 x 102 
 
 
8.79 x 10-3 
 
 
7.52 x 103 
 
 
3.40 x 10-1 
 
 
5 µM 
 
1.34  x 102 
 
 
1.07 x 10-2 
 
 
8.16 x 103 
 
 
4.70 x 10-1 
 
 
7.5 µM 
 
2.30  x 102 
 
 
1.43 x 10-2 
 
 
7.93 x 103 
 
 
3.90 x 10-1 
 
 
10 µM 
 
1.11  x 102 
 
 
1.29 x 10-2 
 
 
5.26 x 103 
 
5.12 x 10-1 
 
 
20 µM 
 
1.37  x 102 
 
 
8.69 x 10-3 
 
 
5.36 x 103 
 
 
2.61 x 10-1 
 
 
30 µM 
 
5.88  x 101 
 
 
8.41 x 10-3 
 
 
2.58 x 103 
 
 
2.36 x 10-1 
 
 
MEAN 
 
1.63 x 102 
 
 
1.06 x 10-2 
 
 
6.14 x 103 
 
 
3.69 x 10-1 
 
 
 
 
KD1= 65 x 10-6 M 
 
 
KD2= 60 x 10-6 M 
 
Figure 13: Plot of the RUmax vs IgE-TRAP ox concentrations fitted by non-linear regression (A) 
and the corresponding Scatchard analysis (B). 
Table V: Table of kinetic and thermodynamic constants extrapolated for the binding of IgE-
TRAP ox by the equilibrium affinity measurements by SPR. All data fit optimally with a 
biphasic association and dissociation.  
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For IgE-TRAP red, a similar analysis was carried out, obtaining the following average 
kinetic parameters: kd1 (6.43 + 0.03 x 10-1 s-1), kd2 (1.05 + 0.08 x 10-2 s-1), ka1 (3.30 + 
0.4 x 104 M-1
 
s-1) and ka2 (2.87 + 0.82 x 102 M-1 s-1). The thermodynamic KD 
extrapolated by these data were: KD1 = 19 µM + 0.1 and KD2 = 37 µM + 0.9 (table 
VI). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
                                             
 
 
 
 
 
 
 
 
 
Analyte 
Concentration 
IgE-TRAP red 
 
 
Association rate 
(M-1
 
s-1) 
Ka1 
 
Dissociation rate 
(s-1) 
Kd1 
 
Association rate 
(M-1
 
s-1) 
Ka2 
 
Dissociation rate 
(s-1) 
Kd2 
 
 
2.5 µM 
 
1.40 x 104 
 
 
7.25 x 10-1 
 
 
3.53 x 102 
 
 
1.88 x 10-2 
 
 
5 µM 
 
1.92 x 104 
 
 
6.29 x 10-1 
 
 
3.69 x 102 
 
 
1.45 x 10-2 
 
 
7.5 µM 
 
7.02 x 104 
 
 
0.18 x 10-1 
 
 
2.95 x 102 
 
 
1.26 x 10-2 
 
 
20 µM 
 
2.44 x 104 
 
 
2.12 x 10-1 
 
 
3.31 x 102 
 
6.73 x 10-3 
 
 
30 µM 
 
6.20 x 104 
 
 
4.18 x 10-1 
 
 
2.20 x 102 
 
 
8.18 x 10-3 
 
 
50 µM 
 
7.99 x 103 
 
 
4.96 x 10-2 
 
 
1.58 x 102 
 
 
2.55 x 10-3 
 
 
MEAN 
 
3.30 x 104 
 
 
6.43 x 10-1 
 
2.87 x 102 
 
 
1.05 x 10-2 
 
 
 
KD1= 19 x 10-6 M 
 
 
KD2= 37 x 10-6 M  
 
IgE-TRAP red 5µMIgE-TRAP red 2.5µM
IgE-TRAP red 20µM IgE-TRAP red 30µM
IgE-TRAP red 7.5µM
IgE-TRAP red 50µM
Figure 14: Overlapping sensorgrams for IgE interacting with IgE-TRAP red. 
The interaction were monitored at six IgE-TRAP red concentrations (2.5 µM, 5 
µM, 7.5 µM, 20 µM, 30 µM, and 50 µM) injected in HBS buffer pH 7.4 at 25°C, 
at flow rate of 20 µL/min.  
Table VI: Table of kinetic and thermodynamic constants for the binding of IgE-TRAP 
red to IgE extrapolated to the equilibrium affinity measurements by SPR. All data fit 
optimally with a biphasic association and dissociation.  
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By data fitting using a non-linear regression and Scatchard analysis, reported in 
Fig.16, a KD of 6.2 ± 0.7 µM was extrapolated as a global apparent binding constant. 
 
0 10 20 30 40 50 60
0
100
200
300
400
500
600
A lgE-TRAP red [µM]
R
Um
ax
 
0 100 200 300 400 500 600 700
0
25
50
75
100
B Bound
B
o
u
n
d/
Fr
ee
 
 
 
 
 
Importantly, for both the IgE-TRAP polypeptides, the global affinity constant (KD) is 
lower than the two separate equilibrium constants, supporting the existence of a two 
phase event and suggesting a cooperative mechanism between the two sites. 
However the macroscopic affinity constants are much lower than the overall receptor 
affinity (KD =10-9–10-10M). Interestingly, the value of affinity for IgE of the IgE-TRAP 
red is 2.5 times stronger than the cyclized variant and this increase of affinity is 
arises from the absence of the disulfide bridge between Cys151 and the newly 
created Cys162. This result, is probably due to a greater conformational flexibility of 
the polypeptide than can more easily adapt to the immunoglobulin surface.  
Strictly, the stronger affinity of the reduced molecule in solution is also reflected by 
the two separate KD for the two binding sites. Indeed, KD1
 
and KD2 for the two 
Figure 15: Analysis of SPR data for binding IgE-TRAP red at 2.5 µM to immobilized IgE. The fitted 
lines (black) are overlaid with the experimental curves (brown) for the association (A) and 
dissociation phases (B). The corresponding residual plots are shown (C and D, respectively). 
Curves from all other experiments were similarly fitted.                                                                   
Figure 16: A plot of the RUmax vs the concentration of the protein fitted by a non-linear 
regression (A) and the corresponding Scatchard analysis (B). 
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molecules are 19 µM and 37 µM (reduced form) versus 65 µM and 60 µM (oxidized 
form), respectively. On the basis of these data, the binding difference between the 
two polypeptides could essentially be ascribed to an improved recognition of the first 
site which is dependent on the presence/absence of the disulfide bridge and which 
seemingly corresponds to the peptide 1st Loop that resume partially 2 site also.  
Correspondingly, also the KD2 of IgE-TRAP red is lower (1.5 times) than that of 
oxidized form (37 µM compared with 60 µM) thus suggesting a better recognition also 
for site 2. Overall, results indicate that the reduced form shares many of the bound 
structural features or that it must overcome a lower energy barrier to adopt a binding 
conformation. In order to improve the affinity of the designed polypeptide and to 
understand a possible correlation between structure and activity, a set of peptidic 
fragments of the IgE-TRAP was prepared and studied by SPR. Sub-domains 
reproducing the two separate binding sites, previously reported in table IV, were 
designed, chemically synthesized and characterized. Remarkably, only the so-called 
1st Loop bound in a dose-dependent way to the IgE (Fig.17) and we again found, on 
the basis of fitting residuals, that an optimal fit was obtained with bi-phasic curves 
(Fig.18). For the 1st Loop, the rate constants kd1 (8.73 + 0.38 x 10-1 s-1), kd2 (2.54 + 
0.29 x 10-2 s-1), ka1 (1.35 + 0.17 x 104 M-1 s-1) and ka2 (1.33 + 0.17 x 102 M-1 s-1) were 
extrapolated by averaging data from all experiments (table VII) and KD1
 
= 65 + 0.2 
µM and KD2 = 19 + 0.2 x10-5M were calculated as the two equilibrium constants.  
                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Overlapping sensorgrams for IgE interacting with 1st Loop. Interactions 
were monitored at eight concentrations (2.5 µM, 5 µM, 10 µM, 20 µM, 30 µM, 40 
µM, 45 µM, 50 µM) injected in HBS buffer pH 7.4 at 25°C, at flow rate of 20 
µL/min.  
1 loop 30µM
1 loop 10µM1 loop 2.5µM 1 loop 5µM
1 loop 45µM 
1 loop 20µM
1 loop 50µM1 loop 40µM
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Analyte 
Concentration 
1st LOOP 
 
Association rate 
(M-1
 
s-1) 
Ka1 
 
 
Dissociated rate 
(s-1) 
Kd1 
 
Association rate 
(M-1
 
s-1) 
Ka2 
 
Dissociated rate 
(s-1) 
Kd2 
 
 
2.5 µM 
 
2.25 x 104 
 
 
0.23 x 10-1 
 
 
2.26 x 102 
 
 
1.82 x 10-2 
 
 
10 µM 
 
1.31 x 104 
 
 
0.23 x 10-1 
 
 
2.21 x 102 
 
 
3.63 x 10-2 
 
 
20 µM 
 
7.19 x 104 
 
 
9.22 x 10-1 
 
 
1.18 x 102 
 
 
3.94 x 10-2 
 
 
30 µM 
 
1.21 x 104 
 
 
3.48 x 10-1 
 
 
1.20 x 102 
 
 
2.59 x 10-2 
 
 
40 µM 
 
1.20 x 104 
 
 
4.31 x 10-1 
 
 
1.02 x 102 
 
 
2.79 x 10-2 
 
 
45 µM 
 
9.18 x 103 
 
 
5.33 x 10-1 
 
 
4.31 x 102 
 
 
1.91 x 10-2 
 
 
50µM 
 
1.81 x 104 
 
 
1.97 x 10-2 
 
 
1.03 x 102 
 
 
1.14 x 10-2 
 
 
MEAN 
 
1.35 x 104 
 
 
8.73 x 10-1 
 
 
1.33 x 102 
 
 
2.54 x 10-2 
 
 
KD1= 65 x 10-6 M 
 
 
KD2= 19 x 10-5 M 
 
Table VII: Table of kinetic and thermodynamic constants for the binding of 1stLoop to IgE 
extrapolated by the equilibrium affinity measurements by SPR. All data fit optimally with 
a biphasic association and dissociation.  
Figure 18: Analysis of SPR data for binding 1st Loop 10 µM to immobilized IgE. The fitted lines 
(black) are overlaid with the experimental curves (fuchsia) for association phase (A) and 
dissociation phase (B) with corresponding residual plots are shown (C and D, respectively).                         
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To obtain the macroscopic KD for the binding of this peptide, we again carried out a 
non-linear regression and Scatchard analysis of RUmax versus concentration data 
(Fig.19). A KD of 19 ± 4 µM was extrapolated as a global apparent binding constant, 
which also in this case, was lower than the two single KD. This result confirms that a 
biphasic event occurs also for the binding of the 1st Loop to IgE and that a 
cooperative mechanism underlines the binding. 
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We next analyzed the synthetic 2nd Loop, and found that both the reduced and 
oxidized variants showed no binding to immobilized IgE. 
This outcome, though unexpected on the basis of the different activity of the oxidized 
and reduced IgE-TRAP, can be explained by a very poor association rate of this 
peptide for IgE, which instead is greatly enhanced in the presence of the first loop. 
The 1st Loop therefore presumably acts as an anchor, favouring the subsequent 
interaction of the 2nd Loop. On the basis of the binding affinities between the different 
peptides (Summarized in the following table VIII), we can conclude that: 
 
The overall affinity of the originally designed peptide IgE-TRAP ox, about 16 µM is 
higher than the respective KDs for the two distinct binding sites, which are very 
similar each other.  
Reduction of the disulfide bridge produces a 3-fold increase of affinity, mostly 
due to an effect on the site 1 (the KD1 decreases from 65 µM to 19 µM) and a partial 
effect on the site 2. This effect can be explained by a contribution from the 2nd Loop, 
which, when not cyclized can probably more rapidly adopt a conformation useful for 
binding. However, the 2nd Loop, when separated from the 1st Loop is ineffective 
probably because of a very poor association rate. The cooperative effect of the 2nd 
Loop is higher on site 1 than on site 2, indeed when it is removed the KD1 is restored 
(65 µM); at the same time, the presence of the 2nd Loop (in both the reduced or the 
cyclized form) seems to increase the recognition on site 2, as a 3-4 fold decreased of 
affinity is measured when it is absent.  
 
 
 
 
 
Figure 19: Plot of the RUmax vs the concentration of the protein fitted by a non-linear 
regression (A) and the corresponding Scatchard analysis (B). 
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We next investigated the separated effects of 1st miniLoop; 2nd miniLoop and the so-
called Peptide S (table IV). Remarkably, the 1st miniLoop and Peptide S were 
incapable of binding to IgE while the 2nd miniLoop, assayed at concentration up to 75 
µM (at higher concentration it was insoluble), bound very weakly the immobilized 
immunoglobulins (Fig. 20-21-23 and table IX). As shown, the binding was dose-
dependent, but we only observed a linear dependence between the two variables 
without any saturation up to 75 µM. This outcome confirmed the very weak 
interaction (KD = 8.3 + 0.5 x 10-4 M) of this fragment.  
The data obtained with 1st miniLoop; 2nd miniLoop clearly show that a high 
cooperation occurs between these two peptide fragments when they are covalently 
interconnected, while they essentially appear inactive when assayed separately.     
Altogether, the comparative analyses of binding affinities of this set of peptides 
derived from the FcεRI recognition site, indicates that, despite the relative low affinity 
(all in the µM range), a strong cooperativity occurs between the different peptide 
blocks present at the interface with the immunoglobulin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule 
 
KD1(µM) 
 
KD2(µM) 
 
KD(µM) 
 
Fold affinity increase relative 
 to IgE-TRAPox 
IgE-TRAP ox 65 60 16 -- 
IgE-TRAP red 19 37 6.2 3 
1st Loop 65 190 19 -- 
2nd Loop -- -- -- -- 
Table VIII: Summary of binding affinities between the different molecules and   
immobilized IgE, as obtained by SPR. 
Figure 20: Overlapping sensorgrams for the interaction of immobilized IgE with 2nd 
miniLoop. The interaction was monitored at four concentrations (20 µM, 30 µM, 50 µM, 
75 µM) injected in HBS buffer pH 7.4 at 25°C, at a flow rate of 20 µL/min. According to 
the hypothesis that 2nd miniLoop reproduced only one site of the αFcεRI, binding and 
dissociation curves fit  better with a monophasic model, assuming a 1:1 stoichiometry. 
2 nd MiniLoop 20µM 2 nd MiniLoop 30µM
2 nd MiniLoop 50µM 2 nd MiniLoop 75µM
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Analyte 
Concentration 
2nd miniLoop 
Association rate 
(M-1
 
s-1) 
Ka 
Dissociated rate 
(s-1) 
Kd 
 
20 µM 
 
 
2.47 x 102 
 
5.47 x 10-1 
 
30 µM 
 
 
2.16 x 103 
 
3.87 x 10-2 
 
50 µM 
 
 
3.38 x 102 
 
3.85 x 10-3 
 
75 µM 
 
 
1.18 x 102 
 
2.07 x 10-2 
 
Mean 
 
 
KD= 8.3 x 10-4 
Table IX: Table of kinetic and thermodynamic constants for the binding of 2nd miniLoop to 
IgE extrapolated by the equilibrium affinity measurements by SPR.  
Figure 21: Analysis of SPR data for binding 2nd miniLoop to immobilized IgE at 20 µM. The fitted 
lines (black) are overlaid with the experimental curves (fuchsia) for association phase (A) and 
dissociation phase (B), corresponding residual plots are shown (C and D, respectively). Data fit 
optimally with a single phase association and dissociation. 
Figure 22: Plot of RUmax vs concentration for the binding of 2nd miniLoop to the 
Immobilized IgE. Data points were fitted with a non linear regression algorithm. The 
binding was dose-dependent, but not saturable within this concentrations range. 
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II.4.1.4 Selectivity affinity measurements between 
Immunoglobulins–receptor mimicking polypeptides by SPR assay 
 
The specificity of the designed peptides for Immunoglobulins E was tested again by 
SPR. For this purpose, IgG and IgA were chosen as controls, since they represent 
the most abundant immunoglobulins circulating within plasma and show the highest 
structure similarity to IgE. A multiple alignment between IgE, IgG, IgM and IgA is 
reported in the following Fig.23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
 
 
 
IgG and IgA were efficiently immobilized on the CM5 sensor chips, following the 
same procedure utilized for IgE, achieving a similar extent of immobilization (about 
50000 RU).  
 
 
 
CLUSTAL W (1.82) multiple sequence alignment 
 
 
sp|P01876|IGHA1_HUMAN       CPVPSTPPTPSPSTPPTP-------------------------------- 
tr|Q9BU10|IGHM_HUMAN        PVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGK 
sp|P01857|IGHG1_HUMAN       EPKSCDKTHTCPPCPA---------------------------------- 
tr|Q6P6C4|IGHG2_HUMAN       ERKCCVECPPCP-------------------------------------- 
sp|P01854|IGHE_HUMAN        CADSNPRGVS---------------------------------------- 
                                                                               
 
sp|P01876|IGHA1_HUMAN       -------------------------------------------------- 
tr|Q9BU10|IGHM_HUMAN        QVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRG 
sp|P01857|IGHG1_HUMAN       -------------------------------------------------- 
tr|Q6P6C4|IGHG2_HUMAN       -------------------------------------------------- 
sp|P01854|IGHE_HUMAN        -------------------------------------------------- 
                                                                               
 
sp|P01876|IGHA1_HUMAN       ------SPSCCHP------RLSLHRPALEDLLLGSEANLTCTLTGLRDAS 
tr|Q9BU10|IGHM_HUMAN        LTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYD 
sp|P01857|IGHG1_HUMAN       ------PELLGGPS-----VFLFPPKPKDTLMISRTPEVTCVVVDVSHED 
tr|Q6P6C4|IGHG2_HUMAN       ------APPVAGPS-----VFLFPPKPKDTLMISRTPEVTCVVVDVSHED 
sp|P01854|IGHE_HUMAN        --------------------AYLSRPSPFDLFIRKSPTITCLVVDLAPSK 
                                                      .   :::   . :** :..:   . 
 
sp|P01876|IGHA1_HUMAN       G-VTFTWTPSSGKSAVQGP--PERDLCGCYSVSSVLPGCAEPWNHGKTFT 
tr|Q9BU10|IGHM_HUMAN        S-VTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFT 
sp|P01857|IGHG1_HUMAN       PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK 
tr|Q6P6C4|IGHG2_HUMAN       PEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYK 
sp|P01854|IGHE_HUMAN        GTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQ 
      * :.*   . :     .   * .  .   . .  .     *  *: :  
 
sp|P01876|IGHA1_HUMAN       CTAAYPESKTPLTATLS--KSGNTFRPEVHLLPPPSEELALNELVTLTCL 
tr|Q9BU10|IGHM_HUMAN        CTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCL 
sp|P01857|IGHG1_HUMAN       CKVSNKALPAPIEKTISKAKG-QPREPQVYTLPPSRDELTKNQVS-LTCL 
tr|Q6P6C4|IGHG2_HUMAN       CKVSNKGLPAPIEKTISKTKG-QPREPQVYTLPPSREEMTKNQVS-LTCL 
sp|P01854|IGHE_HUMAN        CRVTHPHLPRALMRSTTKTSG-PRAAPEVYAFATP-EWPGSRDKRTLACL 
                            * .:      .:  : :  ..     *:*: :... :    .:   ::** 
 
 
424 
334 
392 
361 
Figure 23: Multiple alignment of the human heavy chains of IgA, IgM, IgG1, IgG2 and IgE. 
Highlighted are the region of complementarity with the IgE receptor. Alignments were performed 
used BLAST on the Expasy server (http://www.expasy.org/cgi-bin/blast.pl). Numbers in red refer 
to human IgE numbering. The highest regions of similarity are between IgGs and IgE, whereas 
the sequences of IgM and IgA are highly divergent throughout this sequences. 
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All active peptides were then injected on the sensor chip at fixed concentrations. As 
can be seen, IgE-TRAP ox (30 µM), 1st loop (50 µM) and 2nd miniLoop (25 µM) were 
tested and, as expected, no binding was detected on IgG and IgA (Fig.24 A-B-C). 
This is a result suggestive of high specificity of the designed peptides for binding E-
type antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: SPR binding assay to IgE, IgG and IgA. A) Sensorgrams of IgE-TRAPox at 30 
µM; B) Sensorgrams of 1st Loop at 50 µM; C) Sensorgrams of 2nd miniLoop at 25 µM. No 
interaction was detected for three peptides with IgG and IgA.  
A 
C 
B 
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II.4.2 Expression of human FcεRI αchain as recombinant 
protein  
The expression of the extra-cellular portion of the human FcεRI alpha subunit in 
alternative systems has been already described, including the expression in 
insect cells [16], bacteria [17-19], yeast [20] and mammalian cells [21]. The 
reported expression in bacteria present several problems associated with the 
refolding of the protein, the yield and overall activity. Nevertheless, in order to 
try to obtain large amounts of αFcεRI to be evaluated as an optimal soluble 
antagonist of the circulating IgE and to have a source of protein for the set up of 
assays to be used in the screening of inhibitors, E.coli prokaryotic strains has 
been identified as an easy, quick and economic expression system. As outlined 
in the Introduction, all binding residues are located in the D2 domain and the 
linker between the D1 and the D2 domain, however in a first attempt of 
stabilizing the entire receptor structure, the preparation of the human full length 
FcεRI alpha subunit (Fig.24A) and the D1-D2 domain from ECD were 
pursued(Fig. 24B). Subsequently the D2 domain from ECD was chosen as the 
final target protein (Fig. 24B). 
     
 
 
     A 
 
 
 
 
  
     
 
 
 
B  
   
II.4.2.1 Expression and purification of full length hFcεRI αchain  
 
The full-length (FL) α-chain (residues 1-257) was amplified by PCR from the 
cDNA of the human αFcεRI using suitable primers, allowing its cloning in pET 
and pGEX expression vectors. The FL α-chain protein was cloned and 
expressed both cytoplasmatic and periplasmatic recombinant protein. The 
addition of "tags" during the cloning is a successful and useful method to 
Figure 24: A) Schematic representation of the human full-length FcεRI receptor α-chain [1-
257]. B) Amino acid sequence of the receptor α-chain, positively numerated beginning from 
EDC (extra-cellular domain). The N-terminal part is yellow; the D1 domain is in red; the linker 
between D1-D2 is sky blue; the D2 domain is green, the trasmembrane part is blu and the C-
terminal part in black. The 5 cysteines are underscored: Cys13 is free instead Cys26-Cys68 
and Cys107-Cys151 are involved in two disulfide bridges within the two distinct Ig-like domains.  
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simplify the purification process of recombinant proteins. Therefore, the optimal 
expression conditions (vector, E.coli strain, time, temperature and inducing 
agent concentration) were selected for each recombinant protein and are 
reported in table X. Each recombinant protein was purified according to the 
specific tag properties. 
                           
         
 
 
 
 
 
 
 
 
One of the most commonly used tag consists of six consecutive histidine 
residues (His6x) added to either the N- or C-terminal part of the protein of 
interest.  
The purification of His6x-tagged fusion proteins is facilitated by the immobilized 
metal affinity chromatography (IMAC), a powerful and versatile system. 
The His6x α-chain FL (Theoretical M.W. 32708.2 Da) is a protein very rich in 
hydrophobic aminoacidics and contains 5 cysteines. This protein was soluble in 
30 mM Tris-HCl, 500 mM NaCl, 1 mM DTT and 6 M urea pH 8.0. The total cell 
protein fraction, the soluble fraction (supernatant of cell lysate) and the affinity 
purified fraction were analyzed by SDS-PAGE (Fig.25), observing protein 
bands of the expected size. The purified protein was thus dialyzed gradually 
decreasing the urea concentration to 2 M. Further attempts to reduce the urea 
concentration were unsuccessful because of immediate precipitation of the 
protein. The final product in 2 M urea, obtained with about 60% purity was 
again submitted to a step of anionic exchange chromatography, but the 
material, under these conditions (30 mM Tris-HCl, 150 mM NaCl, 1mM DTT 
and 2 M urea pH 8.0), though quite pure, was not active and unable to 
recognize IgE in ELISA binding assay.  
 
 
          
 
 
 
 
 
 
 
vector N-terminal 
TAG 
E.coli strain Optimal Expression 
conditions 
pETM11 His6x Bl21 (DE3) 0.2mM IPTG 16h 22°C 
pGEX6P GST Bl21 (DE3)trxB 0.1mM IPTG 16h 22°C 
Cytoplasmatic 
expression 
pETM40 MBP Bl21 (DE3) 0.1mM IPTG 16h 22°C 
pET22b His6x Origami (DE3) 0.2mM IPTG 16h 22°C Periplasmatic  
expression pEM50 Dsb-His6x Bl21 (DE3) 0.5mM IPTG 16h 22°C 
TABLE X: A summary of the expression conditions attempted to try to obtain the  
recombinant α-chain of the IgE receptor. 
 
Figure 25: 10% SDS-PAGE analysis: A) His-Trap purification of the 
His6x-α-chain FL receptor: lane M, Perfect Protein Marker 15-150 KDa 
(Novagen); lane 1, total fraction; lane 2, soluble fraction; lane 3, purified 
fraction; B) a protein sample after Mono Q purification (lane 4). 
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To improve solubility, the same protein was expressed as a recombinant 
protein with GST (Glutatione-S-Transferase) and with the MBP (Maltose 
Binding Protein) fusion proteins. The GST-α-chain FL (Theoretical M.W 
56332.9 Da), purified in batch using a GST-trap resin, and the MBP-α-chain FL 
receptor (Theoretical M.W 72533.2 Da), purified in batch using an amylose 
resin, were soluble in 30 mM Tris-HCl, 150 mM NaCl pH 8.0 buffer, without 
added urea. For both constructs, the total cell protein fraction, the soluble 
fraction (supernatant of cell lysate) and purified fractions were analyzed by 
SDS-PAGE (Fig.26). The yield achieved for the two recombinant proteins was 
different. Higher expression levels were obtained for MBP than for the GST-
fused protein. From a 50 mL bacterial culture, 2 mg of MBP-α-chain FL 
receptor were obtained, which was about 3-fold more than the GST-α-chain FL 
receptor. However, in both cases, after digestion with the specific proteases 
(TEV for the MBP-protein and Prescission protease for the GST-fused), the 
protein resulted largely insoluble. Importantly, both fusion proteins, resulted as 
being incorrectly folded, as demonstrated by the lack of binding to IgE in ELISA 
as well as SPR assays.  
 
 
 
A further attempt to obtain a correctly folded recombinant protein was made by 
using periplasmatic expression. Although the levels of periplasmatic expression 
are lower than in cytoplasm, the slightly oxidizing environment of the 
periplasmatic space can allow the formation of correctly formed disulfide bonds. 
Therefore the His6x-αchain and the Dsb-His6x-α-chain (Dsb, Disulfide bond 
protein) FL receptor were expressed in the periplasm. The periplasmatic  
His6x-α-chain and the Dsb-His6x-α-chain proteins (Theoretical M.W. 30660.9 
Da and M.W 55963.8 Da, respectively), after purification on a His-trap column, 
were soluble in 30 mM Tris-HCl, 500 mM NaCl, 1 mM DTT and 4 M urea pH 
8.0. Both recombinant proteins were then dialyzed, decreasing the urea 
concentration slowly, to 1 M and removing the DTT (buffer 30 mM Tris-HCl, 150 
mM NaCl, pH 8.0). The periplasmatic FL His6x-α-chain protein was obtained 
with 90% purity after anion exchange chromatography. The purified fractions 
were analyzed by SDS-PAGE (Fig.27). 
 
A B 
Figure 26: A) 12% SDS-PAGE analysis of the GST-α-chain FL receptor purification: lane M, 
Perfect Protein Marker 15-150 KDa (Novagen); lane 1, total fraction; lane 2, soluble fraction; 
lane 3, purified fraction under reducing condition; B) 15% SDS-PAGE analysis of the MBP-α-
chain FL receptor fraction during the purification on amylase resin. Lane 4, total fraction; lane 
5, soluble fraction; lane 6, purified fraction under reducing condition. The tag-fused proteins 
were recovered with a purity higher than 85%, but resulted inactive in the binding assay. 
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The pure proteins, obtained very pure after the two chromatographic steps but 
in low yield, show no activity in ELISA and SPR binding assays. 
From all these experiments, we conclude that the expression and refolding 
difficulties persists also under the conditions we have explored, as low yields 
and lack of activity are consistent with previous reports. These difficulties may 
arise from the presence of the unpaired cysteines and the hydrophobic 
transmembrane region, therefore the new D1-D2 domain from ECD of hFcεRI, 
containing only residues 1-170 (Fig.24B) was designed and produced as a 
recombinant protein. 
 
II.4.2.2 Expression and purification of the D1-D2 domain  
 
The D1-D2 domain was amplified by PCR from the cDNA of the α-chain of the 
FcεRI using suitable primers, allowing its cloning in pETM11 vector. The His6x-
D1-D2 domain (residues 1-170 from ECD) (Theoretical M.W. 23274.9 Da) 
recombinant protein was expressed in Bl21(DE3) 1 mM IPTG 4h 37°C and was 
retrieved only from inclusion bodies. From 250 mL pellet, 0.1 g of inclusion 
bodies were obtained and solubilized in 50 mM Tris-HCl, 100 mM NaCl, 10 mM 
EDTA, 2 mM DTT, pH 8.0 buffer, containing 6 M guanidine chloride. The 
residual insoluble fraction was removed by centrifugation while the soluble 
fraction was analyzed by SDS-PAGE (Fig.28). The denatured protein His6x-D1-
D2 domain was used for subsequent refolding experiments. Several refolding 
strategies [52-56] were tested in order to obtain the recombinant protein with 
the correct arrangement of disulphide bonds, but they all failed, leading 
invariably to an inactive, though pure protein. The His6x-D1-D2 domain 
recombinant protein was stable in 30 mM Tris-HCl, 150 mM NaCl pH 8.0 buffer 
but SDS-PAGE analysis shows that, under non-reducing conditions, it possess 
a strong tendency to form aggregate. 
 
 
Figure 27: 15% SDS-PAGE: A) His-trap purification of periplasmatic His6x-αchain full-length: 
lane M, Perfect Protein Marker 15-150 KDa (Novagen); lane 1, purified fraction; B) after Mono 
Q: lane 2, purified fraction; C) His-trap purification of periplasmatic Dsb-His6x-α-chain full-
length: lane 3, purified fraction. 
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      Since the expression of the D1-D2 domain as active and soluble recombinant    
      protein was unsuccessful, the expression of D2 domain only was considered. 
 
II.3.2.3 Expression and purification of D2 domain  
D2 domain (residues 84-170 from ECD) was amplified by PCR from the cDNA 
of the human αFcεRI using suitable primers allowing its cloning in two pET 
expression vectors. Optimal expression conditions were selected for both 
recombinant proteins, as reported in table XI. 
                           
 
The D2 domain was initially expressed as a recombinant protein with MBP 
(Maltose Binding Protein) fused at the N-terminal part. The protein, named 
MBP-D2, was isolated as a soluble and stable product after an affinity step on 
an amylose derivatized resin in 30 mM Tris-HCl, 150 mM NaCl pH 8.0 buffer. 
The total cell protein fraction, the soluble fraction (supernatant of cell lysate) of 
cytoplasmatic fraction and the purified fraction were analyzed by SDS-PAGE 
(Fig.29). After digestion with TEV protease, the D2 domain alone resulted 
highly unstable and poorly soluble. However the residual protein in solution was 
assayed by ELISA and SPR for binding to immobilized IgE, but resulted 
essentially inactive.  
 
 Vector N-terminal 
TAG 
E.Coli strain Optimal Expression 
conditions 
pETM40 MBP Bl21(DE3) 0.1 mM IPTG 16h 22°C Cytoplasmatic 
expression pETMA11 His6x Bl21(DE3)trxB 0.2 mM IPTG 16h 22°C 
Figure 28: 15% SDS-PAGE analysis of the His6x-D1-D2 domain recovered from the 
inclusion bodies after E.coli expression. Lane 1, purified His6x-D1-D2 domain under non 
reducing conditions; lane M, Perfect Protein Marker 15-150 KDa (Novagen); lane 2, purified 
His6x-D1-D2 domain under reducing conditions. 
TABLE XI: A summary of the optimal expression conditions for the recombinant D2 domain of 
αhFcεRI.  
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II.4.2.4 Expression, purification and characterization of His6x-D2 domain 
 
II.3.2.4a His6x-D2 domain expression and purification 
   
The aminoacid sequence His6x-D2 domain expressed is reported in Fig.30:  
 
The His6x-D2 domain (Theoretical M.W. 13548.1 Da), was recovered within the 
soluble fraction buffered with 30 mM Tris-HCl, 500 mM NaCl and 3 M Urea, pH 
8.0. The total cell protein fraction, the soluble fraction (supernatant of cell 
lysate) and the purified fractions were analyzed by SDS-PAGE to assess purity 
(Fig.31A). The same fraction was also analyzed by western blot analysis using 
an anti-His6x antibody conjugated with HRP to assess the protein identity 
(Fig.31B). 
 
 
 
Figure 29: 15% SDS-PAGE analysis of MBP-D2 domain purification: lane M, Perfect 
Protein Marker 15-150 KDa (Novagen); lane 1, total fraction; lane 2, soluble fraction; 
lanes 3-4, purified fractions under reducing condition. 
                                                                   85                        95                      105                          115  
MKHHHHHHP    MSDYDIPTTE    NLYFEGAMFS   DWLLLQASAE   VVMEGQPLFL    RCHGWRNWDV    
                  125                       135                 145                          155                      165 
YKVIYYKDGE   ALKYWYENHN   ISITNATVED       SGTYYCTGKV   WQLDYESEPL   NITVI 
Figure 30: Amino acid sequence of N terminal His6x tag (in black); TEV site (in red); linker 
D1-D2 (in sky blue); D2 domain (in green) C-terminal part. Two cysteines are underscore: 
Cys107-Cys151 are involved in disulfide bridge to form Ig-like domain.   
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II.4.2.4b Refolding of His6x-D2 domain  
 
The His6x-D2 domain was refolded by gradually removing the urea from the 
refolding buffer by dialysis. Finally, the protein resulted soluble in 30 mM Tris-
HCl, 150 mM NaCl, 2 M urea pH 8.0 buffer. The final step of dialysis was 
performed at 4°C overnight against 30 mM Tris-HCl, 150 mM NaCl, 5 mM 
reduced glutathione, 0.5 mM oxidized glutathione at pH 8.0. The precipitate that 
formed during the refolding procedure was removed by centrifugation and the 
recovered His6x-D2 was analyzed by SDS-PAGE under reducing and non-
reducing conditions (Fig.32). The reduced His6x-D2 domain under reducing 
conditions migrated much slower on SDS-PAGE compared to the refolded 
protein, and this was likely due to the more compact structure of the disulfide 
bonded protein.  
 
 
 
 
Figure 32: 15% SDS-PAGE analysis after refolding procedure: lane M, Perfect Protein Marker 
15-150 KDa (Novagen); lane 1, His6x-D2 domain under reducing conditions; lane 2, His6x-D2 
domain under no reducing conditions.  
Figure 31: A) 15% SDS-PAGE analysis of the His6x-D2 domain purification. Lane M, 
Perfect Protein Marker 15-150 KDa (Novagen); lane 1, total fraction; lane 2, soluble fraction; 
lanes 3-4-5, purified fractions under denaturing condition. B) Western blot analysis using an 
anti-His6x antibody HRP-conjugated: lane M1. Marker Precision Plus Protein 10-250 KDa 
(Biorad); lane 6, His6x-D2 domain purified fraction. The M.W. is consistent with the protein 
sequence. 
A B 
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II.4.2.4c His6x-D2 domain characterization 
 
The formation of the single disulfide bond was assessed by alkylating the 
protein and verifying cisteine derivatizaton by mass spectrometry. The reaction 
was performed using 4-vinylpyridine (4-VP) on the refolded His6x-D2 domain. 
The protein was unaffected by this reaction, indicating the absence of free 
thiols. Importantly, LC-MS analysis of the domain under reducing and non 
reducing conditions reproducibly indicated the difference of only 2 amu 
between the two mass values. (Fig.33A and 33B). The resulting value of 
molecular weight are 13546 amu for reduced His6x-D2 domain and 13542 amu 
for His6x-D2 domain in agreement with that calculated respectively 
(MWexp/MWtheor.:13546 ± 2/13548 amu and MWexp/MWtheor.:13542 ± 4/13546 
amu ).  
 
The His6x-D2 domain was dialyzed over night at 4°C against 20 mM phosphate 
pH 8.0 buffer and analysed by CD to assess the protein conformation in 
solution. The spectrum shown in Fig.34, as expected, showed a predominance 
of β-sheet structures, with a minimum at 215 nm and a positive band at about 
195 nm. CD spectra are reported in molar ellipticity [θ]. 
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Figure 33: A) Deconvoluted mass spectrum of the DTT-reduced recombinant His6x-D2 
domain and B) spectrum of the same protein before reduction.  
Figure 34: CD spectrum of the recombinant refolded His6x-D2 
domain. The protein exhibits a spectrum with a large content of β-
structures. 
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All attempts to obtain the D2 domain without the polyhistidine tag using TEV 
protease, were unsuccessful. Indeed, despite the correct formation of the 
disulfide bridge, the protein has a very strong tendency to form non covalent 
oligomers, as demonstrated by gel filtration. The protein analyzed under both 
reducing and non reducing conditions eluted at a volume consistent with an 
aggregate of molecular size greater than about 80 kDa (Fig.35), thereby 
suggesting the occurrence of non covalent oligomers. Addition of different salt 
concentrations to increase the ionic strength and detergents to disrupt 
hydrophobic unspecific interactions lead invariably to the same result. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II.4.4.5 His6x-D2 domain–Immunoglobulins E binding assay 
 
The refolded His6x-D2 domain, despite its oligomeric form, was tested for 
binding to IgE by ELISA and SPR assays. In a first ELISA assay, IgE were 
immobilized at 2 µg/mL (10 nM) on the surface of the microtiter plate and the 
refolded receptor domain was assayed at concentrations ranging between 0.15 
µM to 40 µM. 30 mM Tris-HCl, 150 mM NaCl, pH 8.0 was used as buffer. 
Detection was achieved using an anti-polyhistidine antibody conjugated to HRP 
(Methods section II.3.2.18). Data obtained are reported in Fig.36, where a dose-
dependent and saturable binding is observable. By data analysis and fitting using 
a non-linear regression algorithm, a KD
 
of 2.29 ± 0.06 µM was estimated. 
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Figure 35: Gel filtration analysis on a Superdex75 10/300 GL column 
of the refolded His6x-D2 domain (brown line) and reduced His6x-D2 
domain (blue line). Both proteins were eluted at the void volume, 
suggesting the presence of large aggregates. 
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The binding was further confirmed by SPR assays. In this instance, solutions of 
the receptor domain at increasing concentration were injected at  20 µL/min on 
the IgE-activated chip. Fig.37 A-E show the recombinant protein bound in a 
dose-dependent manner to the immobilized IgE. 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The association and dissociation phases of the response curves, as previously 
shown for the synthetic peptides, were fitted to biphasic models assuming a 1:1 
stoichiometry.  
The ability of the model to describe the experimental data was evaluated by 
examination of the residual plots, which were calculated by subtracting the 
experimental data points from the fitted curve. Also in this case, residual values 
were considerably small as compared to the monophasic fitting and largely 
scattered throughout the data points, thus suggesting a better fitting. 
Figure 36: Dose-dependent ELISA binding assay between coated IgE (10 nM) and 
the refolded His6x-D2 domain of the IgE receptor.  
Figure 37 A: Overlapping sensorgrams relative to the binding between 
His6xD2 domain and IgE. Curves refer to the concentration of 2 µM, 10 µM and 
20 µM.  
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The biphasic fitting is characterized by two association rates and two 
dissociation rates which yield an affinity constant for each phase of the 
interaction. A summary of association rate and dissociation rate constants 
obtained by fitting the data, as well as the affinity constants are reported in the 
following Table XII. 
The rate constant kd1 (5.82 + 0.73 x10-3 s-1), kd2 (3.44 + 0.19 x10-1 s-1), ka1 (6.99 + 
0.16 x 102 M-1
 
s-1) and ka2 (3.10 + 0.32 x 104 M-1 s-1) were extrapolated and 
obtained by averaging all experiments. The thermodynamic equilibrium constants 
are: KD1= 8.3 µM and KD2= 11.1 µM , which are both higher than that obtained 
by the ELISA assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte 
Concentration 
His6x-D2 
domain 
 
Association rate 
(M-1
 
s-1) 
Ka1 
 
 
Dissociated rate 
(s-1) 
Kd1 
 
Association rate 
(M-1
 
s-1) 
Ka2 
 
Dissociated rate 
(s-1) 
Kd2 
 
 
2 µM 
 
8.91 x 102 
 
 
6.81 x 10-3 
 
 
1.69 x 104 
 
 
3.02 x 10-1 
 
 
10 µM 
 
1.02 x 103 
 
 
2.44 x 10-4 
 
 
2.01 x 104 
 
 
9.70 x 10-2 
 
 
20 µM 
 
1.85 x 102 
 
 
1.04 x 10-2 
 
 
5.59 x 104 
 
 
6.33 x 10-1 
 
 
MEAN 
 
6.99 x 102 
 
 
5.82 x 10-3 
 
 
3.10 x 104 
 
 
3.44 x 10-\ 
 
 
KD1 = 8.33 x 10-6 M 
 
 
KD2 = 11.1 x 10-6 M 
 
Table XII: Kinetic and thermodynamic parameters for association of the D2 domain 
to immobilized IgE. Data refer to the indicated concentrations. Association and 
dissociation rate constants were averaged and used to calculate the thermodynamic 
dissociation constants for the two association sites. All data fit optimally with a 
biphasic association and dissociation.  
Figure 37 B-E : Analysis of SPR data for the binding of His6xD2 domain at a concentration of 
10 µM to immobilized IgE. The fitted lines (black) are overlaid with the experimental curves 
(fuchsia) for the association (B) and dissociation phases (D). The corresponding residual plots 
are shown (C and E respectively). 
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To obtain a macroscopic dissociation constant that takes into account both 
binding sites, we plotted (as for the synthetic peptides) the RUmax for all 
concentrations explored versus the concentration and then fitting the data by a 
non-linear regression algorithm followed by a Scatchard analysis (Fig.38A-B). 
By this approach we could measure a KD of 1.8 ± 0.9 µM that was in very good 
agreement with that obtained by the ELISA assay. Again, as experienced with 
the synthetic peptides, the global apparent KD was lower (stronger affinity) than 
that referred to the single constants, confirming the two-site association and the 
cooperative mechanism between them.  
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The His6x-D2 recombinant protein shows reduced affinity for IgE compared to 
the native receptor, exhibiting a KD in the very low µM range. As reported in the 
literature, the D1 domain is required for optimal binding with the IgE. Although 
D1 domain is not directly involved in the binding, it structurally contribute to the 
high affinity maintenance [10]. The linker region between the D1 and D2 
(residues 85-89), at the membrane distal portion of the interface, is reported to 
affect the display of the two domains and the ligand-binding region, therefore 
could have a critical supportive role in the maintenance of the D1-D2 interface 
(overall complex organization). In addition, the low affinity displayed by this 
single domain, could suffer the occurrence of the oligomeric structure leading to 
a reduced exposure of contact sites. This behaviour could also be attributed to 
the presence of the polyhistidine tag which is indeed inaccessible to the TEV 
protease and could therefore contribute to the aggregation. If the protein 
aggregates to greater extent at the N-terminus, this could also make the linker 
residues (belonging to the binding site 2) poorly accessible for binding to the 
immunoglobulin. To try to optimize the binding conditions, the effects of the 
ionic strength, the presence of detergents and various pH values were 
evaluated. This screening was carried by ELISA assay using IgE immobilized at 
2 µg/mL (10 nM) and the His6x-D2 domain at 5 µM. The binding was carried 
out using 4 different buffers, reported in Table XIII, which accounted for the 
indicated conditions. As shown in Fig.39, the binding between IgE and the 
His6x-D2 domain, diluted in Buffer 4, was 1.5 fold higher than that in Buffer 1.  
 
 
Figure 38: Plot of the RUmax vs His6x-D2 domain concentration fitted by a non-linear 
regression (A) and corresponding Scatchard analysis (B). 
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TABLE XIII: summary of conditions explored for 
binding of the receptor D2 domain to IgE. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the basis of these results, we have assumed that slightly acidic conditions 
could influence the N-terminal His6x-tag by introducing positive charges on the 
histidine side chains. These conditions were utilized in all subsequent binding 
experiments.  
New dose-dependent binding assays were then carried out by ELISA 
immobilizing IgE at 5 µg/mL (25 nM) and the His6x-D2 domain at progressively 
increasing concentrations [0.05 - 20 µM] in 25 mM Bis-Tris, 150 mM NaCl pH 
6.5 buffer. Analysis of these data by non-linear regression and by Scatchard 
plot, showed that clearly two independently saturable sites are present (Fig.40 
A). One is saturated for concentrations up to about 1 µM (Fig.40 B-C) and has 
a binding affinity of 112 ± 0.04 nM, while the second (site 2) is saturated only 
for concentrations between 1 µM and 20 µM and displays a much higher KD 
4.1 ± 0.06 µM (Fig.40 D-E).  
 
 
 
 
 
Buffer 
1 Tris-HCl 30mM pH 8.0 NaCl 0.15M 
2 Tris-HCl 30mM pH 8.0 NaCl 0.5M 
3 Tris-HCl 30mM pH 8.0 Triton 0.02% 
4 Bis-Tris 25 mM pH 6.5 NaCl 0.15M 
Figure 39: ELISA test of binding between the recombinant His6x- D2 domain 
and IgE to monitor the effects of salts detergents and buffer. As shown the 
binding seems to be optimal at pH 6.5 in the presence of a low concentration 
of buffering salt. 
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II.4.3. ELISA Competition assay 
 
In order to assess the binding of the designed peptides on the IgE binding site, 
we carried out binding competition ELISA assays using the recombinant His6x-D2 
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Figure 40: ELISA dose-dependent assay: IgE coated at 5 µg/mL was able to bind the His6x-
D2 domain, diluted in 25 mM Bis-Tris, 150 mM NaCl pH 6.5 buffer, in a dose dependent 
fashion. Detection was achieved using a His-antibody conjugated with HRP and the 
absorbance intensity was measured at 490 nm. The full binding assay, reported in Fig. A, 
show that two saturation points occur: the first over a Abs490=0.18 (highlighted in Fig. B) and 
the second over a Abs490=1.2 (highlighted in Fig. D). The Scatchard analysis corresponding 
for each site are reported in Fig. C and E, respectively. 
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domain and IgE. In a preliminary experiment the pre-saturation conditions were 
set up and identified using 10 nM IgE (2 µg/mL) and 5 µM His6x-D2 domain. At 
this receptor concentration both binding sites are saturated. For the dose-
dependent competition assay, we explored peptide:receptor molar ratios between 
1 and 100. Competitor concentrations therefore ranged between 5 µM and 500 
µM. Results reported in the following Fig.41 A-C are the average of triplicate 
experiments and are reported as (B/B0)*100, where B stands for the average Abs 
from triplicate data points for a given analyte and B0 is the average Abs 
determined without competitor. 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data show that all three peptides efficiently block the interaction between IgE and 
the receptor D2 domain, confirming the view that the peptides actually mimic the 
receptor binding sites, though with a reduced affinity. Noticeably, IC50 values 
determined by this approach, are consistent with the relative binding affinities of 
the 3 bioactive peptides. In particular, IgE-TRAP red has an IC50 of 36 µM, while 
the 1st Loop and 2nd miniLoop show IC50 of 103 and 864 µM, respectively.  
 
 
 
 
-7.0 -6.0 -5.0 -4.0 -3.0
0
20
40
60
80
100
A IgE-TRAP red, Log M
B
/B
0*
10
0
-6.5 -5.5 -4.5 -3.5
0
20
40
60
80
100
B 1
st
 Loop, Log M
B/
B 0
*
10
0
-6.0 -5.0 -4.0 -3.0
0
25
50
75
100
C 2
nd miniLoop, Log M
B/
B
0*
10
0
Figure 41. Dose-dependent binding competition ELISA assays carried out using the 
recombinant His6XD2 domain of the IgE receptor and commercial IgE. The peptides used 
were: IgE-TRAP red (A), 1st Loop (B) and 2nd miniLoop (C). By data fitting and analysis using 
non-linear regression the following IC50 were estimated: IgE-TRAP red: 36.0 ± 0.1 µM; 1st 
Loop: 103.0 ± 0.2 µM; 2nd miniLoop: 864.0 ± 0.2 µM.   
 62 
II.5 CONCLUSIONS AND PERSPECTIVES 
 
One of the major challenges for the comprehension of physiological and pathological 
functions regulating the cellular processes, is the elucidation of molecular 
mechanisms underlining protein–protein interactions.  
Protein–protein interactions, indeed, play a key role in a variety of biological 
processes and are therefore important targets for the design of novel therapeutics. 
Unlike the design of enzyme inhibitors, the disruption of protein–protein interactions 
is far more challenging, due to large interfacial areas involved in protein recognition 
and to the relatively flat topologies of these surfaces. Nevertheless, in spite of such 
difficulties, there has been considerable progress in the recent years.  
In the first part of PhD thesis we have studied small peptides that act as modulators 
of protein–protein interactions playing a crucial role in allergic reactions.  
The binding of IgE to its high affinity receptor FcεRI is a critical step in the 
allergic reaction and the knowledge at atomic level of the interaction interface 
between the two proteins has paved the way to the design of effective drugs blocking 
the receptor signalling and thus to new opportunities for molecular therapeutic 
intervention. The exact three-dimensional structure of the IgE-FcεRI complex, 
elucidated by X-ray crystallography, is indeed the ideal starting scaffold for the 
design of specific inhibitors that bind the receptor or the immunoglobulin as well. 
While binding the receptor binding site could easily lead to agonistic activities, the 
blocking of circulating IgE by soluble factors is an approach validated by the 
demonstrated efficacy of the rhu-Mab 25, a humanized recombinant monoclonal anti-
IgE antibody, known as Omalizumab, which has recently entered the clinical phase 
IV and is therefore already on the market as a unique non-symptomatic treatment of 
allergic asthma. 
Under these premises, on the basis of the receptor structure, we have designed 
small polypeptides that mimic the receptor binding interface and specifically bind IgE. 
The receptor-mimicking polypeptides, named IgE-TRAP, have been designed to 
reproduce the two distinct receptor binding sites unveiled by the crystallographic 
structure.   
Although the polypeptides show a relatively low binding capacity (low micromolar 
range) compared to the full length receptor (KD =10-9–10-10M), they exhibit a very 
high selectivity for IgE, being uncapable to recognize the conserved IgG and IgA. 
Furthermore they clearly show a two-site mechanism of binding, demonstrating the 
efficiency of the design and suggesting a high specificity of recognition on the two 
distinct sites. Worthy of note, peptides, also exhibit a cooperative mechanism of 
interaction, as demonstrated by an average increase in affinity of 2-3 times of 
macroscopic KD compared to single-site KDs.  
The soluble and functional D2 domain of hαFcεRI has been prepared as recombinant 
protein, in order to verify the ability of the selected peptides to inhibit its binding to 
IgE and to validate the hypothesized binding site. As expected, the active peptides 
efficiently block the interaction between IgE and the receptor D2 domain in 
competition ELISA assays, therefore confirming that the peptides mimic the receptor 
binding sites, though with a reduced affinity. Noticeably, IC50 values determined are 
consistent with the relative binding affinities of the 3 bioactive peptides.  
Despite the lower affinity of these new molecules compared to that of the full 
receptor, these peptides are very promising in terms of selectivity as they appear to 
target with high specificity the binding site on the IgE. 
Given the small molecular size (especially the 1st Loop), they also do not show 
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immunogenic properties and can be used in in vivo experiments at high doses and 
without modifications.  
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                                                                                                       CHAPTER III 
 
III. IDENTIFICATION OF A BCL10 INHIBITORY 
PEPTIDE  
 
III.1 INTRODUCTION 
 
Modular protein interaction domains play an important role in signal transduction by 
the assembly of components into specific signalling complexes.  
The interchange of protein modules between signalling molecules has enabled the 
elucidation of new signal transduction pathways due to specific stress and 
developmental stimuli. 
The cytoplasmatic proteins, transporting information from cell surface receptors to 
their intracellular targets, are commonly constructed of modular domains that either 
have a catalytic function (such as protein or lipid kinase activity), or mediate the 
interactions of proteins with one another, or with phospholipids, nucleic acids or small 
molecule second messengers. These interacting domains play a critical role in the 
selective activation of signalling pathways, through their ability to recruit target 
proteins to activated receptors, and to regulate the subsequent formation of signalling 
complexes.  
An intriguing challenge is to understand how interacting domains cooperate to 
establish the complex signalling networks, controlling events as fundamental and 
complex as cell development, maintenance of homeostasis and immune system 
function.  
The cellular life-cycle is actually governed by of one of the most important regulated 
processes: the apoptotic cascade pathway [1]. 
Apoptosis is a conserved, gene-directed mechanism essential for the elimination of 
unnecessary or dangerous cells and for maintaining cellular homeostasis [2]. 
Dysregulation in apoptosis mechanisms may contribute to a variety of human 
diseases such as autoimmune syndromes, lymphomas and solid tumours. 
Apoptosis results in a complex cascade of events and signalling pathways involving a 
large variety of receptors and factors, such as the so called “Death Domain” 
superfamily, composed of the “death domain” (DD), the “death effector domain” 
(DED) and the “caspase recruitment domain” (CARD) proteins. These proteins 
regulate apoptosis signalling through specific interactions necessary for transducing 
a “death signal” in the vital process of normal cell development and maintenance of 
homeostasis [3,4].  
Over the past few years, a number of adaptor molecules containing the CARD 
domain have been identified [5]. 
CARD was originally described as a protein-binding motif that interacts with specific 
caspases through a CARD-CARD homophilic interaction. However, CARD has also 
been found in many adaptor proteins that do not interact with caspases, but rather 
mediate assembly of proteins involved in apoptosis and/or the control of the 
activation state of NF-κB transcription factor [4]. Thus, it is now well established that 
CARD-containing proteins play important roles in the assembly and activation of 
apoptotic and inflammatory complexes, which are mediated by homotypic 
interactions between CARD domains [5]. 
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BCL10 is a CARD-containing protein that several groups have independently 
identified as a regulator of apoptosis and as an activator of NF-κB factor [6,9,34,35]. 
Several studies report that BCL10 oligomerizes through its N-terminal CARD domain 
thus promoting the inappropriate activation of the transcriptional factor NF-κB [4,6]. 
 
III.1.2 The family of CARD containing proteins  
 
Homotypic interactions between proteins containing CARDs, DEDs or DDs have 
been found in divergent signalling pathways resulting in caspase activation and 
apoptosis. A classic example is the CD95 (Fas/APO-1) pathway. After interaction 
with its ligand, the CD95 receptor recruits the adaptor Fas-associated protein with 
death domain (FADD) via DD motifs present in both proteins [7]. In turn, FADD 
recruits caspase-8 to the receptor complex via a single DED motif present in the 
former, and two tandemly arranged DED motifs present in the latter. This interaction 
leads to caspase-8 activation and propagation of the death signal through a cascade 
of further proteolytic events. 
Notably, CARD–CARD interactions between Apaf-1 and caspase-9 are critical for the 
assembly of a protein complex (called the apoptosome) that promotes caspase-9 
activation during apoptosis [8].  
Certain CARD-containing caspases have also been implicated in proteolytic 
processing of cytokines (caspase-1 is required for maturation of IL-1β and IL-18) that 
are involved in the inflammatory response. 
However, in the past years, the family of CARD-containing proteins has been 
extensively investigated and it has recently been confirmed that CARD-containing 
proteins do not only promote the caspase activation. Rather, accumulating evidence 
suggest that many CARD proteins participate in NF-κB signalling pathways 
associated with apoptosis and immune responses [9]. 
Proteins containing CARD domains can be divided into subfamilies based on their 
overall domains structures: nuclear binding CARD domains (NBD-CARDs), coiled-
coiled CARD domains (CC-CARDs), bipartite-CARDs and CARD-only proteins [9]. 
The NBD-CARDs contain a nucleotide-binding domain in addition to a CARD module 
and most also contain repeats, such as leucine-rich, within their C-terminal. The NBD 
module most likely acts as an oligomerisation surface and the repeat region as a 
sensory domain that regulates oligomerisation. 
The CC-CARD proteins are structurally similar to the NBD-CARDs but the central 
NBD is replaced by a coiled-coil motif acting as an oligomerisation surface.  
The bipartite-CARDs contain a CARD domain plus an other motif such as a kinase 
domain, a DD motif or a protease domain. After recruitment by the NBD-CARDs or 
the CC-CARDs they either become active in the process or to recruit additional 
effector molecules to the complex, such as the IκB kinase subunit (IKKγ/NEMO).  
The CARD-only proteins may act as positive or negative regulators of the multi-
domain CARDs (NBD-CARDs and CC-CARDs) by regulating recruitment between 
protein. Alternatively, the CARD-only proteins may compete with the bipartite CARDs 
for binding to their targets. 
Although all CARDs possess a remarkably similar secondary structure and often a 
discrete sequence identity, the members of each group act in related signalling 
pathways. 
CARD domains are 10-15 kDa, located at the N-terminal end, and consist of anti-
parallel six-helices bundles in the Greek key topology that form highly specific 
homophilic interactions between signalling partners [10,11]. 
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There are, at least, three major pathways in which CARD proteins act: the regulation 
of caspase activation in the context of apoptosis; the regulation of caspase activation 
in the context of inflammation; the regulation of NF-κB activation in the context of 
innate or adaptive immune responses.  
All CARD proteins described so far have been implicated in one way or other in host 
defense against infection, environmental stress, or cellular damage. Clearly, there is 
significant cross-talk between the pathways that result in NF-κB activation and those 
that lead to caspase-mediated inflammation or apoptosis. Thus, it is not much of a 
surprise to find that similar protein modules are found repeatedly in proteins from all 
pathways.  
 
III.1.3 BCL10 protein: a modular protein 
 
BCL10 (B-cell lymphoma 10) belongs to a family of proteins containing caspase 
recruitment domains (CARD). It has a bipartite structure consisting of an N-terminal 
CARD and a C-terminal domain that is rich in serine and threonine residues which 
undergo multiple phosphorylations and are therefore structural elements with a 
regulative role. 
Although the BCL10 pathway is still to be clarified, several studies have been 
focused on its homophilic interactions with other protein partners mediated by its 
CARD domain. These include interactions with RIP2 [14], CARMA1 (also known as 
CARD11 or Bimp2) [14-16], CARMA2 (also known as CARD14 or Bimp3) [14], 
CARMA3 (also known as CARD10 or Bimp1) [17,18] and CARD9 [19].  
These three CARMA proteins share similar structural motifs, with an N-terminal 
CARD domain, followed by a coiled-coil domain, a PDZ domain (acronym combining 
the first letters of three proteins: Psd95 (post synaptic density protein 95), DlgA 
(Drosophila disc large tumor suppressor), and Zo-1 (zonula occludens-1 protein)), a 
SH3 domain, and a C-terminal GUK domain (guanylate kinase-like domain). Their 
expression and diversification in signalling pathways depends on their cellular 
localization [14-19]. Functionally, CARMA proteins are supposed to function as 
molecular scaffolds that assist recruitment and assembly of signal transduction 
molecules. 
Several studies report that BCL10 acts at a convergence point between the T- and B-
cell receptor-driven NF-κB signalling pathways [12,13,20,21].  
In the TCR (T cell receptor) signalling pathway (Fig.1), phosphorylated CARMA1 
recruits BCL10, MALT1, and TRAF6 [19-22]. MALT1 and TRAF6 then functions as 
E2 ligase to further induce K63-linked poly-ubiquitination of NEMO, leading to 
phosphorylation and activation of the IKK complex [23-25]. 
Thus, in lymphocytes, the N-terminal CARD domain of BCL10 binds to the CARD 
domain of CARMA1, and this interaction is required for the correct transduction of the 
NF-κB activating signal [26].  
Targeted mutation of the gene encoding either proteins results in severe impairment 
of T cell and B cell proliferative responses to antigen stimulation, due to the failure to 
activate NF-κB [15,19-21,25-27]. Additionally, cytogenetic studies have revealed that, 
whereas BCL10 translocation is associated with mucosa associated lymphatic tissue 
(MALT) B cell lymphomas, missense mutations in the CC-domain of CARMA1 are 
frequently detected in diffuse large B cell lymphomas [28,29]. 
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Figure 1: Physiological (A) and pathological (B) BCL10 signalling in T-cell receptor-mediate activation 
 
 
Instead, the complex of proteins that comprises CARMA3, BCL10 and MALT1, 
appears to play an important role in cells outside of the immune system. In fact, 
recent studies indicate that CARMA3 and BCL10 are implicated in the signal 
transduction pathways elicited by G protein-coupled receptors, a large family of cell 
surface receptors that regulate cell migration, differentiation, proliferation, and 
survival [30-32]. Specifically, it appears that NF-кB activation induced by G protein-
coupled receptors utilize a pathway dependent on the molecular complex containing 
CARMA3 and BCL10 [33].  
Altogether, these data indicate that BCL10 is a cytosolic signalling 
intermediate in the pathway connecting antigen receptors to activation of the NF-κB 
transcription factor [34,35] and is likely to play a significant role in the etiology and/or 
pathogenesis of MALT lymphoma [36,37]. It therefore represents the molecular target 
for the treatment of pathologic conditions associated with inappropriate NF-κB 
activation, ranging from the MALT B cell lymphomas with t(1;14)(p22;q32), to the 
inflammatory disorders involving G protein-coupled receptors, such as chronic liver 
injury, atherosclerosis and cardiac hypertrophy [33].   
Several studies have reported that the BCL10-CARD oligomerization event assist the 
formation of cytoplasmatic filaments that serve as scaffold for recruitment of NF-κB-
activating signal transduction elements [6] and these filaments seem to be 
responsible for the inappropriate NF-κB activation which induces cell proliferation and 
tumorgenesis, as in the Lymphomas of Malt.  
 
Physiological Pathway Pathological Pathway
Antigen receptor
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III.2 PROJECT AIMS 
The emerging importance of BCL10 as a target for modulating the NF-κB mediated 
inflammation and tumorgenesis and the involvement of an oligomerization process in 
these mechanisms, has lead us to investigate the self-association regions of the 
BCL10 CARD domain and the possibility of inhibiting the BCL10-mediated functions 
by peptides able to interfere with protein oligomerization process. While it is widely 
accepted that BCL10 oligomerizes through its N-terminal CARD domain [4,6] the 
structural basis for this interaction remains to be defined. Following a simple and 
effective methodology based on the use of fragments derived by limited proteolysis of 
the protein, we have selected a peptide that mimics the self-recognition interface and 
disrupts the interaction at nM concentrations. By this method, coupled to the use of 
synthetic peptides, we have been able to identify single residues involved in CARD-
CARD contacts and to demonstrate that by interfering with the protein 
oligomerization, NF-κB activation is also strongly impaired. 
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III.3 EXPERIMENTAL PROCEDURES 
 
III.3.1 Materials 
 
N-protected Fmoc-amino acid derivatives and coupling reagents for peptidic 
synthesis were from Inbios (Pozzuoli, Napoli). HPLC-grade solvents and 
trifluoroacetic acid (TFA) are from LabScan (Stillorgan, Dublin, Ireland).  
Trypsin treated with L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK-
trypsin), streptavidin horseradish peroxidase conjugated (STR-HRP), o-
phenyldiamine (OPD) table sets, Rink amide p-Methylbenzhydrylamine (MBHA) 
resin, tri-isopropyl-silane (TIS), Fluorescein isothicyanate (FITC), Phorbol12-
myristate13-acetate (PMA) and ionomycin are from Sigma-Aldrich (Milan, Italy).  
Enhanced Chemiluminiscent (ECL) substrate and EZ Link NHS-LC biotin reagent 
(succinimidyl-6-(biotinamido) hexanoate) is from Pierce (Milano, Italy). 
TransBlot SD semi-dry, blotting grade blocker Non-Fat Dry Milk (NFDM) are from 
Biorad.  
Anti-BCL10 antibodies were provided by Dr. P. Vito, Università del Sannio [6]. 
Horseradish peroxidise (HRP) conjugated secondary antibodies, luciferase assay Kit 
are from Promega.  
All molecular biology kits are from Qiagen (Milano, Italy) except Quik Change Site-
Directed Mutagenesis Kit that is from Stratagene. All plasmids and expression 
vectors used in this study were generated by standard procedures and confirmed by 
sequencing.  
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal calf serum (FCS), and Trypsin 
are from GIBCO (Milan, Italy). 
Solid-phase peptide synthesis was carried out on a fully automated peptide 
synthesizer AAPTECH 348 W, Advanced Chemtech (Louisville, KY).  
Preparative RP-HPLC was carried out on a Shimadzu LC-8A system, equipped with 
a SPD-M10 AV detector.  
LC-MS analyses were carried out on an LCQ DCA XP Ion Trap mass spectrometer 
(ThermoElectron, Milan, Italy) equipped with an OPTON ESI source, operating at 4.2 
kV needle voltage and 320°C and with a complete Surveyor HPLC system. LC-MS 
columns were from ThermoElectron.  
CD spectra were recorded using a Jasco J-810 spectropolarimeter (JASCO Corp) 
equipped with a Peltier-type temperature control system 
Other reagents and chemical suppliers are indicated in the section of methods. 
 
III.3.2 Methods 
 
III.3.2.1 BCL10-CARD domain cloning, expression and purification 
 
The doubly mutated Cys29Ser-Cys57Ser N-terminal region of BCL10, comprising 
residues 1-107, named BCL10-CARD, was recombinantly expressed in E.Coli as a 
His6x-tagged fusion protein. Mutations, designed to minimize the possible protein 
aggregation due to disulfide formation, were introduced by site-directed mutagenesis 
of the wild-type gene using Quik Change Site-Directed Mutagenesis Kit following 
manufacturer’s instructions. The mutated sequence was cloned in the pET28 vector 
to obtain the fusion-His6x protein with a ∆-link of 36 residues (poly-histidine tag 
included). Protein expression was carried out in BL21 (DE3) at 37°C and inducing 
overnight with 1 mM IPTG before lysing the pellets in PBS buffer (137 mM NaCl, 2.7 
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mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 pH 7.4) containing 8 M urea. Fractions of 
purified protein were obtained by affinity chromatography purification on Ni-NTA 
columns equilibrated in 100 mM phosphate, 10 mM Tris-HCl, 8 M urea pH 8.0 buffer. 
The protein was eluted by gradually lowering the pH from pH 8.0 to pH 4.5, then the 
pooled fractions were further purified by gel filtration on a Sephadex G150 column in 
a 50 mM Tris pH 4.0 buffer and finally dialyzed against a 100 mM sodium acetate 
buffer at pH 4.0. This buffer was used throughout all the experiments as the protein 
displayed a strong tendency to precipitate at pH values comprised between 5.0 and 
8.0. About 5 mg of protein from 100 g of pellets were recovered in typical 
preparations. The recombinant protein was prepared at the Dipartimento di Biologia e 
Patologia Cellulare e Molecolare, Università Federico II, Napoli. 
 
III.3.2.2 Circular Dichroism analysis 
 
CD spectra of BCL10-CARD was acquired in sodium acetate 1x10-6M buffer solution 
at pH 4.5, calculated by Bradford measurements [43], and at room temperature.  
CD spectra of BCL10 peptides were acquired in 10 mM phosphate pH 7.0 buffer with 
Cpep = 20 x 10-6 M, calculated by UV measurements, and R.T. 
Spectra were recorded using a 0.1 mm path length quartz cuvette. Data were 
collected at 0.2 nm intervals with a 20 nm min-1 scan speed, a 2 nm bandwidth, and a 
16 s response, from 260 to 190 nm, under constant N2 flow. The recorded spectra 
were then signal-averaged over at least three scans, and the baseline was corrected 
by subtracting the spectrum of the buffer. Spectra were then transformed in molar 
ellipticity/mean residue [θ], expressed in deg·cm2·dmol-1. 
 
III.3.2.3 Biotinylation of BCL10-CARD domain 
 
Aliquots of the recombinant BCL10-CARD domain were biotinylated using the EZ 
Link NHS-LC biotin reagent according to the manufacturer’s instructions. A freshly 
prepared solution of NHS-LC-biotin (10 mM in DMSO:water 1:9 v/v) was added to a 
protein at a 20:1 mol/mol ratio; the pH was then adjusted to 8.0 with NaOH and the 
solution incubated for 30 minutes at R.T. Biotinylated samples were dialyzed against 
50 mM sodium acetate pH 4.0 buffer in order to remove the excess free biotin. The 
biotinilated BCL10-CARD domain solution was sterilized by passing the solution 
through a 0.22 µm filter and stored in working aliquots at -80°C. Protein biotinylation 
was confirmed by LC-MS analysis as determined by the MW increase of 340 amu 
due to the biotin moiety. 
 
III.3.2.4 Protein digestion with trypsin and peptide fractionation 
 
An aliquot of BCL10-CARD domain (1.0 mg; 62 nmoles) was dissolved in 1.0 mL of 
50 mM Tris-HCl, 20 mM CaCl2 pH 8.0 buffer, 10% acetonitrile was then added to 
enhance peptide solubility. TPCK-treated trypsin was then added at a final 1:100 
enzyme-substrate ratio (w/w) and the reaction was left at 37°C under gentle agitation 
for 16 hours. A protein sample (0.1 mg) was analyzed by LC-MS/MS to assess 
protein digestion and to identify the fragments obtained. For this analysis a C18 
BioBasic 30x2 mm ID column (ThermoElectron), equilibrated at 0.2 mL/min with 5% 
CH3CN, 0.05% TFA, was utilized and applying a gradient from 5% to 55% in CH3CN, 
0.05% TFA over 65 minutes. Tryptic products were fractionated by RP-HPLC using a 
C18 250x4.6 mm ID column equilibrated at 1.5 mL/min flow rate with 5% CH3CN, 
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0.1% TFA, and applying a gradient of the same solvent from 5% to 70% in 50 
minutes. Ten fractions, 1F to 10F, were collected and subsequently analyzed by 
analytical LC-MS/MS to obtain their relative composition. Fractions 1-3, putatively 
containing highly hydrophilic fragments, were analysed with a gradient of CH3CN, 
0.05% TFA from 1% to 30% over 30 minutes, while the remaining were analyzed 
under the same analytical conditions reported above. Lyophilized fractions were 
stored at –80°C until use. 
For the identification of the tryptic fragments the program MS-Digest for trypsin 
digestion cleavage was used on the web page http://www.expasy.org/tools. 
 
III.3.2.5 BCL10-CARD domain self-association and binding competition ELISA 
assays 
 
To monitor BCL10-CARD domain self-association, we set up an ELISA-like assay 
where the protein was adsorbed on the plate surface at different concentrations, 
whereas the biotinylated variant was utilized to detect the binding [44]. Adsorption 
was performed in a 96-well plate (Nunc, Falcon) in sodium acetate 50 mM pH 4.0 
buffer (AcNa buffer) at protein concentrations of 0.12 µM, 0.31 µM and 0.62 µM 
overnight at 4°C (100 µL/well). Some wells were filled with buffer alone and were 
used as blank. After washing 3 times with the same buffer, the wells were filled with 
200 µL of 1% w/v BSA in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4 pH 7.4 buffer) and incubated for 2 h at 37°C. The plate was washed again 
with PBS-T (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 pH 7.4 with 
0.004% w/v Tween 20), then solutions of biotinylated protein in AcNa buffer were 
added to wells at concentrations ranging between 0.18 µM and 3.1 µM (0.18 µM, 
0.36 µM, 0.75 µM, 1.6 µM, 3.1 µM; 100 µL/well) and incubated for 1 h at R.T. After 
washing 3 times with AcNa-T buffer (AcNa buffer with 0.004% Tween), the wells 
were filled with 100 µL HRP-conjugated streptavidin (STRV-HRP) at 1:10000 dilution 
in PBS, and incubated for 1 h at 37°C. After washing, detection was achieved using 
o-phenylendiamine (OPD) at 0.4 mg/mL in 50 mM Phosphate citrate buffer pH 5.0, 
containing urea-hydrogen peroxide 0.4 mg/mL. The reaction was stopped by adding 
50 µL of 2.5 M H2SO4 and the adsorbance was measured at 490 nm using a Synergy 
4 multi-wavelength reader (BIOTEK Instruments, Inc. Highland Park, VT, USA).  
For the binding competition experiment unlabelled BCL10-CARD domain at 0.12 µM 
in coating and soluble biotinylated protein at 0.80 µM (1:7 mol/mol ratio) was fixed as 
pre-saturation condition by previous experiments. In the screening competition assay 
peptides contained in the 11 RP-HPLC fractions, obtained by tryptic digestion, were 
used at a nominal concentration of 0.80 µM (1:1 ratio with the biotinylated protein) 
and 8.0 µM (10:1 ratio with the biotinylated protein). Peptide concentration was 
calculated assuming a 100% trypsin cleavage and a 50% recovery from the RP-
HPLC fractionation. In dose-dependent competition assay with the synthetic 
fragments, peptide concentrations ranging from 0.03 µM to 15 µM were used and 
pre-incubated with biotinylated BCL10-CARD domain 0.8 µM for 45 min. at R.T. 
before addition to each well. The subsequent steps were carried out as described. All 
assays were carried out at least twice. 
Competition results were reported as (B/B0)*100, where B stands for the average OD 
from triplicate data points for a given analyte and B0 is the average OD determined 
without competitor. Data fitting and analysis was carried out by non-linear regression 
using GraphPad Prism, vers. 4.00 for Windows, GraphPad Software, San Diego 
California, USA. 
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III.3.2.6 Peptide synthesis, purification and characterization 
 
All peptides were prepared by solid phase synthesis as C-terminally amidated and N-
terminally acetylated derivatives following standard Fmoc chemistry protocols [45]. A 
Rink-amide MBHA resin (substitution 1.1 mmol/g) and amino acid derivatives with 
standard protections were used in all syntheses. Cleavage from the solid support 
was performed by treatment with a trifluoroacetic acid (TFA)/tri-isopropylsilane (TIS) 
/water (90:5:5, v/v/v) mixture for 90 min. at R.T., then crude peptides were 
precipitated in cold ether, dissolved in a water/acetonitrile (1:1, v/v) mixture and 
lyophilized. Products were purified by RP-HPLC applying a linear gradient of 0.1% 
TFA/CH3CN in 0.1% TFA water from 5% to 70% over 50 min. using a semi-
preparative 2.2x5 cm C18 column at a flow rate of 20 mL/min. Peptide purity and 
identity were confirmed by LC-MS analyses using a LCQ DCA XP Ion Trap mass 
spectrometer, previously described. The peptides BCL10[91-98] and BCL10[91-
98]T91A,Q92A, utilized for cellular assays, were also prepared fused to the basic 
region of the HIV Tat protein (fragment 48-60) [43]. Aliquots of peptides VIII and IX 
were also prepared with N-terminal fluorescein labelling to monitor cell delivery. FITC 
(fluorescein isothiocyanate) was linked to an N-terminal-β-alanine. A solution of FITC 
(1.1 equivalents) dissolved in DMF/DCM/DIEA (12:7:5) was added to the resin and 
left over night under agitation. 
Peptide purity and integrity were confirmed by LC-MS on a LCQ DCA XP Ion Trap 
mass spectrometer (Thermo Electron, Milan, Italy), as previously described.  
 
III.3.2.7 Size Exclusion Chromatography analysis 
 
SEC analysis was carried out on a Biosep/SEC/S 2000 at 1.0 mL/min. Both peptides 
I and II were loaded onto the SEC column, opportunely equilibrated in phosphate 50 
mM pH 6.8 buffer, at increasing concentrations (5 µM,10 µM, 50 µM,100 µM, 400 µM 
). A calibration curve was used to determine the MWs. Specific molecular mass 
markers were run on the column under the same conditions in duplicate for 
calibration. The selected calibrants were: Trypsinogen, 23.0 kDa; Myoglobin, 17.0 
kDa; Cytochrome C, 12.4 kDa; Angiotensin II, 1.0 kDa; an unrelated synthetic 
Peptide I, 3.5 kDa; an unrelated synthetic Peptide II, 1.67 kDa. All measurements 
were done at least twice. Elution volumes and partition coefficients of the standards 
and samples were calculated according to manufacturer’s protocol. 
 
III.3.2.8 Serum stability 
 
The TAT-fused Peptides VIII and IX were dissolved in H2O at a 10 mg/mL. The 
samples, serially diluted in PBS pH 7.4 buffer containing 10% FCS in order to obtain 
100 µg/mL solutions, were incubated at 37°C for 24 h. 10 µL aliquots (1.0 µg total 
peptide) were removed at 0, 4 h, 8 h, 12 h, 16 h and 20 h. After centrifugation, the 
recovered samples were analyzed by RP-HPLC applying a linear gradient of 0.1% 
TFA/CH3CN in 0.1% TFA/H2O from 5% to 70% over 50 minutes using a semi-
preparative 2.2x5 cm C18 column at a flow rate of 20 mL/min. A reference curve was 
obtained by analyzing different amounts of the pure compounds under the same 
conditions. The reference curve was used to exclude effects of sample subtraction by 
non-specific binding to albumin or other serum proteins that were pelleted during 
centrifugation. Experiments were carried out twice and data were reported as a plot 
of peak area (%) versus time. 
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III.3.2.9 Cell culture  
 
All experiments with cells were carried out in the laboratory of Prof. P. Vito, 
Università del Sannio, Benevento.  
HEK293 (Human Embryonic Kidney cells) cells (ATCC, Manassas, VA, USA) were 
grown in complete DMEM supplemented with 10% FCS and 100 µg/mL penicillin / 
streptomycin, and maintained at 37°C with 5% CO2.  
 
III.3.2.10 Immunoblot analysis and co-immunoprecipitation 
 
HEK293 cells transfected, with plasmids encoding for two tagged versions of BCL10 
(1-127) bearing the HA and the FLAG epitopes by calcium phosphate precipitation, 
were prepared by Dipartimento di Biologia Molecolare, II Policlinico, Napoli. 
HEK293 cells co-transfected with HA-BCL10 (1-127) and FLAG-BCL10 (1-127) were 
resuspended in lysis buffer (150 mM NaCl, 20 mM Hepes pH 7.4, 1% Triton X-100, 
10% glycerol, and a mixture of protease inhibitors). Proteins were resolved by 10% 
SDS-PAGE, and gels were transferred to nitrocellulose membrane using Trans Blot 
SD semi-dry (Bio-Rad). The membranes were then blocked for 1 h at R.T. in PBS 
containing 0.05% Tween 20 and 5% NFDM. After washing 3 times for 10 min., the 
filter was incubated with the primary antibody overnight at 4°C in blocking buffer 
(PBS containing 0.05% Tween 20 and 2.5% NFDM). After washing 5 times for 10 
min., the filter was incubated with the HRP-conjugated secondary antibody for 1 h at 
R.T. in blocking buffer. Detection was achieved using the ECL system following 
manufacturing’s protocol. For the co-immunoprecipitation experiments, cells were 
resuspended in lysis buffer and immunocomplexes were bound to protein A/G, 
resolved by SDS-PAGE and analyzed by immunoblot assay as already described. 
 
III.3.2.11 Fluorescence peptide assay 
 
Peptide entry tests were carried out using fluorescently labelled molecules. HEK293 
cells transfected were grown onto glass covers lips in 6 wells multi-dishes. After 24 h 
the cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4) and fixed with 3% paraformaldehyde. After additional washes with 
PBS, the cells were treated for 5 h at R.T. with FITC and TAT-conjugated Peptides 
VIII and Peptide IX (used as a control) at 100 µM, 200 µM and 300 µM. Samples 
were then analyzed by fluorescence microscopy (Axiovert, Carl Zeiss). 
 
III.3.2.12 NFκB luciferase reporter gene assays  
 
The inhibition of NF-κB activation induced by BCL10 (1-127) over-expression in 
HEK293 cells and PKC activation was determined by luciferase activity 
measurement. HEK293 cells transiently co-transfected with an expression vector 
encoding for BCL10 (HA-BCL10 (1-127) or FLAG-BCL10 (1-127)) together with an 
NF-κB-luciferase and β-galactosidase reporter vectors were used. 
The total amount of transfected plasmidic DNA was maintained constant by adding 
the empty vector. 16 h after trasfection, the cells were treated with FITC and TAT-
conjugated Peptides VIII and Peptide IX (used as a control) at different 
concentrations for 5 h at R.T. Cells were lysed and assayed using the Luciferase 
Assay System (Promega) according to the manufacturer’s instructions using a 
luminometer (Berthold Analytical Instruments, Nashua, NH, USA). Luciferase activity 
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was normalized against β-galactosidase activity and the data are representative of 
six independent experiments done in triplicate. 
HEK293 cells were transfected with an NF-κB-luciferase reporter plasmid. 24 h after 
trasfection, the cells were untreated or treated with 40 ng/mL PMA and 1 µM 
ionomycin together with TAT-Peptide VIII or TAT-ctr (Peptide IX) for 5 h. The cells 
were harvested, and the luciferase activity was measured as already described. A 
dose and time dependent assay were carried out. Data are representative of five 
independent experiments.  
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III.4 RESULTS AND DISCUSSION 
 
III.4.1 Expression, purification and characterization of the BCL10-
CARD domain  
 
Expression of the N-terminal region of BCL10 (the CARD domain, M.W.16238 Da) 
doubly mutated on Cys29 and Cys57 to Serines, was carried out in BL21(DE3). The 
sequence of recombinant domain carried an N-terminal linker used for the affinity 
purification is reported in Fig.1  
 
                                                  
 
 
 
 
 
 
 
 
 
 
The purified protein, soluble in 100 mM sodium acetate pH 4.5 buffer, was analyzed 
by SDS-PAGE (Fig.2A). Furthermore, to assess the proper folding, an analysis by 
far-UV circular dichroism was performed. Spectra were acquired in sodium acetate 
1x10-6 M buffer solution at pH 4.5 at room temperature. The final CD spectrum, 
reported in Fig.2B, shows one negative band centred at 208 nm with a shoulder at 
222 nm and a positive band at 196 nm. These values are typical for α-helical 
structures. 
 
            
A                                                       B 
 
 
 
 
Figure 2: A) 15% SDS-PAGE analysis of the recombinant CARD domain of BCL10. Lane M, 
Perfect Protein Marker 15-150 KDa (Novagen); lane 1, purified BCL-10 CARD domain B) BCL10-
CARD domain CD spectrum. 
Figure 1: Amino acidic sequence of the BCL-10 CARD domain used in this study. The two 
mutated cysteines and the linker (without numbering) are underlined. 
MEPTAPSLTEEDLTEVKKDALENLRVYLCEKIIAERHFDHLRAKKILSREDTEEISCRTSSRKRAGKLLD
10        20        30        40        50        60        70  
YLQENPKGLDTLVESIRREKTQNFLIQKITDEVLKLR
80        90           100
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEF
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III.4.2 Identification of BCL10-CARD regions involved in self-
association 
 
To identify the specific regions involved in BCL10-CARD domain self-association a 
simple and effective approach was followed [38,39]. 
An ELISA assay wass set up to monitor the binding, measure the affinity and select 
the pre-saturation concentrations needed to carry out competition assays. The 
protein was enzymatically fragmented and the resulting peptides were fractionated by 
RP-HPLC and then used as competitors in the binding competition assay, identifying 
those able to disrupt the binding [40].  
 
III.4.2.1 BCL10–CARD domain self association assay 
 
Preliminary ELISA-like assay experiments were performed immobilizing the BCL10-
CARD domain on the microtiter plate and verifying its binding to the biotin-labelled 
BCL10-CARD domain, using the biotin-streptavidin system to detect association. 
Increasing concentrations of biotinylated BCL10-CARD domain (0.2 µM, 0.4 µM, 0.8 
µM, 1.3 µM, 2.6 µM) were applied to the unlabelled BCL10-CARD domain coated at 
three different concentrations (0.12 µM, 0.30 µM and 0.6 µM). Detection was 
achieved using the STR-HRP conjugate and the absorbance was measured at 490 
nm. Binding was saturable for concentrations of soluble protein higher than about 1.5 
µM, suggesting that several BCL10-CARD molecule can bind to one coated 
polypeptide. In Fig. 3, the plot of curves relative to these bindings at different protein 
concentrations is reported. KD values were obtained by averaging the KD on the 
three curves derived by non-linear regression fitting of data and was estimated to be 
1.33 ± 0.16 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the binding competition assay, BCL-CARD was coated at 0.12 µM and the 
biotinylated variant was used at 0.80 µM.  
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Figure 3: Dose-dependent binding curves of biotinylated BCL10-CARD 
domain to the unlabelled protein.  
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III.4.2.2 Protein digestion with trypsin and peptide fractionation 
 
Proteolytic digestion with trypsin was carried out on the BCL10-CARD domain as 
reported in the section III.3.2.4 of Methods. 
The tryptic digestion mixture was separated by RP-HPLC and 11 fractions, 1F to 
11F, were collected. The lyophilized fractions were reconstituted in water, properly 
diluted with buffer and subsequently assayed as competitors in the BCL10-CARD 
domain self-association test.  
 
III.4.2.3 Protein fragments characterization and screening 
competition assay 
 
Competitors were used at a nominal 5-fold excess over the soluble protein. Peptide 
fragments concentration was deduced by assuming an initial quantitative protein 
cleavage by trypsin and a subsequent recovery of 50% by RP-HPLC fractionation. 
Tryptic peptides were identified by LC-MS/MS analysis (Fig.4). An LC-MS analysis of 
single fractions also allowed the determination of fragments distribution and 
composition as described in Table I. Relative distribution of fragments, in column 3, 
were calculated by comparing area integration of extracted ion peaks from a given 
fragment taken from the different fractions. The relative composition within each 
fraction was derived by comparing area integrations of extracted ion peaks of all 
fraction components. As can be seen, fractions F1 and F2 contained no peptides, 
whereas fractions F3-F8 and fraction F10 contained more than one fragment. 
Fraction F9 contained only the L68-K77 fragment. In spite of the prolonged reaction 
times and of the high temperature (37°C), many fragments contained uncleaved 
lysines and arginines peptide bonds, suggesting the presence of poorly accessible 
cleavage site. Several other fragments, such as the N-terminal M1-K17 bearing the 
linker tetrapeptide GSEF (see Fig.1) and H38-K45 and T59-K67 peptides were only 
poorly detected and thus not considered further.  
 
 
Figure 4: LC-MS chromatogram of digested CARD domain with the identified sequences. 
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For the assay purpose, the lyophilized fractions were reconstituted in water, properly 
diluted with buffer and subsequently assayed as competitors in the BCL10-CARD 
self-association test. Screening results are expressed as percentage of inhibition of 
self-association and are summarized in Table I. As expected, fractions F1 and F2 
where no peptides were detected, provided no binding reduction. Among the 
remaining fractions, only fraction F8 containing the peptides BCL10 [91-98] 
(sequence: TQNFLIQK, relative abundance 63%) and the homolog BCL10 [89-98] 
(sequence: EKTQNFLIQK, abundance 37%), produced a relevant binding reduction 
(about 50%). The sequence EKTQNFLIQK, compared to the most abundant [91-98] 
fragment only contained two additional residues at the N-terminus and was not 
considered for further investigations, while the peptide BCL10 [91-98] (Peptide I) was 
re-prepared by chemical synthesis as a C-terminally amidated and N-terminally 
acetylated variant. 
Table I 
 
 
 
III.4.3 Design of BCL10 peptides 
 
A model for the BCL10-CARD, retrieved from the ModBase server of the University 
of California at San Francisco (http://modbase.compbio.ucsf.edu/) and visualized by 
the WebLab ViewerPro software, vers. 3.7 (Molecular Simulations Inc.), was used to 
localize the putative structure of the selected peptide [91-98] within the CARD 
structure. The model, obtained using as template the X-ray crystallography structure 
of the apoptotic protease activating factor 1 CARD (pdb code: 1cy5 [48]) despite the 
very low sequence identity (17%), has a very low E-value (2x10-8) and a model score 
of 0.99. This putative homology model of CARD domain shows that the segment [91-
98] is inserted in the 6th helix of the bundle. 
To also investigate the influence of the structured flanking region of the selected 
peptide on CARD self-association, two additional BCL10 peptides containing the 91-
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98 stretch at the C-terminus were designed and synthesized. These peptides, named 
Peptide II and Peptide III, contained residues 78-98 and 68-98, respectively (table II). 
Thus, on examination of this model, it can be seen that the 91-98 region is inside the 
modelled sequence and virtually corresponds to the 6th helix (partially distorted); the 
sequence 78-98 instead, covers the 5th and the 6th helix, and the 68-98 fragment 
corresponds to the protein region including helices 5 and 6, the loop between helix 5 
and helix 4 and part of the helix 4.  
 
 
Peptide   I   TQNFLIQK                                         BCL10 [91-98]  M.W.1031.58 
 
Peptide  II   GLDTLVESIRREKTQNFLIQK                 BCL10 [78-98]   M.W.2746.41 
 
Peptide III   LLDYLQENPKGLDTLVESIRREKTQNFLIQK   BCL10 [68-98]  M.W.3731.01 
 
TABLE II: The three peptides used to identify residues involved in protein-protein interactions. 
 
III.4.3.1 Synthesis, purification and characterization of BCL10 
peptides 
 
Peptides I-III were synthesized by SPPS following Fmoc chemistry, purified by RP-
LC and characterized by LC-MS. 
Far UV-Circular dichroism experiments were carried out to investigate their structural 
behaviour. CD experiments were performed in 10 mM phosphate pH 7.0 buffer at 
room temperature, using all peptides at the concentration of 20 µM. The spectra do 
not show the occurrence of canonical structures for the three synthetic fragments 
(Fig.5). However, negative bands at 208 nm and shoulders at 222 nm are indicative 
of a tendency to adopt α-helical conformations. 
 
 
 
 
 
 
 
 
Figure 5: Far-UV CD spectrum of the BCL10-CARD 
peptides: Peptide I BCL10[91-98] (red), Peptide II 
BCL10[78-98] (green) and Peptide III BCL10[68-98] (blu). 
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III.4.3.2 Competitive ELISA assay with BCL10 peptides  
 
The synthetic peptides I-III were utilized in a dose response competition assay under 
the same conditions used for the protein fragments screening (coating 0.12 µM; 
biotinylated protein 0.80 µM). They were utilized at increasing concentrations 
between 0.03 µM and 15 µM. Results are reported in Fig. 6. Data show that the 
shorter Peptide I BCL10[91-98] strongly reduces protein self-association in a dose-
dependent fashion, whereas, unexpectedly, the longer polypeptides II and III, 
containing this active sequence, only slightly interfered with the interaction. In 
particular, Peptide I inhibited the protein association by 90% at the highest dose of 15 
µM and exhibited an IC50 of 70 nM. Conversely, Peptides II and III exhibited an 
efficacy between 30% and 40% only at the highest concentration tested this result 
being suggestive of a tendency of peptides to self-aggregation. 
 
                              
 
 
 
 
 
 
 
 
 
 
     
    
 
 
 
 
 
.  
 
III.4.3.3 Characterisation of the oligomeric state of Peptide I and 
Peptide II by SEC analysis  
 
The oligomeritazion state of peptides and their apparent molecular weight were 
determined by Size Exclusion Chromatography analysis. Peptide I and Peptide II 
were loaded onto the Biosep/SEC/S 2000 column at five different concentrations (5 
µM,10 µM, 50 µM, 100 µM, 400 µM) using phosphate 50 mM, pH 6.8 buffer. A 
calibration curve was built using molecular mass markers under the same conditions. 
Data analysis, reported in table III, shows that, while the Peptide I BCL10[91-98] 
appeared invariably monomeric, the [78-98] variant eluted as a dimer even at the 
lowest concentration of 5 µM (Log M = -5.3). This property, together with the inability 
to efficiently suppress the BCL10-CARD domain self association at concentrations 
higher than about 1 µM, suggests that the presence of residues 78-90 may favour the 
formation of peptide oligomers or that the longer structure might induce a 
conformation more suitable for self-recognition. 
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Figure 6: Dose-dependent competitive ELISA 
assay with synthetic Peptide I-III corresponding to 
fragments [91-98], [78-98] and [68-98] of BCL10-
CARD domain, respectively. 
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III.4.3.4 Ala-scanning assay  
                                                                        
To further investigate the inhibiting properties of Peptide III and to explore residues 
involved in protein-protein interactions, four mutated variants of Peptide III, where 
adjacent residue pairs were substituted by alanines, were next designed and 
synthesized, as reported in table IV.  
These peptides were synthesized by SPPS following Fmoc chemistry, purified by 
RP-LC and characterized by LC-MS. 
 
 
Peptide IV  AANFLIQK          BCL10[91-98]T91A,Q92A      M.W. 945.14 
 
Peptide V   TQAALIQK          BCL10[91-98]N93A,F94A      M.W. 913.09 
 
Peptide VI   TQNFAAQK        BCL10[91-98]L95A,I96A       M.W. 948.05 
 
Peptide VII  TQNFLIAA          BCL10[91-98]Q97A,K98A     M.W. 918.03 
 
TABLE IV: The four double alanine mutated peptides used to identify residues involved in protein-
protein interactions. 
Conc (µM) Peptide I 
MWexp(Da)/MWth= 1032 
Peptide II 
MWexp (Da)/MWth= 2746 
400 1314 5802 
100 1322 5470 
50 1309 5352 
10 1294 4981 
5 1245 5045 
0.4 0.5 0.6 0.7 0.8 0.9 1.0
2
3
4
5
KD
Lo
gM
W
Figure 7: Calibration curve used to determine the apparent Mr of Peptide I and Peptide II. 
KD is the partition coefficient, calculated as (Vt-Vo)/(Vf-Vo), where (Vt is the elution volume 
at the elution time of the peptide, Vo is the column void volume, while Vf is the column total 
volume. 
TABLE III: Characterisation of the oligomeric state of Peptide I and Peptide II. Gel-
filtration analysis of synthetic peptides on Biosep/SEC/S 2000 buffer phosphate 50 mM, 
pH=6.8. Gel-filtration analyses were performed at five different concentrations between 
400 and 5 µM (each run was repeated at least twice). A calibration curve was used to 
determine the MWs. Calibrants were: Trypsinogen, 23.0 kDa; Myoglobin, 17.0 kDa; 
Cytochrome C, 12.4 kDa; Angiotensin II, 1.0 kDa; an unrelated synthetic peptide I, 3.5 
kDa; an unrelated synthetic peptide II, 1.67 kDa. 
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The mutated variants, Peptides IV, V, VI and VII were tested in a dose-response 
assay along with the parent BCL10[91-98] again using pre-saturation conditions 
(coating 0.12 µM; biotinylated protein 0.80 µM). For this assay, competitor 
concentrations ranged between 0.03 µM and 15 µM. Subsequent steps were carried 
out as described. The results are summarized in Fig. 8. As shown, Peptides I, V, VI 
and VII still reduced the BCL10-CARD domain self-association, whereas Peptide IV 
with Thr91 and Gln92 changed to alanine was almost ineffective even at the highest 
dose (15 µM). Notably, Peptide VI, having residues Leu95 and Ile96 changed to 
alanines, exhibited only a reduced efficacy, being able to lessen the interaction to 
50% only at the highest concentration. Also the Peptide V, with substitutions on 
residues N93 and F94, had a ten folds lower efficacy (about 10-6 M) than Peptides IV 
and VII. Together, these data suggest that residues BCL10 [91-98] can have a 
relevant role in BCL10-CARD domain self-association and that the side chains of 
Thr91, Gln92, Leu95 and Ile96 may represent key contact points between protein 
monomers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III.4.4 Cellular assays 
 
In order to confirm the efficacy of the selected peptide to block self-association 
between CARDs of BCL10 and possibly the association between BCL10 and other 
protein partners, we planned cellular experiments of co-immunoprecipitation and 
luciferase activity. For this purpose the peptides BCL10[91-98] and BCL10[91-
98]T91A,Q92A were opportunely prepared using TAT-conjugated variants to favour 
cell entry [49]. Peptides were also labelled with fluorescein to confirm quantitative 
peptide cellular viability. 
 
III.4.4.1 Synthesis, purification, serum stability and characterization 
of TAT-conjugated and FITC-TAT-conjugated Peptide VIII and IX 
 
Peptides BCL10[91-98] and BCL10[91-98]T91A,Q92A were prepared fused to the 
basic region of the HIV TAT protein (fragment 48-60) [41]. These peptides, reported 
in table V, were synthesized by SPPS following Fmoc chemistry, purified by RP-LC 
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Figure 8: Dose-dependent competitive ELISA assay with  synthetic 
Peptides I, IV, V, VI, VII. Peptides IV-VII are doubly-mutated synthetic 
variants of the most active [91-98] fragment. 
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and characterized by LC-MS. Aliquots of Peptides VIII and IX were also prepared 
with N-terminal fluorescein labelling to monitor cell delivery.  
 
 
Peptide VIII  FITC-βA-GRKKRRQRRRPPQ-AA-TQNFLIQK   TAT-BCL10[91-98]                 
 
Peptide IX  FITC-βA-GRKKRRQRRRPPQ-AA-AANFLIQK   TAT-BCL10[91-98]T91A,Q92A   
 
TABLE V: Sequences of TAT-conjugated peptides utilized in the cellular assays. 
 
The stability of TAT-fused Peptides VIII and IX was determined by RP-HPLC analysis 
of peptide samples incubated with serum. The samples, serially diluted in PBS pH 
7.4 buffer containing 10% FCS were incubated at 37°C for 24 h. Aliquots were 
removed at different times (0, 4 h, 8 h, 12 h, 16 h and 20 h) and were analyzed after 
centrifugation. In Fig.9, a plot of peak area (%) versus time is reported and shows 
that peptides resulted stable in serum for at least 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Stability of the TAT-fused Peptide VIII in serum.  
 
 
III.4.4.2 Immunoblotting and co-precipitation analysis 
 
HEK293 cells were co-transfected with plasmids encoding for two tagged versions of 
BCL10 (1-127) bearing the HA and the FLAG epitope. Lysates from transfected cells 
were immunoprecipitated with anti-FLAG antibodies either in the absence or 
presence of increasing concentrations of Peptide VIII added at concentrations 
ranging between 5 and 100 µM. Co-precipitating HA-tagged BCL10 (1-127) was 
detected by immunoblot assay. Importantly, the peptide repressed self association of 
BCL10 (1-127) in a dose dependent manner and at 100 µM the binding was totally 
abolished (Fig.10). 
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III.4.4.3 Assessment of peptide entry into HEK 293 cells 
 
HEK293 cells transfected with BCL10 (1-127) were treated for 5 h at R.T. with FITC 
and TAT-conjugated Peptides VIII and IX (used as a control) at 100 µM, 200 µM and 
300 µM. Samples were analyzed by fluorescence microscopy. Under these 
conditions, both peptides appeared uniformly distributed in HEK293 cells at the 
concentration of 200 µM (Fig. 11).  
 
 
Figure 11: Assessment of peptide entry within BCL10-
transfected HEK293 cells. Cells were incubated with peptide 
solutions at different concentrations (100 µM, 200 µM and 300 
µM) and subsequently analyzed by fluorescence microscopy. A 
picture of the untreated cells is also reported in the middle.  
 
Figure 10: In vitro inhibition of BCL10-CARD (region 1-127) self-association in lysates of BCL10-
overexpressing HEK293 cells. Two differentially tagged protein constructs were utilized in these 
assays. Roughly 50% binding inhibition was achieved at 5 µM Peptide VIII.  
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III.4.4.4 NFκB luciferase reporter gene assay  
 
The ability of the selected peptides to inhibit NF-κB activation induced by BCL10 (1-
127) over-expression and PKC activation was determined by luciferase activity 
measurement using HEK293 cells. This system provides a reporter gene containing 
the NF-κB promoter (the DNA sequence that regulates NF-κB-induced genes) cloned 
upstream of the luciferase gene. The protein encoded by the luciferase gene 
fluoresces strongly when the NF-κB promoter is active, making it easy to determine 
the level of activation based on the level of luminescence.  
HEK293 cells were transiently co-transfected with an expression vector encoding 
BCL10 (1-127), together with an NF-κB-luciferase and β-galactosidase reporter 
vector. After 16 h, the cells were treated for 5 h with TAT-Peptide VIII and TAT-
Peptide IX, used as a control, at 5 µM, 10 µM and 50 µM. Luciferase activity was 
determined from cell extracts using a luciferase assay system and a luminometer. 
The results of these experiments, shown in Fig.12, indicated that Peptide VIII 
repressed the activation of NF-κB promoted by BCL10 over-expression in a dose 
dependent manner with a maximum efficacy of about 50% at the highest dose of 50 
µM. In the same experiment, treatment of cells with the control Peptide IX had no 
effect on NF-κB activity.  
 
 
 
 
Since PKC activity is required for LPA-induced NF-κB activation, we also tested 
whether Peptide VIII inhibited activation of NF-κB following PKC activation [42]. 
HEK293 cells were transiently transfected with an NF-κB-luciferase and β-
galactosidase reporter vector. In a preliminary experiment, a dose dependent assay 
was carried out adding the TAT- Peptide VIII and control at 5 µM, 10 µM and 50 µM 
to cells left untreated or stimulated with 40 ng/mL PMA, a surrogate of 1,2-
diacylglycerol (the natural activator of conventional and novel PKCs) and 1 µM 
ionomycin, a calcium ionophore. After 5 h luciferase activity was measured, as 
previously described. Data analysis shows that the TAT-Peptide VIII repressed the 
activation of NF-κB following PKCs activation in a dose dependent manner (Fig.13). 
50 µM TAT-Peptide VIII  was able to bock NF-κB activation by about 70%.  
Figure 12: Luciferase assay: TAT-BCL10[91-98] peptide inhibits in a dose-
dependent manner BCL10 overexpression-mediated NF-κB activation. 
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Subsequently a time dependent assay was carried out by adding the TAT-Peptide 
VIII and the control at 50 µM to cells left untreated or stimulated with ionomycin and 
PMA. Luciferase activity was measured after 1h, 3h and 5 h (Fig.14). In agreement 
with the previous results, data confirmed that the TAT-BCL10[91-98] peptide inhibits 
at 50 µM PKC-mediated NF-κB activation in a time-dependent and dose-dependent 
way. 
                           
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
Figure 13: Luciferase assay: TAT-BCL10[91-98] peptide inhibits 
PKC-mediated NF-κB activation in a dose-dependent manner. 
Figure 14: Luciferase assay: TAT-BCL10[91-98] peptide inhibits at 
50 µM PKC-mediated NF-κB activation in a time-dependent manner 
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III.5 CONCLUSIONS AND PERSPECTIVES 
 
In lymphocytes, the N-terminal CARD domain of BCL10 binds to the CARD domain 
of CARMA1, this interaction is necessary for the correct transduction of the NF-κB 
activating signal [26].  
Accordingly, the experimental hypothesis addressed here is that disruption of the 
pattern of interactions involving the CARD of BCL10 should down-regulate BCL10-
dependent NF-κB activation. 
Given these premises, knowledge of regions involved in protein-protein interactions 
becomes of utmost importance for the design of BCL-10-targeted NF-κB inhibitors. 
Hence, by means of a procedure described in a previous paper [40]. The CARD 
domain of BCL10 has been fragmented with trypsin and the peptides obtained 
following HPLC fractionation have been used as competitors in a CARD-CARD 
interaction assay. Using this method, a fragment corresponding to residues 91-98 of 
the protein (Peptide I), that strongly abolishes protein self-association both in vitro 
and in a BCL-10-overexpressing cell line, has been isolated. Noticeably, Peptide I 
has an IC50 of about 70 nM, although when fused to the basic region of the TAT 
protein (Peptide VIII) it is less effective, and shows an IC50 of only about 5 µM (see 
Fig.10 ). This result implies both a reduced affinity of the modified peptide for the 
protein domain and to a higher stability of the complexes formed by BCL10 in the 
presence of other proteins. This hypothesis is confirmed by the cellular assays, 
where a concentration of about 50 µM is needed to block NF-κB activation by 70% 
(Fig.12,13,14). Importantly, the loss of activity of Peptide VIII is not due to peptide 
degradation within the cell medium, as it appeared highly stable when in contact with 
serum for over 24 h. Also Peptides II and III, designed to account for adjacent CARD 
helices and containing the wild type sequence 91-98 at the C-terminus, resulted 
poorly effective in reducing the BCL10-CARD self-association in vitro. This behaviour 
can be explained by the propensity of the longer polypeptides to self-aggregation and 
by a consequent, inaccessibility of contact residues even at low concentrations. This 
hypothesis is supported by the observation that the 78-98 segment is dimeric even at 
5 µM and a similar dimeric structure can be also expected for the 68-98 peptide. 
Indeed, the oligomeric organization of these peptides reflects the CARD tendency to 
self-associate and corroborates the view that recognition is mediated by the C-
terminal helix of the globular domain. However the possibility that other residues 
within the 78-90 stretch mediates self-recognition or that the longer peptides likely 
adopt a conformation which is closer to that within the full length CARD, can not be 
ruled out. These biochemical data also provide evidence that the side chains of 
Thr91, Gln92, Leu95 and Ile96 are implicated in the pattern of interactions involving 
CARD self-recognition of BCL10 and the inability of the ThrGln91,92AlaAla synthetic 
mutant to activate NF-κB even after PMA/ionomycin stimulation, suggesting a critical 
role for these amino acids in mediating CARD-CARD contacts. Notably, residues 91, 
92, 95 and 96, given their alternate distribution along the sequence, could be part of 
an extended surface on one side of the putative helix 6. It is well known that BCL10 
forms a large protein complex known with CARMA1 and MALT1 known as CBM 
(CARMA1-BCL10-MALT1), which is the ultimate effector of BCL10 activity [46]. 
Several studies have reported direct interactions between the CARDs of BCL10 and 
CARMA1 and between the Ig-like domain of MALT1 and residues 107-119 of BCL10. 
Very recently it has also been reported that residues from the putative helix 5 of the 
BCL10 CARD (D80 and E84) mediate the binding to the death domain (DD) of 
MALT1 and are essential for downstream NF-κB activation; furthermore it has been 
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demonstrated that mutations within the 6th helix (Q92, L95, I96) preclude this binding 
by seemingly altering the CARD structural stability [13]. Out findings essentially 
agree with these data as they fit with a model of multiple interactions between 
CARDs and between CARD and the MALT1 DD, whereby helix 5 mediates the 
recognition with MALT1 and residues from the adjacent helix 6 are involved in CARD 
self association. 
This work offers the proof of concept that blocking the CARD domain of BCL10 (and 
possibly the association with other interacting partners) is an effective way to 
selectively reduce NF-κB activation and can be a valuable therapeutic approach for 
treatment of specific pathologic conditions associated with inappropriate NF-κB 
activation.  
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IV. ABBREVIATIONS INDEX 
 
αFcεRI: alpha subunit of the human FcεRI  
Apaf 1: Apoptotic Protease-Activating Factor 1 
APC: antigen-presenting cells 
BCL10: B-cell lymphoma 10 
βFcεRI: beta subunit of the human FcεRI  
βtFcεRI: truncated beta subunit of the human FcεRI 
BSA: Bovine Serum Albumin 
CARD: Caspase Recruitment Domain 
CC-CARD: coiled-coiled caspase recruitment domain 
CD: Circular Dichroism 
DD: Death Domain  
DCM: dichloromethane 
DED: Death Effector Domain  
DIPEA: diisopropil-etilendiammina 
DMEM: Dulbecco’s Modified Eagle’s Medium 
DMF: N,N-dimethylformamide 
DMSO: dimethyl sulfoxide 
DNP-HBS: 2,4-dinitrophenol conjugated human serum albumin 
DTT: 1,4-Dithiothreitol 
ECD: extracellular domain 
EDC: N-ethyl-N′-(dimethylaminopropyl) carbodiimide  
EDTA: ethylenediaminetetraacetic acid 
ELISA: Enzyme-Linked Immunosorbent Assay 
ER:Endoplasmic Reticulum  
FCS: fetal calf serum 
Fc-IgE: Fc fragment of immunoglobulin E 
Fc-IgG: Fc fragment of immunoglobulin E 
FPLC: Fast Protein Liquid Chromatography 
4-VP: 4-vinyl pyridine 
γFcεRI: γ-chains of the human FcεRI 
hFcεRI: human FcεRI  
hαFcεRI:alpha subunit of the human FcεRI 
HBS: Hepes buffer saline 
HPLC: High Performance Liquid Chromatography 
HRP: horseradish peroxidase  
IgA: immunoglobulins A 
IgE: monoclonal anti-DNP mouse IgE 
IgG: immunoglobulins G 
IgM immunoglobulins M 
IPTG: isopropyl-beta-D-thiogalactopyranoside 
ITAM: immunoreceptor tyrosine-based activation motif 
LB: Lauria-Bertani medium 
LC-MS: Liquid Chromatography-Mass Spectrometry 
MAGUK: Membrane-Associated Guanylate Kinase 
MALT: Mucosa-Associated Lymphoid Tissue  
MALT1: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 
MHC: Major Histocompatibility Complex 
NBD: Nucleotide-Binding Domain 
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NFDM: Non Fat Dry Milk 
NF-κB: Nuclear Factor-κB 
NHS: N-hydroxysuccinimide 
NTA: nitrilotriacetic acid 
OD600: Optical Density at 600 nm 
OPD: ortophenyldiamine 
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
PDB: Protein Data Bank 
PKCδ: Protein kinase C 
PMSF: Phenylmethylsulphonylfluoride (Inhibitor of Serine proteases) 
p-NAG: p-nitrophenyl-N-acetyl-β-d-glucosaminide 
RP-HPLC: Reverse Phase-High Pressure Liquid Chromatography 
R.T.: room temperature 
RU: response unit 
SDS: sodio-dodecil solfato 
SPR surface plasmon resonance 
TEV: Tobacco Etch Virus (TEV) NIa protease 
TFA: Trifluoroacetic acid 
TIS: triisopropylsilane 
TNF-α: Tumor Necrosis Factor-α 
TPCK: Tosyl Phenylalanyl ChloromethylKetone 1-Chloro-3-tosylamido-4-phenyl-2-
butanone (irreversible inhibitor of chimotrypsin) 
TRIS:tris(hydroxymethyl)aminomethane 
TTBS :Tween Tris-buffered saline  
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